

Supplemental Material to:

*Benchmarking AWaRe: estimating optimal levels of
AWaRe antibiotic use in 186 countries, territories and
areas based on clinical infection and resistance burden*

Cook, Aislinn et al.

CONTENTS

List of Figures.....	3
List of Tables.....	6
1 Supplemental Methods.....	7
1.1 Data sources and processing.....	7
1.1.1 Antibiotic Use Data	7
1.1.2 Infection data	7
1.1.3 Antibiotic resistance data.....	8
1.1.4 Other covariate data	9
1.1.5 Missing data imputation.....	17
1.1.6 Data processing post imputation	17
1.1.7 Re-classifying Not Recommended antibiotics to AWaRe Category.....	17
1.2 Statistical Analysis	19
1.2.1 Antibiotic use Regression model	19
1.2.2 Optimal AWaRe Antibiotic Use Benchmarking.....	20
1.2.3 Sensitivity analyses.....	41
2 Supplemental results	47
2.1 Antibiotic Use Regression Model.....	47
2.2 Optimal AWaRe Antibiotic Use Benchmarking.....	49
2.2.1 Clustering analysis.....	49
2.2.2 Benchmark CTA selection.....	53
2.2.3 Estimated expected antibiotic use	54
2.2.4 Actual vs. estimated optimal antibiotic use	54
2.3 Sensitivity analyses	55
2.3.1 Global antibiotic use	55
2.3.2 CTA-level scenario comparisons.....	56
2.3.3 Actual vs. estimated optimal scenario comparison	93
References	103

LIST OF FIGURES

Figure 1. Factors that would be expected to impact on necessary antibiotic use for both total use and AWARe antibiotic use. Created in BioRender. Cook, A. (2025) https://BioRender.com/d94em8e	7
Figure 2. Imputation matrix showing the variables used as predictors for imputation of each antibiotic and covariate of interest for the full MIDAS® dataset which includes Not Recommended antibiotics	17
Figure 3. Imputation matrix showing the variables used as predictors for imputation of each antibiotic and covariate of interest for the MIDAS® dataset with the re-classified Not Recommended antibiotics.....	18
Figure 4. Study schema for deriving estimates of expected AWARe antibiotic use based on infection burden, antibiotic resistance, socio-demographics, healthcare infrastructure and access using the WHO AWARe book as a clinical framework. This figure is also presented in the main manuscript but is included here for ease. 1. Data preparation, 2. Missing data imputation, 3. Antibiotic use regression model, 4. Latent Class Model, 5. Benchmark CTA selection, 6. Estimate optimal total DID, 7. Estimate optimal Reserve DID, 8, Estimate optimal Watch DID, 9. Estimate optimal Access DID	19
Figure 5. Distribution of covariates by World Bank Income Group. GNI = gross national income, UHC = universal health coverage, LRI = lower respiratory tract infection, MDR & XDR TB = multi-drug resistant and extremely-drug resistant tuberculosis, URTI = upper respiratory tract infection, UTI = urinary tract infection, CR = carbapenem resistant, ESBL = extended-spectrum beta-lactamase, MRSA = methicillin-resistant Staphylococcus aureus, VR. E faecium = vancomycin-resistant Enterococcus faecium, VR-S.aureus = vancomycin-resistant Staphylococcus aureus, Prop = proportion, pop = population, PCV = pneumococcal conjugate vaccine	22
Figure 6. Distribution of covariates by WHO Region. GNI = gross national income, UHC = universal health coverage, LRI = lower respiratory tract infection, MDR & XDR TB = multi-drug resistant and extremely-drug resistant tuberculosis, URTI = upper respiratory tract infection, UTI = urinary tract infection, CR = carbapenem resistant, ESBL = extended-spectrum beta-lactamase, MRSA = methicillin-resistant Staphylococcus aureus, VR. E faecium = vancomycin-resistant Enterococcus faecium, VR-S.aureus = vancomycin-resistant Staphylococcus aureus, Prop = proportion, pop = population, PCV = pneumococcal conjugate vaccine.....	23
Figure 7. Bayesian information criterion (BIC) of latent class models considering 1 to 6 clusters using available covariates (n=40) for 186 analysis CTAs.	24
Figure 8. Point estimates of infection incidence vs. infection mortality by benchmark group and coloured by Healthcare Access and Quality Index (HAQI) showing the MIDAS® CTAs with available antibiotic use data available.....	26
Figure 9. MIDAS® CTAs with available antibiotic use data by benchmark group (note: no benchmark group 1 CTAs had antibiotic use data available in MIDAS®) showing infection mortality per 100,000 people against total DID sized by % Access antibiotics and coloured by Healthcare Access and Quality Index (HAQI). Uncertainty bars are for infection mortality. Source: Total DID based on IQVIA MIDAS® data for 2019, reflecting estimates of real-world activity. Copyright IQVIA. All Rights Reserved.....	27
Figure 10. A) Plot of doctors per 1000 people against infection incidence for infections included in GBD. B) Zoomed plot of doctors per 1000 people against urinary tract infection (UTI) incidence and C) Zoomed plot of doctors per 1000 people against cellulitis incidence where we see an increasing relationship	32
Figure 11. Scatterplot of the adjusted incidence (blue) compared to observed incidence (red) on a subset of 100 draws for A) UTI and B) cellulitis.....	34
Figure 12. Overview of the process to estimate expected AWARe antibiotic use in defined daily doses (DDD) per 1000 inhabitants per day (DID).	35
Figure 13. The median typhoid incidence per 100,000 people from GBD for 186 CTAs, territories and areas (CTAs) in the analysis with cut-offs at 10 cases per 100,000, 50 cases per 100,000 and 100 cases per 100,000. CTAs are coloured by cluster assignment.	39
Figure 14. A figure describing the process of estimating what percentage of urinary tract infections (UTIs) could be upper UTIs and thus requiring Watch antibiotics per the AWARe Book. The figure outlines the classification	

strategy for assumed lower UTI requiring Access antibiotics and upper UTI requiring Watch antibiotics from cases in Clinical Practice Research Datalink (CPRD) between 2015 and 2021. The figure shows three scenarios and we use scenario 2 for our analysis which gives the highest estimate of upper UTI (21%). 40

Figure 15. Illustration of the subset of cases from GBD considered A) Upper UTI and B) severe LRI used for estimating Watch antibiotic use out of total cases. For UTI, in the primary analysis, the subset of cases was taken after adjusting the case counts (described in supplemental methods 1.2.2.5) 41

Figure 16. Results of antibiotic use regression model showing the distribution of the posterior draws and 95%CrI for Access, Watch and Reserve antibiotic use. DID = defined daily doses (DDD)/1000 inhabitants/year. GNI = gross national income; UHC = universal health coverage; PCV = pneumococcal vaccine; LRI = lower respiratory infection; URI = upper respiratory infection; UTI = urinary tract infection; STI = sexually transmitted infection; MDR & XDR TB = multidrug resistant and extensively drug resistant tuberculosis; EBSL = extended spectrum beta-lactamase producing Enterobacterales; MRSA = methicillin-resistant staphylococcus aureus; CRO = carbapenem resistant organism; VRO = vancomycin-resistant organism..... 47

Figure 17. Discriminative power of the variables included in the four groups cluster model. Negative bars indicate the variable was not discriminative and was not used by the model. 49

Figure 18. Distribution of covariates by cluster for the four-group cluster model. GNI = gross national income, UHC = universal health coverage, LRI = lower respiratory tract infection, MDR & XDR TB = multi-drug resistant and extremely-drug resistant tuberculosis, URTI = upper respiratory tract infection, UTI = urinary tract infection, CR = carbapenem resistant, ESBL = extended-spectrum beta-lactamase, MRSA = methicillin-resistant Staphylococcus aureus, VR. E faecium = vancomycin-resistant Enterococcus faecium, VR-S.aureus = vancomycin-resistant Staphylococcus aureus, Prop = proportion, pop = population, PCV = pneumococcal conjugate vaccine 50

Figure 19. Comparison of cluster assignments to World Bank Income Groups. 51

Figure 20. Comparison of cluster assignments to WHO regions 52

Figure 21. Infection deaths per 100,000 people and Total DID by cluster for CTAs with data available in IQVIA MIDAS® showing percentage Access antibiotics (size) and Healthcare Access and Quality Index (HAQI) (colour) with potential benchmark CTA codes highlighted in red (MAR (Morocco), COL (Colombia) in benchmark group 3 and CHE (Switzerland) in benchmark group 4). Source: Total DID based on IQVIA MIDAS® data for 2019, reflecting estimates of real-world activity. Copyright IQVIA. All Rights Reserved... 53

Figure 22. Distribution of the 1000 draws of estimated expected Total, Access, Watch and Reserve (AWaRe) antibiotic use by cluster for primary analyses. Note: x-axis scales are different between the AWaRe categories. 54

Figure 23. Median observed (IQVIA MIDAS®) vs. median estimated expected antibiotic use by AWaRe category and benchmark group for primary analyses for CTAs in IQVIA MIDAS® with observed antibiotic use data available. Dashed line indicates where observed = expected. Source: Actual DID based on IQVIA MIDAS® data for 2019, reflecting estimates of real-world activity. Copyright IQVIA. All Rights Reserved... 54

Figure 24. Estimated optimal Total defined daily doses/1000 inhabitants/year (DID) by CTA and cluster assignment for each analysis scenario. Scenario 1 = primary analysis, Scenario 2 = high watch scenario, Scenario 3 = unadjusted cases & excl. TB, Scenario 4 = alternate benchmark CTA 56

Figure 25. Estimated optimal Access defined daily doses/1000 inhabitants/year (DID) by CTA and cluster assignment for each analysis scenario. Scenario 1 = primary analysis, Scenario 2 = high watch scenario, Scenario 3 = unadjusted cases & excl. TB, Scenario 4 = alternate benchmark CTA 56

Figure 26. Estimated optimal Watch defined daily doses/1000 inhabitants/year (DID) by CTA and cluster assignment for each analysis scenario. Scenario 1 = primary analysis, Scenario 2 = high watch scenario, Scenario 3 = unadjusted cases & excl. TB, Scenario 4 = alternate benchmark CTA 57

Figure 27 Estimated optimal Reserve defined daily doses/1000 inhabitants/year (DID) by CTA and cluster assignment for each analysis scenario. Scenario 1 = primary analysis, Scenario 2 = high watch scenario, Scenario 3 = unadjusted cases & excl. TB, Scenario 4 = alternate benchmark CTA 57

Figure 28. Comparison of actual (IQVIA MIDAS) vs. median estimated optimal by analysis scenario (rows) and AWARe category (columns) for CTAs in IQVIA MIDAS® with observed antibiotic use data available. Dashed line indicates where observed = expected. Scenario 1 = primary analysis, Scenario 2 = high watch scenario, Scenario 3 = unadjusted case counts & excl. TB, Scenario 4 = alternate benchmark CTA. Source: Actual DID based on IQVIA MIDAS® data for 2019, reflecting estimates of real-world activity. Copyright IQVIA. All Rights Reserved..... 93

LIST OF TABLES

Table 1. Summary of covariates included across the analysis workflow, data sources and process for dealing with missing data from the primary data source	11
Table 2. Covariates included per AWaRe antibiotic category for the multivariate model and priors on intercepts and covariates.	20
Table 3. Latent class model fitting showing variables not selected by the model comparing 1 to 6 clusters.	24
Table 4. Criteria used to select benchmark CTAs within each cluster for which IQVIA MIDAS data is available. For CTAs in IQVIA MIDAS where only retail sector was available, data were imputed for the missing sector and therefore Total DID, percent Access and Not Recommended DID are shown with their 95% CI. Infection deaths and infection incidence are the sum of infections of interest available in GBD.	28
Table 5. Values from Cluster 4 benchmark CTA (Switzerland) of DID of Reserve antibiotics covering Gram-positive/MDR&XDR TB and Gram-negative resistance pathogens.	36
Table 6. Highest DDDs per treatment course of the infections included in analysis for estimating Watch antibiotic use. Where the AWaRe Book recommends several Watch antibiotics, we used the Watch antibiotic with the highest DDD per treatment course. There are also several infections for which the first choice of treatment is recommended as either an Access or Watch antibiotic and for these we use the Watch DDD estimate unless otherwise stated in the case adjustments. Note that some oral antibiotics have higher DDDs than parenteral treatment recommended for the same infection.	37
Table 7. Table of the analysis scenarios used for estimating expected total and AWaRe antibiotic use.	43
Table 8. Summary table of the variables included in the different stages of the analysis workflow from imputation through estimates of optimal antibiotic levels.	44
Table 9. Model estimates from the Bayesian multivariate model for AWaRe antibiotic use modelled using IQVIA MIDAS® data for 67 CTAs.	48
Table 10. Table of characteristics for considered benchmark CTAs. Benchmark CTA selected from cluster 3 is used as the benchmark CTA to estimate minimum antibiotic need in clusters 1 and 2. Colombia is used only in a sensitivity analysis (scenario 4).	53
Table 11. Estimated expected global antibiotic use for Total, Access, Watch and Reserve in billions of defined daily doses (DDD) and DDD/1000 inhabitants/day (DID), and estimated expected global percentage of Access antibiotic use for each analysis scenario.	55
Table 12. Estimated optimal total defined daily doses/1000 inhabitants/year (DID) and Access, Watch and Reserve DID for all four analysis scenarios. Scenario 1 = primary analysis, Scenario 2 = high watch scenario, Scenario 3 = unadjusted cases & excl. TB, Scenario 4 = alternate benchmark CTA	58
Table 13. Estimated optimal percentage Access for each analysis scenario. Scenario 1 = primary analysis, Scenario 2 = high watch scenario, Scenario 3 = unadjusted cases & excl. TB, Scenario 4 = alternate benchmark CTA	89
Table 14. Estimated optimal total defined daily doses/1000 inhabitants/year (DID) and Access, Watch and Reserve DID for all four analysis scenarios compared to Actual DID in IQVIA MIDAS for 67 CTAs with available actual antibiotic use in IQVIA MIDAS. Scenario 1 = primary analysis, Scenario 2 = high watch scenario, Scenario 3 = unadjusted cases & excl. TB, Scenario 4 = alternate benchmark CTA	94

1 SUPPLEMENTAL METHODS




Figure 1. Factors that would be expected to impact on necessary antibiotic use for both total use and AWaRe antibiotic use. Created in BioRender. Cook, A. (2025) <https://BioRender.com/d94em8e>

1.1 DATA SOURCES AND PROCESSING

1.1.1 Antibiotic Use Data

IQIVA MIDAS® quarterly sales data for 2019 for antibiotics were obtained under license from IQVIA and reflect estimates of real-world activity (Copyright IQVIA. All rights reserved). Antibiotic data in 2019 covers 75 countries, territories and areas (CTAs); we excluded the aggregate areas of French West Africa and Central America and Hong Kong given unavailability of covariates leaving 72 CTAs. Antibiotic data is reported by kilograms of individual product and separately by healthcare sector (hospital or retail). We removed any antibiotics and combinations that were exclusively for tuberculosis and any combinations of methenamine (a urinary antiseptic). Kilograms were converted to defined daily doses (DDD) using the WHO/ATC methodology.⁽¹⁾ Where DDDs were unavailable for a given product on the WHO/ATC site, best efforts were made to find a relevant DDD to ensure as much data as possible was retained for analysis. Antibiotics that were from the “Not Recommended” AWaRe category or were in MIDAS® but unclassified by the AWaRe system were grouped together into a single “Not Recommended” category.⁽²⁾

Data were reported from the retail sector for all 72 CTAs and from the hospital sector for 46 CTAs. DDDs were summed separately by sector and AWaRe category and converted to DDD/1000 inhabitants/day (DID) using World Bank population estimates.

1.1.2 Infection data

We extracted 2019 incidence and mortality for infections where antibiotics are recommended in the WHO AWaRe Antibiotic book from the Global Burden of Disease 2021 release (GBD)⁽³⁻⁵⁾ where available, including cellulitis, upper respiratory infections, otitis media, lower respiratory infections (excludes hospital-acquired pneumonia (HAP)), , multi-drug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (for which non-TB-exclusive antibiotics are recommended), typhoid and paratyphoid, all-cause diarrhoea, urinary tract infections, chlamydia, syphilis, gonorrhoea, and trichomoniasis. Sepsis was not available in the GBD 2021, so incidence and mortality were extracted from a previous GBD publication for the year 2017; we assumed sepsis

rates were similar between 2017 and 2019.⁽⁶⁾ We include MDR and XDR TB cases because treatment recommendations include Watch (levofloxacin or moxifloxacin) and Reserve (linezolid) antibiotics in addition to exclusively TB medications.

The AWARe Book recommends antibiotics for bloody diarrhoea/dysentery, not for acute watery diarrhoea, therefore to estimate dysentery-specific cases of diarrhoea, we approximated using diarrhoeal bacterial aetiologies commonly associated with dysentery per the AWARe Book⁽⁷⁾: *Shigella* spp., enterotoxigenic *E. coli*, non-typhoidal *Salmonella* spp. and *Campylobacter* spp.⁸ Aetiology-specific and all-cause diarrhoea years lived with disability (YLD) were used from GBD.⁽⁸⁾ We estimated the incidence of each aetiology by estimating the non-fatal attributable fraction of all-cause diarrhoea cases attributed to each pathogen and multiplying this by the incident all-cause diarrhoea cases. Non-fatal attributable fraction was estimated using the YLDs for each aetiology divided by the YLDs for all-cause diarrhoea. That fraction was then multiplied by the total diarrhoea cases to get the aetiology-specific case counts. We used the same process to estimate incident cases of cholera. Diarrhoea aetiology-specific mortality is provided by GBD so this was used directly.

Estimates of incidence for non-GBD infections

For hospital infections in the AWARe Book but not included in GBD, such as hospital-acquired pneumonia (HAP)⁽⁹⁾ and intra-abdominal infections (IAI), these were estimated using data from alternate sources.

For HAP, we used surveillance data from the European Centres for Disease Prevention and Control (ECDC) from point prevalence surveys (PPS) on HAI for 2022-2023.⁽¹⁰⁾ ECDC estimates the total number of HAP cases per year in European hospitals therefore we used the estimate of the number of HAP cases per year in the participating CTAs (953,971 cases (95%CI: 626,128-1,449,959)) to estimate the number of HAP cases in other CTAs. We took the ratio of the total HAP cases in the ECDC HAI PPS CTAs to the sum of the LRI cases from GBD for the same CTAs. We then multiplied this ratio of HAP:LRI by the number of LRI cases in all other CTAs to estimate total number of HAP cases per CTA assuming the ratio between HAP:LRI is the same in all CTAs. This calculation was done draw-wise on 1000 draws from the distribution of ECDC HAP cases and 1000 draws from the distribution of LRI cases from GBD to account for uncertainty from both case estimates.

For IAI, we used data extracted from Versporten et al⁽¹¹⁾ (extracted from eTable2 in the publication) of the distribution of patients receiving antibiotics with each type of diagnosis included in the study.

We assume all IAI cases require antibiotics, thus took the ratio of the total IAI cases in the study to the total sepsis cases reported (ratio = 2.6 IAI cases to sepsis cases), assuming the case mix is similar across CTAs given limited data by region or CTA. Using this ratio, we multiply the GBD sepsis case estimates for each CTA by this ratio to get a national estimate of total IAI cases. This operation was repeated on 1000 draws from the distribution of sepsis cases to populate uncertainty around IAI cases.

1.1.3 Antibiotic resistance data

We used interim data from the GRAM project (see GRAM methods for complete details^(12,13)) to estimate incidence of infections caused by resistant pathogens, where resistance may require shifting AWARe category (e.g. where carbapenem resistance is common, sepsis treatment may more frequently be a Reserve antibiotic (e.g. colistin) than a Watch antibiotic). We focused on extended-spectrum beta-lactamase (ESBL) *Enterobacterales*, carbapenem-resistant *Acinetobacter baumannii* (CRAB), *Pseudomonas aeruginosa* (CRPA), *Enterobacterales* (CRE), methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin-resistant *Staphylococcus aureus* (VRSA) and *Enterococcus faecium* (VR-*E.faecium*).

First, we estimate of the relative prevalence of each bug-drug specific resistance pattern and relative prevalence of that pathogen within the total number of pathogens for each CTA. To estimate incidence of resistant cases of severe infections, we multiplied the proportions of resistance and proportions of pathogens by the case counts for sepsis from GBD (Equation 1).

$$\begin{aligned} \text{Cases of bug} - \text{drug } XY &= \text{Proportion of total caused by bug } X * \text{Proportion of bug } X \text{ resistant to drug } Y \\ &\quad * \text{sepsis cases} \end{aligned}$$

Equation 1. Formula for calculating cases of specific pathogen (bug) and antibiotic (drug) combinations where X represents pathogen of interest and Y represents antibiotic of interest.

1.1.4 Other covariate data

We included other covariates that may be associated with antibiotic use at a population level including proportion of population in different age groups (0-4, 5-14, 15-64, 65-74, 75+ years),^(14,15) proportion of population living in rural areas,^(16,17) proportion of population with comorbidities⁽¹⁸⁾, universal health coverage (UHC) index,^(19,20) vaccination coverage for pneumococcal vaccine⁽²¹⁻²³⁾ and rotavirus vaccine^(22,24,25), time to travel to health facilities⁽²⁶⁾, pharmacists^(27,28), doctors⁽²⁷⁻²⁹⁾ and nurses^(27,28,30) per 1,000 people, gross national income (GNI) per capita⁽³¹⁻³⁷⁾, proportion of population living beneath the \$2.15 per day poverty line⁽³⁸⁾, proportion of the population with access to safe sanitation⁽³⁹⁾. We also included malaria incidence estimates from GBD⁽⁵⁾ as febrile illnesses in malaria endemic areas are commonly treated with antibiotics even if unnecessary,⁽⁴⁰⁾ protein energy malnutrition prevalence estimates⁽⁵⁾ which can put people at risk of increased susceptibility to infection and worse infection outcomes and incidence of burns and wounds from road traffic accidents and fires as these injuries may be at risk of infection. Data sources for covariates are summarised in Table 1.

Where data was not in the primary data source, alternate data sources were sought to limit missing data as much as possible. Generally, we sourced as many years as possible of data between 1998 and 2023 for our covariates for processing even where there was missing data for the year of interest (2019). Linear interpolation using the *zoo* package in R was used in some cases to fill in missing years of data where data for 2019 was not available but at least two other years were available. Data processing for covariates is described below and in Table 1..

For healthcare workforce estimates of doctors, nurses and pharmacists per 1000 people, we used a mix of World Bank World Development Indicators,^(29,30) WHO Global Data Observatory⁽²⁷⁾ and Global Burden of Disease estimates.⁽²⁸⁾ For doctors and nurses per 1000 people, our primary data source was World Bank. Where data was missing for any CTA-years (1998-2023) from World Bank, we used estimates from WHO Global Data Observatory to fill in those years. If CTA-years were still missing after combining World Bank and WHO data, we used linear interpolation where at least two years of data were available to estimate 2019 work force. Data for pharmacists per 1000 people was only available in the WHO Global Data Observatory; linear interpolation was used to fill in missing years where at least two years of data were available. Where data was missing for CTAs for all years (i.e. no available data in World Bank or WHO), we used GBD estimates of healthcare workforce for doctors, nurses and pharmacists for 2019⁽²⁸⁾ for these CTAs.

Universal health coverage (UHC) service coverage index data was sourced from the World Bank World Development Indicators database⁽¹⁹⁾ which is a combined index measuring access to affordable essential healthcare using tracer indicators across the health spectrum. Generally, UHC was reported on evenly numbered years (e.g. 2016, 2018, etc) so linear interpolation was used to estimate coverage in the missing years. Where a CTA did not have any data available or only one year available in World Bank, alternate UHC index data were used from Global Burden of Disease estimates of progress towards Sustainable Development Goals.⁽²⁰⁾

Travel time to healthcare facilities was estimated using spatial raster files from Weiss et al.⁽²⁶⁾ which provide pixel-level estimates of motorised travel time to the nearest healthcare facility⁽⁴¹⁾. To derive CTA-level estimates, we combined these data with gridded population counts from WorldPop⁽⁴²⁾ and calculated population-weighted average travel time to healthcare for each CTA.

Vaccination coverage for pneumococcal conjugate vaccine (PCV) and rotavirus vaccine were downloaded from the WHO Immunization Data portal (<https://immunizationdata.who.int/global?topic=&location=>). For PCV, we used the coverage estimate of the percentage of children receiving the final dose as estimated by WHO/UNICEF estimates of national immunization coverage (WUENIC).⁽²³⁾ For rotavirus we used the estimates of percentage of children receiving the final dose (either 2 or 3 doses depending on which vaccine is used) as estimated by WUENIC⁽²⁵⁾. Where a coverage estimate wasn't available for a year, we checked whether the vaccine had been introduced in the CTA using data from VIEW-hub from the International Vaccine Access Center (IVAC).^(21,24) Where the year of universal introduction was after 2019, we assumed that vaccination coverage prior to this was zero; where the introduction status was indicated as "No Decision", "Gavi approved/approved with clarification", "Gavi plan to apply", "Program Suspended", "Non-Gavi planning introduction", or "Private Market Use", we also assumed coverage was 0 in the year of interest (this may have underestimated true coverage if there had been large private market use prior to universal introduction). Where vaccination coverage estimates were still missing for CTAs after checking introduction year (either no data in WUENIC or the vaccine had been introduced but no estimates), we used vaccination coverage estimates from the Global Burden of Disease study to fill in missing data.⁽²²⁾

Data on proportion of the population living below \$2.15 (2017 PPP) poverty line and proportion of the population with access to safe sanitation were sourced from World Bank.^(38,39) After interpolation, 40 CTAs were missing poverty estimates and 66 CTAs were missing sanitation estimates for 2019. CTAs missing data for 2019 were imputed using multiple imputation by chained equations (MICE) (see supplemental methods section 1.1.5 for details). Imputed values for safe sanitation were restricted to be not more than the proportion of population with access to basic sanitation⁽⁴³⁾ where this data was available in the same CTA (n=58/66).

Data for the proportion of population living with 1 or more comorbidity that contributes to higher risk of infection or worse infection outcomes was sourced from estimates of the population at increased risk of severe COVID-19 due to underlying health conditions⁽¹⁸⁾ with the assumption that these similar comorbidities also put people at risk of worse outcomes due to bacterial infections. Estimates were downloaded from the available tool for the proportion of the population with 1+ underlying condition

(<https://www.dropbox.com/scl/fi/2tvsjo8w58cz50htjekk7/Covid-19-analysis-v1.50-release.xlsb?rlkey=3rygfvghipue809slzuah8jlw&e=1&dl=0>; accessed 05 September 2023).

Table 1. Summary of covariates included across the analysis workflow, data sources and process for dealing with missing data from the primary data source

Covariate type	Variable	Primary Source	Dealing with missing data	References	Notes
Population demographics	Population age group proportions (0-4, 5-14, 15-64, 65-74, 75+)	World Bank	Taiwan is not in World Bank	World Bank Data Bank: Population estimates and projections; accessed 08/July/2024	
			Taiwan	Downloaded from the Taiwan Dept. of Household Registration Date accessed: 25/09/2023 https://www.ris.gov.tw/app/en/3910	
	Rural population proportion	World Bank	Taiwan is not in World Bank	World Bank Data Bank: World Development Indicators; Rural population (% of total pop); accessed 08/July/2024	
Income	GNI per capita	World Bank	Several CTAs did not have GNI per capita (Atlas method, USD) in World Bank so alternate sources for these were sought	World Bank Data Bank: World Development Indicators; GNI per capita, Atlas method (current US\$); accessed 08/July/2024 World Bank Country and Lending Groups; https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups ; accessed 08/July/2024	
			Taiwan (TWN)	National Statistics Republic of China (Taiwan); 09. National Economics and Business Activities: Per capita income and consumption; https://eng.stat.gov.tw/News_Content.aspx?n=4302&s=232171 ; accessed on 25/09/2023	
			Venezuela (VEN)	Maldonado, L., & Olivo, V. (2022). Is Venezuela Still an Upper-Middle-Income Country? Estimating the GNI per Capita for 2015–2021. https://doi.org/10.18235/0004612	
			American Samoa (ASM)	https://www.doc.as.gov/post/press-release-american-samoa-statistical-yearbook-2022	gross domestic income 2019: 647 million dollars; 8425\$ estimated per capita income 2020 census
			Eritrea (ERI)	https://data.un.org/Data.aspx?q=GNI+per+capita&d=SNA&f=grID%3a103%3bcurrID%3aUSD%3bpcFlag%3a1 ; accessed 15/Feb/2025	Per capita GNI at current prices - USD; year = 2019
			Greenland (GRL)	https://data.un.org/Data.aspx?q=GNI+per+capita&d=SNA&f=grID%3a103%3bcurrID%3aUSD%3bpcFlag%3a1 ; accessed 15/Feb/2025	Per capita GNI at current prices - USD; year = 2019
			Guam (GUM)	https://bsp.guam.gov/guam-statistical-yearbook-2/	Gross Domestic Income 2019: 6355 million dollars
			Northern Mariana Island (MNP)	Not found - excluded	
			North Korea (PRK)	National accounts statistics from here: https://kosis.kr/bukhan/statisticsList/statisticsListIndex.do?menuId=M_01_01_01&vwcd=MT_BUKHAN&rootId=101_001&parmTabId=M_01_01_01	per capita GNI in 2019 = 1408000 SK won, converted to USD on 15 Feb 2025;
			South Sudan (SSD)	https://data.un.org/Data.aspx?q=GNI+per+capita&d=SNA&f=grID%3a103%3bcurrID%3aUSD%3bpcFlag%3a1 ; accessed 15/Feb/2025	Per capita GNI at current prices - USD; year = 2019
			Yemen (YEM)	https://data.un.org/Data.aspx?q=GNI+per+capita&d=SNA&f=grID%3a103%3bcurrID%3aUSD%3bpcFlag%3a1 ; accessed 15/Feb/2025	Per capita GNI at current prices - USD; year = 2019

Covariate type	Variable	Primary Source	Dealing with missing data	References	Notes
	Proportion of population living below \$2.15 poverty line	World Bank	1. Where missing in World Bank, but available for at least two years between 1998 and 2023, used linear interpolation to fill in gaps (<i>zoo</i> package in R) 2. Where still missing for 2019 after linear interpolation (40 CTAs), did multiple imputation with chained equations	World Bank Data Bank: World Development Indicators; Poverty headcount ratio at \$2.15 a day (2017 PPP); accessed 05/July/2024	Missing in Afghanistan, Andorra, American Samoa, Antigua and Barbuda, Bahrain, The Bahamas, Bermuda, Barbados, Brunei Darussalam, Cuba, Dominica, Algeria, Eritrea, Equatorial Guinea, Grenada, Greenland, Guam, Guyana, Haiti, Cambodia, Kuwait, Lebanon, Libya, St. Lucia, Marshall Islands, Northern Mariana Islands, New Zealand, Oman, Papua New Guinea, Puerto Rico, North Korea, Qatar, Saudi Arabia, Singapore, Somalia, Suriname, Turkmenistan, Trinidad and Tobago, Taiwan, St. Vincent and the Grenadines; Note: WB has updated its poverty line to \$3.00 (2021 PPP) in June 2025
Healthcare workforce	Doctors per 1000 people	World Bank	Not all CTA-year combinations available in World Bank	World Bank Data Bank: World Development Indicators; Physicians (per 1000 people); accessed 08/July/2024	
		WHO Global Data Observatory	1. Where data was missing on number of doctors, used WHO Global Data Observatory estimate of number of medical doctors per 10,000 for all years 1998-2023 2. Where both WHO and World Bank were available but missing for 2019, used linear interpolation to fill in gaps given there were at least two data points available	The National health Workforce Accounts database, World Health Organization, Geneva; accessed 05/July/2024 (https://apps.who.int/nhwportal , https://www.who.int/activities/improving-health-workforce-data-and-evidence)	
		Global Burden of Disease	3. Data was further missing in seven CTAs - sought alternate sources from GBD	Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) Human Resources for Health 1990-2019. Seattle, United States of America: Institute for Health Metrics and Evaluation (IHME), 2022.	
	Nurses & midwives per 1000 people	World Bank	Not all CTA-year combinations available in World Bank	World Bank Data Bank: World Development Indicators; Nurses and midwives (per 1000 people); accessed 08/July/2024	
		WHO Global Data Observatory	1. Where data was missing on number of doctors, used WHO Global Data Observatory estimate of number of nursing and midwifery personnel per 10,000 for all years 1998-2023 2. Where both WHO and World Bank were available but missing for 2019, used linear interpolation (<i>zoo</i>) to fill in gaps given there were at least two data points available	The National health Workforce Accounts database, World Health Organization, Geneva; accessed 05/July/2024 (https://apps.who.int/nhwportal , https://www.who.int/activities/improving-health-workforce-data-and-evidence)	
		Global Burden of Disease	3. Data was missing in World Bank and WHO in seven CTAs - sought alternate sources from GBD	Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) Human Resources for Health 1990-2019. Seattle, United States of America: Institute for Health Metrics and Evaluation (IHME), 2022.	
	Pharmacists per 1000 people	WHO Global Data Observatory	1. Linear interpolation to fill in missing years where data is available for at least two years in WHO data (<i>zoo</i> package)	The National health Workforce Accounts database, World Health Organization, Geneva; accessed 05/July/2024 (https://apps.who.int/nhwportal , https://www.who.int/activities/improving-health-workforce-data-and-evidence)	

Covariate type	Variable	Primary Source	Dealing with missing data	References	Notes
		Global Burden of Disease	2. Missing in World Bank and WHO for 17 CTAs, sought alternate sources from GBD	Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) Human Resources for Health 1990-2019. Seattle, United States of America: Institute for Health Metrics and Evaluation (IHME), 2022.	
Healthcare access	UHC Index	World Bank	1. Data was available for 1998-2023 - used linear interpolation using <code>zoo</code> package in R where there were at least 2 years of data in the dataset	World Bank Data Bank: World Development Indicators; UHC Service Coverage Index; accessed 08/July/2024	
		Global Burden of Disease	2. GBD UHC coverage index used where the CTA didn't have any data available in World Bank/still missing after interpolation	Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2017 (GBD 2017) Health-related Sustainable Development Goals (SDG) Indicators 1990-2030. Seattle, United States of America: Institute for Health Metrics and Evaluation (IHME), 2018.	
	Population weighted time to travel to healthcare facilities	Literature - Malaria Atlas Project - Accessibility to Healthcare	None	Weiss, D. J., et al. (2020). "Global maps of travel time to healthcare facilities." <i>Nature Medicine</i> 26(12): 1835-1838. Raster file for motorized travel time to healthcare downloaded on 05 July 2024: https://malariaatlas.org/project-resources/accessibility-to-healthcare/	
	Healthcare Access & Quality Index (HAQI)	Global Burden of Disease		Haakenstad A, Yearwood JA, Fullman N, Bintz C, Bienhoff K, Weaver MR, et al.. Assessing performance of the Healthcare Access and Quality Index, overall and by select age groups, for 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019. <i>The Lancet Global Health</i> . 2022;10(12):e1715–43; Data accessed on 25 September 2025 from https://doi.org/10.6069/97EM-P280	
Infection prevention	PCV vaccination coverage proportion	WHO Immunization data	Where coverage wasn't available, checked whether the vaccine had been universally introduced (https://view-hub.org/vaccine/pcv?set=curent-vaccine-intro-status&group=vaccine-introduction&category=pcv) (accessed 06 July 2024); if it had not been introduced by 2019 or no decision made, assumed coverage was 0	https://immunizationdata.who.int/global/wiise-detail-page/pneumococcal-vaccination-coverage ; accessed 30 January 2024	Used the coverage of the third dose percentage using WUENIC estimates; assume coverage as 0 prior to universal introduction however this may underestimate true coverage if there is a large private market use
		Global Burden of Disease	Where introduction indicated it had been introduced but there was no estimate for coverage or no data at all from WUENIC, sought alternate data for coverage estimate in GBD	Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2020, Release 1 (GBD 2020 R1) Routine Childhood Vaccination Coverage 1980-2019. Seattle, United States of America: Institute for Health Metrics and Evaluation (IHME), 2021.; accessed 13 August 2024	
	Rotavirus vaccination coverage proportion	WHO Immunization data	Where coverage wasn't available, checked whether the vaccine had been universally introduced on VIEW-hub (https://view-hub.org/vaccine/rota?set=vaccine-introduction-over-time&group=vaccine-introduction&category=rv) (accessed 06 July 2024); if it had not been introduced by 2019 or no decision made, assumed coverage was 0	https://immunizationdata.who.int/global/wiise-detail-page/rotavirus-vaccination-coverage ; accessed 30 January 2024	Used the coverage of the final dose percentage using WUENIC estimates; assume coverage as 0 prior to universal introduction however this may underestimate true coverage if there is a large private market use
		Global Burden of Disease	Where introduction indicated it had been introduced but there was no estimate for coverage or no data at all from WUENIC, sought alternate data for coverage estimate in GBD	Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2020, Release 1 (GBD 2020 R1) Routine Childhood Vaccination Coverage 1980-2019. Seattle, United States of America: Institute for Health Metrics and Evaluation (IHME), 2021.; accessed 13 August 2024	

Covariate type	Variable	Primary Source	Dealing with missing data	References	Notes
	Proportion of population with access to safe sanitation	World Bank	Data missing for 66 CTAs and no option to interpolate for the missing years. We use multiple imputation using chained equations (mice) to impute the data, restricting the imputations to be below the percentage of population with access to basic sanitation services (World Bank) where that data is available	World Bank Data Bank: World Development Indicators; People Using safely managed sanitation services (% of population); accessed on 08 July 2024	
Comorbidities and other clinical risk factors	Proportion of population living with 1 or more comorbidities	CMMID modelled estimates	Missing in 7 CTAs	Clark, A., et al. (2020). "Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study." The Lancet Global Health 8(8): e1003-e1017.	Missing for Andorra (AND), American Samoa (ASM), Bermuda (BMU), Dominica (DMA), Greenland (GRL), Marshall Islands (MHL), Northern Mariana Islands (MNP)
	Malaria incidence	Global Burden of Disease	None	Institute for Health Metrics and Evaluation (IHME). GBD Results 2021. Seattle, WA: IHME, University of Washington, 2024. Available from https://vizhub.healthdata.org/gbd-results/ . (Accessed 05 July 2024)	
	Protein energy malnutrition prevalence	Global Burden of Disease	None	Institute for Health Metrics and Evaluation (IHME). GBD Results 2021. Seattle, WA: IHME, University of Washington, 2024. Available from https://vizhub.healthdata.org/gbd-results/ . (Accessed 05 July 2024)	
Infection incidence	Lower respiratory infection incidence		None		
	Upper respiratory infection incidence		None		
	Otitis media incidence		None		
	Gonorrhoea incidence		None		
	Chlamydia incidence	Global Burden of Disease	None	Institute for Health Metrics and Evaluation (IHME). GBD Results 2021. Seattle, WA: IHME, University of Washington, 2024. Available from https://vizhub.healthdata.org/gbd-results/ . (Accessed 05 July 2024)	
	Syphilis incidence		None		
	Trichomoniasis incidence		None		
	Cellulitis incidence		None		
	Burns and wounds from road traffic accidents and fires incidence		None		
	Dysentery incidence (<i>Shigella</i> spp., non-typhoidal <i>Salmonella</i> spp., Enterotoxigenic <i>E. coli</i> , <i>Campylobacter</i> spp.)		None; derived using aetiology-specific data as incidence by aetiology is not available		

Covariate type	Variable	Primary Source	Dealing with missing data	References	Notes
	Diarrhoea incidence		None		
	Typhoid incidence		None		
	Cholera incidence		None		
	UTI incidence		None		
	MDR and XDR TB incidence		None		
	Sepsis incidence		Data available for 194 CTAs; used the estimates for 2017 and assumed incidence similar for 2019	Rudd, K. E., et al. (2020). "Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study." The Lancet 395(10219): 200-211.	
	HAP incidence	Global PPS & Global Burden of Disease	Data available for 194 CTAs where sepsis estimates are available	Estimates of HAP cases in European countries (Table 22, page 103) of: ECDC (2024). Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals. Stockholm.	
	IAI incidence	Global PPS & Global Burden of Disease	Data available for 194 CTAs where sepsis estimates are available	Case mix of hospital infections (supplemental table 2): Versporten, A., et al. (2018). "Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: results of an internet-based global point prevalence survey." The Lancet Global Health 6(6): e619-e629. Sepsis estimates: Rudd, K. E., et al. (2020). "Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study." The Lancet 395(10219): 200-211.	

Covariate type	Variable	Primary Source	Dealing with missing data	References	Notes
	Necrotising fasciitis incidence	Global PPS & Global Burden of Disease	Data available for 194 CTAs where sepsis estimates are available	Case mix of hospital infections (supplemental table 2): Versporten, A., et al. (2018). "Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: results of an internet-based global point prevalence survey." <i>The Lancet Global Health</i> 6(6): e619-e629. Estimates of necrotising fasciitis out of hospital SSTI: Gomes Siqueira, G. L., et al. (2020). "Non-necrotizing and necrotizing soft tissue infections in South America: A retrospective cohort study." <i>Annals of Medicine and Surgery</i> 59: 24-30. AND Thean, L. J., et al. (2020). "Hospital admissions for skin and soft tissue infections in a population with endemic scabies: A prospective study in Fiji, 2018–2019." <i>PLOS Neglected Tropical Diseases</i> 14(12): e0008887. Sepsis estimates: Rudd, K. E., et al. (2020). "Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study." <i>The Lancet</i> 395(10219): 200-211.	
Antibiotic resistant infection incidence	ESBL sepsis incidence				
	Carbapenem-resistant <i>Acinetobacter baumannii</i> sepsis incidence				
	CR- <i>Pseudomonas aeruginosa</i> sepsis incidence	Global Research on Antimicrobial Resistance	Data available for 194 CTAs where sepsis estimates are available	Sepsis estimates from: Rudd, K. E., et al. (2020). "Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study." <i>The Lancet</i> 395(10219): 200-211.	
	CR-Enterobacterales sepsis incidence	(GRAM) and Global Burden of Disease		Resistance estimates: Murray, C. J. L., et al. (2022). "Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis." <i>The Lancet</i> 399(10325): 629-655. (data from unpublished GRAM modelling)	
	MRSA sepsis incidence				
	Vancomycin resistant <i>S. aureus</i> sepsis incidence				
	Vancomycin resistant <i>Enterococcus faecium</i> sepsis incidence				

1.1.5 Missing data imputation

Given our analysis focuses on national-level antibiotic use, we imputed missing data for the hospital sector for 26/72 CTAs in IQVIA MIDAS and for CTAs missing key covariates in 2019. We used *mice* package in R for multiple imputation using predictive mean matching method for hospital AWARe antibiotic DID. We used passive imputation for the CTA-level totals (summed values of hospital and retail sectors) for total Access, total Watch and total Reserve use and overall total DID. We also imputed proportion of the population with access to safe sanitation for 66 CTAs and proportion of the population living below the \$2.15 poverty line where missing for 40 CTAs. Predictive mean matching is a robust imputation method that uses a regression model to predict values for the missing data; it uses the observed values in the data to find “donor” values from the data to use to replace the missing value. This retains the distribution of the data and draws from realistic values. Passive imputation imputes the totals as sums of the separately imputed sector data to retain the relationships between the variables rather than imputing each variable separately. Variables selected for use in the imputation model focused on those used in the main analysis; where covariates were correlated with each other above 0.8 (absolute value), we retained only one of the covariate pair by priority of use in the main analysis with top priority given to infection and resistance covariates. We imputed data for all 186 CTAs to maintain the relationship between covariates and antibiotic use in the imputation model, however, only retained the antibiotic use estimates for CTAs in IQVIA MIDAS dataset and retained imputed poverty and sanitation for all CTAs.




Figure 2. Imputation matrix showing the variables used as predictors for imputation of each antibiotic and covariate of interest for the full MIDAS® dataset which includes Not Recommended antibiotics

1.1.6 Data processing post imputation

Where an imputed value for proportion of population with access to safe sanitation was greater than the proportion with access to basic sanitation (available in 58/66 CTAs from World Bank Development Indicators), we replaced the imputed value with the proportion with access to basic sanitation; for Taiwan we assumed access to safe sanitation was comparable to other HICs and all imputed values were replaced with 0.99. For computational reasons in downstream analyses, we also took the median of the imputations for safe sanitation and proportion living below the \$2.15 poverty line.

1.1.7 Re-classifying Not Recommended antibiotics to AWARe Category

The WHO AWARe system includes a list of “Not Recommended” antibiotics which are predominantly fixed dose combinations of two or more antibiotics or other products. We assume that expected “Not recommended” antibiotic use should be zero in all CTAs, therefore we did not include that as a category in our model. However, we assume that this total antibiotic use in CTAs where Not Recommended antibiotics are reported in MIDAS® is still needed, therefore we re-classified these antibiotics into a relevant AWARe category as if they were replaced with a similar antibiotic from the Access, Watch or Reserve categories.

To re-classify Not Recommended antibiotics into their relevant AWARe category (Access, Watch or Reserve), we mapped them to the highest AWARe category of the antibiotics in the antibiotic combination (where Access < Watch < Reserve). For example, the Not Recommended combination “Ampicillin+Cloxacillin” maps to Access since both antibiotics are Access, or “Amoxicillin+Clarithromycin+Omeprazole” maps to a derived

category of Watch given the Clarithromycin is a Watch antibiotic. After re-classifying these antibiotics, we recalculated the total DID by AWARe and repeated the missing data imputation by AWARe and hospital and retail sector when using these updated volumes through the same process described in supplemental methods section 1.1.5 and supplemental Figure 3.




Figure 3. Imputation matrix showing the variables used as predictors for imputation of each antibiotic and covariate of interest for the MIDAS® dataset with the re-classified Not Recommended antibiotics

1.2 STATISTICAL ANALYSIS




Figure 4. Study schema for deriving estimates of expected AWaRe antibiotic use based on infection burden, antibiotic resistance, socio-demographics, healthcare infrastructure and access using the WHO AWaRe book as a clinical framework. This figure is also presented in the main manuscript but is included here for ease. 1. Data preparation, 2. Missing data imputation, 3. Antibiotic use regression model, 4. Latent Class Model, 5. Benchmark CTA selection, 6. Estimate optimal total DID, 7. Estimate optimal Reserve DID, 8. Estimate optimal Watch DID, 9. Estimate optimal Access DID

1.2.1 Antibiotic use Regression model

We applied a Bayesian multivariate ecological regression model (Figure 4 Component 1) using CTA-level data to quantify how factors plausibly associated with antibiotic need such as infectious disease burden, ABR and other covariates () relate to antibiotic use volume across AWaRe categories.

We fit the model separately to 1000 imputed datasets, imputed after re-classifying “Not recommended” antibiotics to their relevant AWaRe category (see section 1.1.7). We used DDD/1000 inhabitants/year as the outcome instead of DID to avoid having to model values very close to zero for Reserve DID (<0.5 DID in most CTAs). To avoid that the model was fit on data from CTAs where antibiotic use may have unsafe low levels of antibiotics or implausibly low reported antibiotic use levels, we excluded CTAs where the majority (>50%) of imputed total DIDs were below 9.7 DID, the lowest value observed in a high-income CTA (the Netherlands). Five CTAs (China, Indonesia, Malaysia, Philippines, and Venezuela) were excluded on this basis leaving 67/72 CTAs for model fitting.

Covariates were defined a priori based on a review of the literature with model covariates for Access, Watch and Reserve use based on factors that have been documented in literature and clinical / structural plausibility to affect AWaRe antibiotic use. Covariates for each AWaRe antibiotic volume were specified separately to account for specific clinical and resistance variables that may be relevant to that AWaRe category specifically based on the literature and the AWaRe Book (Table 2). For example, incidence of carbapenem resistant infections were only included in the Reserve model, while sepsis incidence was included in both the Watch and Reserve models based on AWaRe Book & other treatment recommendations. Proportion of population of different age groups were treated as compositional variables for modelling as they contain relative information and the different parts sum to a whole. These types of variables need to be transformed for inclusion in most models because they violate the assumptions of independence (e.g. when the proportion of one age group decreases, another age group proportion increases). We consider these to be Aitchison compositions and use an isometric log-ratio transformation (R package: *compositions*⁽⁴⁴⁾) to transform the variables to be used in modelling.⁽⁴⁵⁻⁴⁷⁾ We excluded any variables in the regression model that were correlated with each other higher than 0.8 and

prioritised retaining infection and resistance data with higher disease burdens or antibiotic prescribing requirements. We used the point estimates of incidence per 100,000 people for all included GBD infection and resistance estimates.

We fit a Bayesian multivariate model with a gamma distribution using a log-link function. We used normal priors for the intercepts (Access, Watch and Reserve) deriving mean and standard deviation from the Browne et al. estimates of antibiotic use in 2018;⁽⁴⁸⁾ these were then log transformed given the model uses a log-link function. For the coefficients, we used horseshoe priors with a parameter ratio of 0.8 for the covariates. Horseshoe priors allow for variable selection and shrinkage of less relevant parameters. A parameter ratio of 0.8 assumes 80% of the predictors are relevant, which puts less shrinkage in the model than a lower parameter ratio.

Table 2. Covariates included per AWaRe antibiotic category for the multivariate model and priors on intercepts and covariates.

Model outcome	Covariates included	Priors on intercept	Priors on covariates
Access DI	GNI per capita, population age group ratio 1*, UHC coverage, population weighted travel time to healthcare facilities, PCV vaccine coverage, rotavirus vaccine coverage, rural population proportion, proportion of population with 1+ comorbidity, URI incidence, LRI incidence, typhoid incidence, dysentery incidence, UTI incidence, burns & wounds incidences, cellulitis incidence, bacterial STI incidence, MRSA incidence and ESBL incidence	Normal(8.21, 1.8)	Horseshoe priors with parameter ratio of 0.8
Watch DI	GNI per capita, population age group ratio 1*, UHC coverage, population weighted travel time to healthcare facilities, PCV vaccine coverage, rotavirus vaccine coverage, rural population proportion, proportion of population with 1+ comorbidity, LRI incidence, typhoid incidence, dysentery incidence, burns & wounds incidence, cellulitis incidence, sepsis incidence, UTI incidence, MDR/XDR TB incidence, MRSA incidence, ESBL incidence	Normal(7.78, 1.61)	Horseshoe priors with parameter ratio of 0.8
Reserve DI	GNI per capita, population age group ratio 1*, UHC coverage, rural population proportion, proportion of population with 1+ comorbidity, LRI incidence, burns & wounds incidence, cellulitis incidence, typhoid incidence, sepsis incidence, MDR/XDR TB incidence, ESBL incidence, CRO incidence, VRO incidence	Normal(2.49, 0.95)	Horseshoe priors with parameter ratio of 0.8

*DI = DDD/1000 Inhabitants/Year; converted from DID (DDD/1000 inhabitants/day) to shift small values away from zero; *population age group ratio 1 is an isometric log ratio of the relationship between the population age group proportions after transformation; only on of the four resulting ratios were retained for the model due to correlation.*

We initially planned to use the fitted model to predict expected optimal national volumes of Access, Watch, and Reserve antibiotic use for all 186 CTAs with available covariate data given each CTA's covariate profile. In this context, optimal antibiotic use refers to model-derived estimates based on the observed associations across all CTAs in the dataset. However, after reviewing the estimated model coefficients, we found that the posterior distributions were dominated by the intercepts, suggesting that the model captured overall antibiotic volume rather than variation explained by CTA-level covariates. We therefore did not use this model to generate predicted value of AWaRe antibiotic use (see Results section 2.1).

1.2.2 Optimal AWaRe Antibiotic Use Benchmarking

1.2.2.1 Overview

We developed an alternate benchmarking methodology for estimating expected optimal AWaRe antibiotic need. In brief, 186 CTAs with complete covariates were clustered into comparable “peer” clusters using latent class modelling, then within each cluster, a benchmark CTA was identified based on minimising total antibiotic use and infection mortality and high Access use percentage. These benchmark CTAs were then used to estimate

optimal total DID antibiotic need for other CTAs in the same cluster. We consider the benchmark CTA as an “optimal” antibiotic prescriber and this approach estimates optimal antibiotic need as though the infection burden for each CTA within a cluster is treated according to the prescribing practices of the benchmark CTA in that cluster (Figure 4:Component 2). Watch and Reserve DID are estimated given relevant infection and ABR burdens and Access is considered residual antibiotics after accounting for Watch and Reserve need.

1.2.2.2 Defining peer groups – clustering analysis

Commonly World Bank income group or WHO region are used to group CTAs to describe patterns of antibiotic use; ⁽⁴⁹⁻⁵¹⁾ however, there may still be differences in other factors such as infection incidence, antibiotic resistance or healthcare infrastructure (Figure 5 and Figure 6) within an income group or WHO region that may make these sub-optimal grouping for benchmarking.

To appropriately identify peer groups for comparison of antibiotic use, we used a Latent Class Model (LCM) and all considered covariates (n=40) across the factors that may influence antibiotic use to group the 186 analysis CTAs into clusters. Covariates were normalised prior to inclusion in LCM. LCM was performed using the R package *VarSelLCM*.^(52,53) This implementation of LCM was used because it allows for variable selection using the integrated complete-data likelihood, computes discriminative power of the variables and allows model comparison of different number of groups. We trialled different number of clusters between 1 and 6 groups, noting that current common methods to group CTAs include World Bank income group (4 clusters) and WHO regions (6 clusters). We used BIC for variable selection and for selection of optimal number of groups to avoid overfitting and prioritise a less complex model. See below for model fitting statistics (Table 3, Figure 7). We ordered clusters by mean GNI per capita within a cluster with cluster 1 being lowest income CTAs and cluster 4 being highest income CTAs.




Figure 5. Distribution of covariates by World Bank Income Group. GNI = gross national income, UHC = universal health coverage, LRI = lower respiratory tract infection, MDR & XDR TB = multi-drug resistant and extremely-drug resistant tuberculosis, URTI = upper respiratory tract infection, UTI = urinary tract infection, CR = carbapenem resistant, ESBL = extended-spectrum beta-lactamase, MRSA = methicillin-resistant *Staphylococcus aureus*, VR- *E. faecium* = vancomycin-resistant *Enterococcus faecium*, VR-*S. aureus* = vancomycin-resistant *Staphylococcus aureus*, Prop = proportion, pop = population, PCV = pneumococcal conjugate vaccine




Figure 6. Distribution of covariates by WHO Region. GNI = gross national income, UHC = universal health coverage, LRI = lower respiratory tract infection, MDR & XDR TB = multi-drug resistant and extremely-drug resistant tuberculosis, URTI = upper respiratory tract infection, UTI = urinary tract infection, CR = carbapenem resistant, ESBL = extended-spectrum beta-lactamase, MRSA = methicillin-resistant *Staphylococcus aureus*, VR- *E. faecium* = vancomycin-resistant *Enterococcus faecium*, VR-*S. aureus* = vancomycin-resistant *Staphylococcus aureus*, Prop = proportion, pop = population, PCV = pneumococcal conjugate vaccine

Table 3. Latent class model fitting showing variables not selected by the model comparing 1 to 6 clusters.

Latent Class Model fitting summary		
	Number of variables included in model	40
1 cluster	BIC	-10745.9
	Variables not used by the model	0
2 clusters	BIC	-7857.8
	Variables not used by the model	Rotavirus vaccination, PCV vaccination, URI incidence, MDR&XDR TB incidence
3 clusters	BIC	-6953.5
	Variables not used by the model	Rotavirus vaccination, PCV vaccination, URI incidence, MDR&XDR TB incidence
4 clusters	BIC	-6465.4
	Variables not used by the model	Rotavirus vaccination, PCV vaccination, URI incidence
5 clusters	BIC	-6265.0
	Variables not used by the model	Rotavirus vaccination, URI incidence
6 clusters	BIC	-6095.7
	Variables not used by the model	Rotavirus vaccination, PCV vaccination, URI incidence

BIC = Bayesian Information Criterion, MDR & XDR TB = multi-drug resistant and extremely-drug resistant tuberculosis, URTI = upper respiratory tract infection, PCV = pneumococcal conjugate vaccine




Figure 7. Bayesian information criterion (BIC) of latent class models considering 1 to 6 clusters using available covariates ($n=40$) for 186 analysis CTAs.

Benchmark CTA selection

Within each cluster, CTAs with total and AwaRe antibiotic use data in IQVIA MIDAS® available after imputation were identified; we excluded the 5 CTAs with total DID less than 9.7 DID as for the regression analysis. We compared total DID of antibiotics to infection mortality per 100,000 people and percentage of Access antibiotic use within each cluster. Supplemental Figure 8 shows infection incidence against infection mortality for all 186 CTAs with infection burden data with the IQVIA MIDAS CTAs highlighted.

In selecting benchmark CTAs, we aimed to minimise total antibiotic use and infection mortality while maximising percentage of Access use and aiming to select a benchmark CTA that used minimal DID of Not Recommended antibiotics (Figure 9). We first identified countries with low DID and low infection mortality then considered their percentage of Access. Given the previous WHO CTA-level target of Access antibiotic use was 60% of total use,⁽⁵⁴⁾ a benchmark CTA needed to meet a minimum of 60% Access to be selected, though many CTAs met a higher target. Where possible we then tried to select a CTA with low or zero Not Recommended antibiotic use. One benchmark CTA was selected for each cluster. Where there were several potential candidates based on the above criteria, we aimed to select a benchmark CTA in each cluster that was a similar or lower range of Healthcare Access and Quality Index⁽⁵⁵⁾ (HAQI) to the other CTAs in the cluster even if that meant antibiotic use was not the lowest in the cluster. This was done to ensure that the benchmark CTA more closely represented the CTAs it was going to be a benchmark for.

Where potential benchmark CTAs in a cluster had low antibiotic use but had higher infection mortality rates than the CTAs in the next cluster with similar antibiotic use levels (i.e. from Cluster 1 to 2, 2 to 3, 3 to 4, moving from lowest income CTAs to highest income CTAs), we considered that those CTAs would be inappropriate benchmarks as they may have possible antibiotic access issues (e.g. low antibiotic use but still higher mortality which could illustrate an access issue). Where there is no suitable benchmark CTA within a cluster, we benchmark to the CTA from the next cluster. However, we note that this represents a minimum estimated range of antibiotic use required for CTAs in that cluster given the higher infection mortality and lower HAQI in the lower clusters where more antibiotics than estimated are likely needed to treat the infection burden.




Figure 8. Point estimates of infection incidence vs. infection mortality by benchmark group and coloured by Healthcare Access and Quality Index (HAQI) showing the MIDAS® CTAs with available antibiotic use data available.




Figure 9. MIDAS® CTAs with available antibiotic use data by benchmark group (note: no benchmark group 1 CTAs had antibiotic use data available in MIDAS®) showing infection mortality per 100,000 people against total DID sized by % Access antibiotics and coloured by Healthcare Access and Quality Index (HAQI). Uncertainty bars are for infection mortality. Source: Total DID based on IQVIA MIDAS® data for 2019, reflecting estimates of real-world activity. Copyright IQVIA. All Rights Reserved

Table 4. Criteria used to select benchmark CTAs within each cluster for which IQVIA MIDAS data is available. For CTAs in IQVIA MIDAS where only retail sector was available, data were imputed for the missing sector and therefore Total DID, percent Access and Not Recommended DID are shown with their 95% CI. Infection deaths and infection incidence are the sum of infections of interest available in GBD.

CTA Name	ISO3 Code	Cluster	Income group	Sectors available in IQVIA MIDAS*	Total DID (95%CI)*	Infection deaths per 100K (95%CI)	Percent Access use*	Not Recommended DID (95%CI)*	Infection incidence per 100k (95%CI)
Sri Lanka	LKA	Cluster 2	Upper middle income	Retail Only	11.2 (10.1, 12.1)	95.4 (82.5, 110.1)	48 (43.3, 52.2)	0 (0, 0)	197939.2 (176202.8, 219449.9)
Peru	PER	Cluster 2	Upper middle income	Retail Only	14.5 (13.2, 16)	172.2 (153.7, 191.4)	47.1 (44.2, 50)	2.2 (2.1, 2.2)	254064.1 (227135.6, 283122)
South Africa	ZAF	Cluster 2	Upper middle income	Hospital and Retail	15.6 (15.6, 15.6)	323.6 (282.8, 371.9)	75.6 (75.6, 75.6)	0.2 (0.2, 0.2)	287747.6 (258798.2, 318324.1)
Kazakhstan	KAZ	Cluster 2	Upper middle income	Hospital and Retail	18.2 (18.2, 18.2)	96.7 (88.2, 106.1)	48.8 (48.8, 48.8)	0.4 (0.4, 0.4)	152525.3 (136912.2, 170662.7)
India	IND	Cluster 2	Lower middle income	Retail Only	18.3 (16, 21)	297.4 (269.6, 328.9)	27.1 (23.8, 37.8)	3.4 (3.3, 3.4)	178812.4 (161216.6, 196578.9)
Bangladesh	BGD	Cluster 2	Lower middle income	Retail Only	18.8 (16.8, 19.9)	180.1 (157.5, 206.3)	36.2 (32.8, 38.5)	1.7 (1.7, 1.8)	228939.2 (206622.5, 254310.9)
Thailand	THA	Cluster 2	Upper middle income	Hospital and Retail	23.6 (23.6, 23.6)	181.1 (163, 203.5)	72.2 (72.2, 72.2)	0.1 (0.1, 0.1)	247037.4 (223428.6, 275012.1)
Pakistan	PAK	Cluster 2	Lower middle income	Retail Only	24.6 (22, 27.4)	268.8 (238, 301.8)	48.9 (45.9, 53.7)	0.9 (0.9, 0.9)	244241.9 (221108.6, 272332)
Viet Nam	VNM	Cluster 2	Lower middle income	Hospital and Retail	26.4 (26.4, 26.4)	120.3 (108.1, 134.7)	51.3 (51.3, 51.3)	0.4 (0.4, 0.4)	174083.2 (154333, 198498.1)
Egypt, Arab Rep.	EGY	Cluster 2	Lower middle income	Hospital and Retail	33.9 (33.9, 33.9)	106.9 (95.6, 118.4)	52.9 (52.9, 52.9)	6.1 (6.1, 6.1)	163564.4 (146832.7, 182845)
Mexico	MEX	Cluster 3	Upper middle income	Retail Only	9.2 (7.9, 10.5)	121.3 (112.3, 131.5)	47.1 (40.2, 51.1)	0.7 (0.6, 0.7)	223039.8 (198026.4, 251299)
Kuwait	KWT	Cluster 3	High income	Retail Only	11.2 (10.1, 12.3)	32.5 (29.4, 35.9)	39.9 (36.1, 43.1)	0.4 (0.4, 0.4)	166596.6 (145822.8, 188933.3)
Jordan	JOR	Cluster 3	Upper middle income	Retail Only	11.9 (10.6, 13.7)	43 (38, 48.7)	56.6 (53.5, 61.2)	0.3 (0.3, 0.3)	155591.4 (136957.3, 176590.3)
Dominican Republic	DOM	Cluster 3	Upper middle income	Retail Only	12.3 (10.3, 14.7)	121.2 (107.7, 136.9)	58 (50.2, 63.5)	0.9 (0.9, 1)	190903 (170997.3, 214575.5)
Colombia	COL	Cluster 3	Upper middle income	Retail Only	12.9 (11.4, 14.5)	84.2 (77.2, 92)	63.8 (57.6, 67.4)	0 (0, 0)	237091.6 (212575.5, 266926.3)
Chile	CHL	Cluster 3	High income	Retail Only	13 (11.8, 14.5)	101.9 (93.6, 111.1)	56.5 (51.5, 59.2)	0.3 (0.3, 0.3)	230155.3 (205971.3, 257610.9)
Brazil	BRA	Cluster 3	Upper middle income	Retail Only	13.4 (11.8, 14.5)	163.1 (152.9, 174.2)	57.5 (50.7, 61.4)	0 (0, 0)	272313.9 (244863.2, 300855.9)

CTA Name	ISO3 Code	Cluster	Income group	Sectors available in IQVIA MIDAS*	Total DID (95%CI)*	Infection deaths per 100K (95%CI)	Percent Access use*	Not Recommended DID (95%CI)*	Infection incidence per 100k (95%CI)
Argentina	ARG	Cluster 3	Upper middle income	Retail Only	14.5 (13.9, 16.1)	223 (205.2, 243.1)	65.2 (63.4, 67.6)	0.6 (0.6, 0.6)	243767.1 (218516.7, 273409.6)
Taiwan	TWN	Cluster 3	High income	Hospital and Retail	15.7 (15.7, 15.7)	149.5 (137.1, 164.1)	67.9 (67.9, 67.9)	0.2 (0.2, 0.2)	134683.7 (121930.3, 149721.8)
Uruguay	URY	Cluster 3	High income	Retail Only	16.1 (15.7, 16.7)	196 (180, 215.1)	59.1 (58, 60.4)	0.3 (0.3, 0.3)	233880.6 (209173.6, 261594.9)
Morocco	MAR	Cluster 3	Lower middle income	Retail Only	16.6 (15.2, 18.4)	103.9 (90.1, 120.5)	71.3 (69, 73.3)	1.1 (1.1, 1.2)	206806.6 (184309.3, 232226.5)
Puerto Rico	PRI	Cluster 3	High income	Hospital and Retail	19.1 (19.1, 19.1)	151.4 (136.9, 168.2)	50.3 (50.3, 50.3)	0 (0, 0)	193291.2 (175469.8, 212595.9)
Saudi Arabia	SAU	Cluster 3	High income	Hospital and Retail	20.8 (20.8, 20.8)	44.2 (39.4, 49.3)	51.5 (51.5, 51.5)	0 (0, 0)	174821.8 (155065.9, 198814.1)
United Arab Emirates	ARE	Cluster 3	High income	Retail Only	27.7 (26.7, 28.6)	35.8 (30.1, 42.6)	44.4 (42.8, 46.1)	0.3 (0.3, 0.3)	169052.2 (146501.6, 193646.3)
Lebanon	LBN	Cluster 3	Upper middle income	Retail Only	28.6 (27.3, 30.4)	77.9 (70.2, 86.6)	58.2 (56.5, 59.6)	1.4 (1.4, 1.4)	162777.5 (144910.6, 183833.2)
Tunisia	TUN	Cluster 3	Lower middle income	Hospital and Retail	33.8 (33.8, 33.8)	66.9 (58, 79.5)	69 (69, 69)	2.2 (2.2, 2.2)	164720.9 (147306.9, 184867)
Türkiye	TUR	Cluster 3	Upper middle income	Hospital and Retail	34.2 (34.2, 34.2)	69.1 (62.1, 76.7)	52.2 (52.2, 52.2)	0.8 (0.8, 0.8)	228252.4 (203959.3, 256747.8)
Algeria	DZA	Cluster 3	Upper middle income	Retail Only	34.8 (33.7, 36.4)	62.3 (55.7, 69.1)	76.5 (75.7, 77.5)	2.6 (2.6, 2.6)	177522.7 (157500.6, 198704.8)
Ecuador	ECU	Cluster 3	Upper middle income	Retail Only	45.2 (43.4, 45.9)	124.9 (114.5, 136.4)	22.4 (21.8, 23.2)	1.5 (1.5, 1.6)	224433.5 (199522.2, 250329.2)
Netherlands	NLD	Cluster 4	High income	Hospital and Retail	9.7 (9.7, 9.7)	104.9 (96, 114.5)	71.2 (71.2, 71.2)	0 (0, 0)	188066.9 (171222.3, 208304.4)
Singapore	SGP	Cluster 4	High income	Hospital and Retail	11 (11, 11)	107.6 (97.2, 120.1)	61.2 (61.2, 61.2)	0 (0, 0)	221668.2 (196817.3, 248219.1)
Switzerland	CHE	Cluster 4	High income	Hospital and Retail	11 (11, 11)	72.3 (65.9, 78.7)	60.8 (60.8, 60.8)	0 (0, 0)	194355.2 (176293.3, 215214.8)
Latvia	LVA	Cluster 4	High income	Hospital and Retail	12.7 (12.7, 12.7)	114.7 (100.9, 130.4)	70.7 (70.7, 70.7)	0 (0, 0)	179845.2 (162656.9, 199002.6)
Japan	JPN	Cluster 4	High income	Hospital and Retail	12.8 (12.8, 12.8)	160.1 (141.4, 182.5)	17.9 (17.9, 17.9)	0 (0, 0)	225512.6 (204863.7, 253226.4)
Estonia	EST	Cluster 4	High income	Retail Only	13.5 (12.1, 14.9)	82 (73.7, 91.8)	58.1 (54.8, 60.7)	0 (0, 0)	178629.7 (160318.6, 197221)
Norway	NOR	Cluster 4	High income	Hospital and Retail	13.5 (13.5, 13.5)	100.7 (91, 111.1)	80.7 (80.7, 80.7)	0 (0, 0)	207336.2 (186603.4, 228786.7)

CTA Name	ISO3 Code	Cluster	Income group	Sectors available in IQVIA MIDAS*	Total DID (95%CI)*	Infection deaths per 100K (95%CI)	Percent Access use*	Not Recommended DID (95%CI)*	Infection incidence per 100k (95%CI)
Sweden	SWE	Cluster 4	High income	Retail Only	13.6 (13.1, 14.5)	86.9 (79.7, 95.6)	70.7 (68.2, 72.4)	0 (0, 0)	206009.3 (186138.6, 226924.2)
Finland	FIN	Cluster 4	High income	Hospital and Retail	13.7 (13.7, 13.7)	61.6 (56.1, 68.5)	75 (75, 75)	0.3 (0.3, 0.3)	186109.7 (168888.4, 207787.3)
Germany	DEU	Cluster 4	High income	Hospital and Retail	14 (14, 14)	106.1 (96.3, 116.7)	57.2 (57.2, 57.2)	0.1 (0.1, 0.1)	191886.2 (174329.8, 210963.2)
Austria	AUT	Cluster 4	High income	Hospital and Retail	14.8 (14.8, 14.8)	63.1 (57.3, 68.6)	59.7 (59.7, 59.7)	0.2 (0.2, 0.2)	190386.4 (173339.8, 211020.9)
Hungary	HUN	Cluster 4	High income	Hospital and Retail	15.2 (15.2, 15.2)	98 (88.7, 108.4)	50.3 (50.3, 50.3)	0 (0, 0)	136699.5 (123952.8, 150929.3)
Slovenia	SVN	Cluster 4	High income	Retail Only	15.7 (15.2, 16.3)	84.9 (77.5, 93.6)	71.1 (69.5, 72.5)	0 (0, 0)	135177.5 (122272.2, 150758.1)
Canada	CAN	Cluster 4	High income	Hospital and Retail	15.8 (15.8, 15.8)	77.1 (70.3, 83.9)	67.9 (67.9, 67.9)	0 (0, 0)	296605.9 (266332.8, 328329.7)
Lithuania	LTU	Cluster 4	High income	Hospital and Retail	16.7 (16.7, 16.7)	113.9 (102, 127.9)	70 (70, 70)	0.1 (0.1, 0.1)	180409.6 (162101.1, 198836.2)
Russian Federation	RUS	Cluster 4	Upper middle income	Hospital and Retail	17.1 (17.1, 17.1)	126.8 (113.7, 140.7)	47.2 (47.2, 47.2)	1.4 (1.4, 1.4)	197108.4 (177994.9, 220286.7)
Czechia	CZE	Cluster 4	High income	Hospital and Retail	17.6 (17.6, 17.6)	112.1 (103.9, 122.5)	56.1 (56.1, 56.1)	1.1 (1.1, 1.1)	139234.8 (126348.8, 153889.1)
United Kingdom	GBR	Cluster 4	High income	Hospital and Retail	19.7 (19.7, 19.7)	146.9 (134.7, 162.3)	66.8 (66.8, 66.8)	0 (0, 0)	203521.9 (184385.8, 225771.7)
Portugal	PRT	Cluster 4	High income	Hospital and Retail	20.8 (20.8, 20.8)	189.4 (172.1, 210.3)	62.2 (62.2, 62.2)	0.1 (0.1, 0.1)	187600.2 (169661.8, 207084.8)
Croatia	HRV	Cluster 4	High income	Hospital and Retail	21.2 (21.2, 21.2)	103.4 (95.3, 113.5)	63 (63, 63)	0 (0, 0)	145251.8 (130997.4, 162232.4)
Bulgaria	BGR	Cluster 4	Upper middle income	Hospital and Retail	22.3 (22.3, 22.3)	132.1 (118, 149.8)	46 (46, 46)	0.3 (0.3, 0.3)	135930.5 (122806.2, 149547.3)
Poland	POL	Cluster 4	High income	Hospital and Retail	22.8 (22.8, 22.8)	124.8 (115.9, 134.8)	54.9 (54.9, 54.9)	1.3 (1.3, 1.3)	147707.2 (133726.2, 164581.5)
Australia	AUS	Cluster 4	High income	Hospital and Retail	22.8 (22.8, 22.8)	60 (54.4, 66.4)	80.9 (80.9, 80.9)	0 (0, 0)	227663.1 (205682.4, 251802.9)
Slovak Republic	SVK	Cluster 4	High income	Hospital and Retail	23 (23, 23)	101.4 (91.8, 112.1)	35.9 (35.9, 35.9)	2.5 (2.5, 2.5)	140303.1 (125935.8, 156595)
Belarus	BLR	Cluster 4	Upper middle income	Hospital and Retail	23.5 (23.5, 23.5)	84.7 (74.7, 95.6)	55.2 (55.2, 55.2)	1.9 (1.9, 1.9)	184081.6 (165903.6, 202843.5)
United States	USA	Cluster 4	High income	Hospital and Retail	23.7 (23.7, 23.7)	87.4 (79.9, 95.4)	70.5 (70.5, 70.5)	0 (0, 0)	284895.5 (257427.6, 312333.6)

CTA Name	ISO3 Code	Cluster	Income group	Sectors available in IQVIA MIDAS*	Total DID (95%CI)*	Infection deaths per 100K (95%CI)	Percent Access use*	Not Recommended DID (95%CI)*	Infection incidence per 100k (95%CI)
Bosnia and Herzegovina	BIH	Cluster 4	Upper middle income	Retail Only	23.8 (22.1, 26.2)	102.6 (90, 118.5)	64.9 (63.2, 66.7)	1 (1, 1.1)	140733.7 (126776, 155850.8)
New Zealand	NZL	Cluster 4	High income	Hospital and Retail	24.1 (24.1, 24.1)	61.5 (56.5, 67.2)	79.5 (79.5, 79.5)	0 (0, 0)	252252.9 (226792.5, 281215.5)
Italy	ITA	Cluster 4	High income	Hospital and Retail	24.7 (24.7, 24.7)	82.6 (75, 90.8)	46.6 (46.6, 46.6)	0 (0, 0)	189354.8 (171742, 209623.2)
France	FRA	Cluster 4	High income	Hospital and Retail	25.1 (25.1, 25.1)	97.8 (89.3, 107.3)	69.7 (69.7, 69.7)	1.1 (1.1, 1.1)	188792.7 (171673.6, 209189.2)
Korea, Rep.	KOR	Cluster 4	High income	Hospital and Retail	25.2 (25.2, 25.2)	75.4 (66, 84.3)	45.1 (45.1, 45.1)	0.5 (0.5, 0.5)	213820.4 (188409.3, 240782.7)
Luxembourg	LUX	Cluster 4	High income	Retail Only	25.2 (23.8, 26.9)	67.3 (60, 75.4)	57.5 (55.5, 59.5)	0.2 (0.2, 0.2)	192543.2 (173067.8, 213175.5)
Ireland	IRL	Cluster 4	High income	Hospital and Retail	25.3 (25.3, 25.3)	76.5 (69, 85.2)	66 (66, 66)	0 (0, 0)	198651.1 (179133.4, 221366.6)
Belgium	BEL	Cluster 4	High income	Hospital and Retail	25.6 (25.6, 25.6)	144.1 (131, 159.4)	61.8 (61.8, 61.8)	0 (0, 0)	190406.2 (172714.3, 210182.8)
Spain	ESP	Cluster 4	High income	Hospital and Retail	26.9 (26.9, 26.9)	105.1 (96, 115.1)	62.7 (62.7, 62.7)	0.4 (0.4, 0.4)	184253.9 (163627.3, 204942.2)
Romania	ROU	Cluster 4	High income	Hospital and Retail	27.3 (27.3, 27.3)	141.5 (129.1, 155.8)	52.2 (52.2, 52.2)	0.4 (0.4, 0.4)	137499.9 (123642.9, 153304.5)
Serbia	SRB	Cluster 4	Upper middle income	Retail Only	29.3 (28.9, 30)	139.9 (123.3, 161.3)	55.7 (54.9, 56.4)	0.6 (0.6, 0.7)	179842.4 (159325.6, 200563.4)
Greece	GRC	Cluster 4	High income	Retail Only	37.5 (36.7, 38.8)	135.7 (123.9, 148.7)	43.8 (42.6, 44.5)	0.3 (0.3, 0.3)	177029.2 (160878.2, 197280)

Source: Total DID based on IQVIA MIDAS® data for 2019, reflecting estimates of real-world activity. Copyright IQVIA. All Rights Reserved

1.2.2.3 Infection draws for uncertainty

To account for uncertainty from GBD infection case estimates throughout the analytical pipeline for estimating optimal Total and AWaRe antibiotic need, we sampled 1000 draws from the distribution of each infection in GBD using the point estimate, upper and lower bounds. Distributions were selected by finding the best fit distribution for each CTA for each infection by minimising the sum of the squared errors (differences between fitted data and observed mean, upper and lower CIs); the most common best fit distribution across CTAs for each infection type was used (i.e. log-normal).

Matrices of case counts per CTA are used in the final estimation of Watch and Reserve antibiotics using the benchmarking approach; for other stages of analysis matrices of incident cases per 100,000 people is used. We drew from the distribution of the case counts for each infection then summed the matrices of infection cases to have a matrix of total infection cases; this was then converted to incidence per 100,000 people using population estimates.

Resistant sepsis cases were converted to incidence as cases per 100,000 people. For estimating resistant cases as outlined in section 1.1.3, for each of the pathogen, resistance and sepsis datasets, we used point estimates and uncertainty intervals to draw 1000 draws from a gamma distribution for each pathogen and bug-drug combination and sepsis cases for each CTA to then calculate the number of resistant sepsis cases for each bug-drug combination of interest which resulted in 1000 draws of resistant cases for each bug-drug combination for each CTA.

1.2.2.4 Adjusted case counts

To assess the infections that may need adjusting due to potential underestimates in GBD, we plotted number of doctors per 1000 people against the infection incidence (per 100,000 people) of all infections from GBD (Figure 10A). A positive relationship exists between doctors per capita and UTI and cellulitis (Figure 10B and Figure 10C). We considered this trend a potential sign of underdiagnosis of these infections where there were fewer doctors per 1000 people and therefore wanted to adjust case counts in these lower doctor areas for estimating expected antibiotic use.




Figure 10. A) Plot of doctors per 1000 people against infection incidence for infections included in GBD. B) Zoomed plot of doctors per 1000 people against urinary tract infection (UTI) incidence and C) Zoomed plot of doctors per 1000 people against cellulitis incidence where we see an increasing relationship

To adjust for this, we fit a logistic growth curve model separately for the relationship between doctors per 1000 people and incidence to datasets containing each one of the 1000 draws per CTA from the incidence distribution for UTI and cellulitis respectively and then predicted cases and adjusted for residuals. The logistic growth curve model was defined as (Equation 2):

$$f(x) = \frac{L}{(1 + e^{-k(x-x_0)})}$$

Equation 2. Logistic growth curve model. L = the asymptote, the maximum value as the curve approaches carrying capacity, k = the growth rate, and x_0 = the inflection point

where L = the asymptote, the maximum value as the curve approaches carrying capacity, k = the growth rate, and x_0 = the inflection point. The model was fit to each dataset where y = infection incidence and x = doctors per 1000 people using nonlinear least squares with Levenberg-Marquardt algorithm.^(56,57) Using the fitted parameters, we then define the threshold x_t which finds the x value where the logistic curve is within a tolerance of L with tolerance defined as 0.01 for our purpose (Equation 3) Equation 3. Threshold definition.:

$$\text{Threshold } x_t = x_0 + \frac{\ln\left(\frac{1}{\text{tolerance}} - 1\right)}{k}$$

Equation 3. Threshold definition. x_0 = inflection point

We adjust the UTI and cellulitis incidence where *number of doctors* (x) $< x_t$ and use observed incidence values where *number of doctors* (x) $\geq x_t$. We adjust incidence using the predicted value from the logistic curve + an adjustment defined as the difference between incidence at the threshold (y_{x_t}) and the predicted value. A sample of the predicted adjusted values vs original observed values are in Figure 11A (UTI) and Figure 11B (cellulitis)




Figure 11. Scatterplot of the adjusted incidence (blue) compared to observed incidence (red) on a subset of 100 draws for A) UTI and B) cellulitis.

1.2.2.5 Optimal antibiotic use benchmarking

An overview of the process for estimating optimal AwaRe antibiotic use is in supplemental Figure 4 and supplemental Figure 12.




Figure 12. Overview of the process to estimate expected AwaRe antibiotic use in defined daily doses (DDD) per 1000 inhabitants per day (DID).

1.2.2.5.1 Expected Total DID

For each benchmark CTA in each cluster, the ratio of total DID to total infection incidence was calculated taken using the reported total DID from MIDAS® and total infection incidence (Equation 4). For each non-benchmark CTA in the cluster, the respective benchmark ratio was multiplied by the total infection incidence in each CTA to estimate the total DID required to treat that infection burden (Equation 5). This was repeated at the draw-level for 1000 imputations of antibiotic use data where the benchmark CTA had imputed data and the 1000 draws of total infection incidence for each CTA in the cluster. For subsequent operations, these estimates of expected total DID were converted to DDD using World Bank population estimates.

Benchmark ratio:

$$\text{Benchmark ratio} = \frac{\text{Total DID in benchmark CTA}}{\text{Total infection incidence in benchmark CTA}}$$

Equation 4. Ratio from benchmark CTAs used to estimate Total DID for CTAs within each cluster. CTA = countries, territories and areas, DID = defined daily doses per 1000 inhabitants per day

Total DID estimate:

$$\begin{aligned} \text{Total DID (nonbenchmark CTA)} \\ = (\text{Benchmark ratio for cluster}) * (\text{Total infection incidence in respective CTA}) \end{aligned}$$

Equation 5. Equation for estimating Total DID for each CTA in a cluster. CTA = countries, territories and areas, DID = defined daily doses per 1000 inhabitants per day

1.2.2.5.2 Expected Reserve antibiotic use estimation

We use a similar approach for estimating Reserve antibiotic need as Total antibiotic need. We used the ratio of Reserve antibiotics to resistant infections from the cluster 4 benchmark CTA in each dataset to estimate the total Reserve antibiotics each CTA would require. We use only the cluster 4 benchmark CTA as it is a high-income CTA and we assume there are no access issues to Reserve antibiotics in this CTA. In MIDAS®, antibiotic use is

reported separately by molecule, so we summed the separate volumes (DDDs) of Reserve antibiotics covering Gram-negative infections (carbapenem-resistant infections) and Gram-positive (vancomycin-resistant infections) and MDR/XDR TB infections separately for cluster 4 benchmark CTA. This allowed us to account for differing burdens in Gram-negative and Gram-positive and TB resistant infections from the benchmark CTA to non-benchmark CTAs. Table 5 presents the antibiotics, median DDD, median infection incidence (95% CI) used for benchmarking. The respective ratios from the benchmark CTA were multiplied by the respective infection burden of CR-infections and VR-infections and MDR/XDR TB for all non-benchmark CTAs. Resistance-specific Reserve needs were summed to estimate total Reserve needs.

To account for resistant infection incidence uncertainty, the ratio operation was repeated draw-wise across the 1000 draws for each respective resistance pattern. Each ratio from the benchmark CTA was multiplied draw-wise by the 1000 draws of respective resistance patterns for the non-benchmark CTAs. Estimates of optimal Reserve are presented as median and 95%CI.

Table 5. Values from Cluster 4 benchmark CTA (Switzerland) of DID of Reserve antibiotics covering Gram-positive/MDR&XDR TB and Gram-negative resistance pathogens.

Resistance pattern	Antibiotic(s) in dataset	Resistance incidence (per 100,000 people)	Antibiotic DID*	Antibiotic DDD*
VRO (VRSA, VR-E.faecium, MDR/XDR TB)	Dalbavancin, Daptomycin, Linezolid, Tedizolid	VRO: 0.047 MDR/XDR TB: 0.0225	0.018	56378.0
CRO (CRE, CRAB, CRPA)	Aztreonam, Ceftaroline-fosamil, Ceftazidime+Avibactam, Ceftolozane+Tazobactam, Colistin, Fosfomycin, Tigecycline	CRO: 0.53	0.002	6420.7

*Note: Switzerland is the cluster 4 (predominantly high income) benchmark CTA. DDD = defined daily doses, DID = DDD/1000 inhabitants/day, VRO = vancomycin resistant organism, VRSA = vancomycin-resistant Staphylococcus aureus, VR-E.faecium = vancomycin-resistant Enterococcus faecium, MDR/XDR TB = multi-drug-resistant/extremely-drug-resistant tuberculosis, CRO = carbapenem resistant organism, CRE = carbapenem resistant Enterobacterales, CRAB = carbapenem resistant Acinetobacter baumannii, CRPA = carbapenem-resistant Pseudomonas aeruginosa. *Source: Total DID based on IQVIA MIDAS® data for 2019, reflecting estimates of real-world activity. Copyright IQVIA. All Rights Reserved*

1.2.2.5.3 Expected Watch antibiotic use estimation

We estimated Watch antibiotic needs based on the case counts of conditions where the AWaRe Book recommends Watch antibiotics and the DDDs of the recommended treatment courses for these infections. From GBD, we include sepsis, typhoid, dysentery, lower respiratory infections and urinary tract infections and MDR TB cases. We include MDR TB cases in Watch as current treatment guidelines include levofloxacin or moxifloxacin (Watch antibiotics). We estimated the burden of hospital infections covered in the AWaRe Book that require Watch antibiotics which do not have estimates in GBD such as severe skin and soft tissue infections (i.e. necrotising fasciitis), hospital-acquired pneumonia (HAP) and intra-abdominal infections using alternate sources (described in section 1.1.2).

The AWaRe Book provides risk-stratified guidance for antibiotic selection and for some infections such as LRIs and UTIs Watch antibiotics are only recommended for more severe infections. Given that GBD does not differentiate between upper and lower UTIs and doesn't estimate severity of LRIs, we assumed only a proportion of the cases for UTI and LRIs may require a Watch antibiotic (see below). We also adjust typhoid case counts to account for treatment needs of suspected typhoid cases in endemic areas (see below).

After adjusting the case counts for each infection, we use the maximum DDDs per treatment course for each infection as recommended in the AWaRe Book or other relevant guideline (Table 6) and multiply the case counts by DDDs for a total DDDs required for each infection. For typhoid where the antibiotic choice can differ due to fluoroquinolone resistance, we use the ciprofloxacin DDD for primary analysis and conduct sensitivity analyses using DDD of alternate treatment choices. This operation is performed on 1000 draws from the distribution of cases for each infection. These estimates are summed to a total Watch need per CTA and converted to DID using population estimates and presented as median and 95% CI.

Watch DDDs per Infection

Table 6. Highest DDDs per treatment course of the infections included in analysis for estimating Watch antibiotic use. Where the AWaRe Book recommends several Watch antibiotics, we used the Watch antibiotic with the highest DDD per treatment course. There are also several infections for which the first choice of treatment is recommended as either an Access or Watch antibiotic and for these we use the Watch DDD estimate unless otherwise stated in the case adjustments. Note that some oral antibiotics have higher DDDs than parenteral treatment recommended for the same infection.

Infection	Antibiotic	Treatment course from AwaRe book	WHO DDD for administration	Total DDDs for a treatment course
Severe diarrhoea / Dysentery	Azithromycin	500mg on day 1 + 250mg once daily for 3 days	0.3g	4.2 DDDs
Cholera	Azithromycin	1g oral single dose	0.3g	3.3 DDDs
Clinical sepsis of unknown origin	Cefotaxime	2g every 8 hours for 7 days	4g	10.5 DDDs
Lower respiratory tract infections (community acquired pneumonia) (severe CAP)	Cefotaxime + Clarithromycin (if CURB-65 $\geq$ 2)	2g every 8 hours for 5 days (Cefotaxime) + 500mg every 12 hours for 5 days (Clarithromycin)	4g, 1g (parenteral Clarithromycin)	12.5 DDD (7.5 DDD Cefotaxime, 5 DDD Clarithromycin)
Lower respiratory tract infections (Hospital acquired pneumonia) (severe)	Cefotaxime	2g every 8 hours for 7 days	4g	10.5 DDDs

Infection	Antibiotic	Treatment course from AwaRe book	WHO DDD for administration	Total DDDs for a treatment course
Typhoid¹	Ciprofloxacin (recommended for mild and severe cases where low risk of fluoroquinolone resistance)	500mg twice daily for 10 days (severe)	1g for oral	10 DDDs
	Azithromycin (recommended for mild cases where there is high risk of fluoroquinolone resistance)	1g on day 1, 500mg every 24 hours for 7 days	0.3g for oral	15 DDD
Upper UTI (severe cases)²	Ciprofloxacin	500mg twice daily for 7 days	1g for oral	7 DDDs
Chlamydia (uncomplicated urogenital infection)	Azithromycin	1g single dose (oral)	0.3g for oral	3.3 DDD
Gonorrhoea (genital / anorectal infections)	Ceftriaxone + Azithromycin	Ceftriaxone 250mg IM + Azithromycin 1g oral single dose	2g parenteral ceftriaxone 0.3g oral azithromycin	3.425 DDD (0.125 DDD ceftriaxone; 3.3 DDD azithromycin)
Multi-drug-resistant Tuberculosis³	Levofloxacin (* weight-based dosing so have used max for adult)	2x500mg tablets per day of Levofloxacin for 26 weeks (26 x 7 x 1000mg = 182g)	0.5g (oral)	364 DDDs Levofloxacin
Extensively drug-resistant Tuberculosis⁴	Levofloxacin (where there is fluoroquinolone susceptibility)	2x500mg tablets per day of Levofloxacin for 87 weeks (87 x 7 x 1000mg = 609g)	0.5g (oral)	1218 DDDs Levofloxacin
Intra-abdominal infections⁵	Cefotaxime (for mild and severe)	2g every 8 hours (3 x per day) for 5 days = 30g	4g	7.5 DDD
SSTIs (necrotising fasciitis)	Piperacillin/ tazobactam	4g + 500mg every 6 hours for 2-3 weeks (14-21 days) = 4.5 x 4 x 21	14g	27 DDD

¹ Per the AwaRe Book, for typhoid where there is high-risk of fluoroquinolone resistance, recommended to use azithromycin for mild cases (7 days) and ceftriaxone for severe cases (10 days) (10 days of IV ceftriaxone or ciprofloxacin – recommended in low risk of fluoroquinolone resistance) have the same DDDs).

² Per the AwaRe Book, the maximum DDDs of Watch antibiotics to treat upper UTI is when using Ciprofloxacin (7 DDDs); severe cases may require IV antibiotics (Cefotaxime or Ceftriaxone) but Watch DDD per treatment course is lower than ciprofloxacin.

³ A rapid communication in June 2024 on updates to TB treatment guidelines for MDR-TB^(58,59) indicated that a 6-month treatment with bedaquiline, delamanid, linezolid (600mg), levofloxacin and clofazimine could be used instead of the 9-month oral regimen. Where there is fluoroquinolone resistance, recommended to drop levofloxacin, however we have included it for all cases in our estimates.

⁴ For XDR-TB, longer treatment regimens of 18-months recommended⁽⁵⁹⁾; levofloxacin and moxifloxacin are not to be used where there is fluoroquinolone resistance in XDR TB however, we have assumed all XDR-TB cases receive a fluoroquinolone for 18 months for our estimates.

⁵ For most IAI, the AwaRe Book also recommends Access antibiotics (oral amoxicillin/clavulanic acid) as a first-line treatment option and recommends adding metronidazole to either amoxicillin/clavulanic acid or third-generation cephalosporin first choice.

Adjustments for suspected typhoid:

We consider that there is diagnostic uncertainty for typhoid in endemic areas given poor diagnostics available^(60,61) and nonspecific symptoms of typhoid such as fever, fatigue, and diarrhoea⁽⁶²⁾ where it may be reasonable for suspected typhoid cases to be treated with Watch antibiotics to prevent the adverse outcomes of untreated typhoid. While diagnostic uncertainty exists even in non-endemic settings, suspected typhoid treatment in typhoid endemic CTAs may have a higher influence on required Watch antibiotics at a national level than in non-endemic settings. In some surveillance studies between 3 to 33 suspected typhoid cases are

diagnosed for every confirmed typhoid case.^(63,64) We assume that GBD estimates of typhoid are confirmed cases, thus would need to be adjusted to estimate suspected typhoid cases that may require antibiotic treatment with Watch antibiotics. Therefore, for CTAs where median typhoid incidence per 100,000 in GBD is above 50 cases per 100,000 people (Figure 13), we multiplied the case counts by 10 (Surveillance of Enteric Fever in Asia Project estimate⁽⁶³⁾) to estimate a higher burden of suspected typhoid that may require antibiotic treatment in these CTAs. In low typhoid CTAs, we have used the typhoid case count as in GBD.




Figure 13. The median typhoid incidence per 100,000 people from GBD for 186 CTAs, territories and areas (CTAs) in the analysis with cut-offs at 10 cases per 100,000, 50 cases per 100,000 and 100 cases per 100,000. CTAs are coloured by cluster assignment.

Upper urinary tract infections requiring Watch antibiotics

The proportion of UTIs cases that may be upper UTIs and thus requiring a Watch antibiotic per the AWaRe Book was estimated using the Clinical Practice Research Datalink (CPRD) Aurum database⁽⁶⁵⁾ (protocol number: 23_003072) a UK database of representative general practices (GP) and has been used extensively as it provides anonymised data for public health research. The database contains information on patients' GP practice, demographic characteristics, diagnoses and symptoms, prescriptions, vaccination history, laboratory tests, and specialist referrals. We estimated the split of cases between upper and lower UTI in CPRD among patients with any UTI diagnosis who received any antibiotic prescription. We first used explicit diagnosis codes for lower and upper UTI, and then for those without an explicit diagnosis code for differentiation, we used the antibiotic treatment choice per NICE guidelines^(66,67) as a proxy for differentiating between upper and lower UTIs. Sensitivity analyses for these estimates were performed using different scenarios for treatment length. The largest estimated percentage (20.7%) from the sensitivity analyses were used to estimate the upper UTI from the total estimated UTI cases for all CTAs (Figure 14). We assumed this proportion does not vary by CTA for the purpose of this analysis. We multiply our adjusted UTI cases counts (see section 1.2.2.4) by this percentage to get the number of UTI cases assumed to upper UTI cases that would require Watch antibiotics (Figure 15A).




Figure 14. A figure describing the process of estimating what percentage of urinary tract infections (UTIs) could be upper UTIs and thus requiring Watch antibiotics per the AWARe Book. The figure outlines the classification strategy for assumed lower UTI requiring Access antibiotics and upper UTI requiring Watch antibiotics from cases in Clinical Practice Research Datalink (CPRD) between 2015 and 2021. The figure shows three scenarios and we use scenario 2 for our analysis which gives the highest estimate of upper UTI (21%).

Lower respiratory infections

The AWARe Book recommends Watch antibiotics for severe LRIs such as severe community-acquired pneumonia or hospital-acquired pneumonia and Access antibiotics for mild to moderate community-acquired pneumonia. GBD LRI case count includes pneumonia and bronchiolitis but excludes HAP.⁽⁹⁾ For estimating the cases of severe CAP that would require Watch antibiotics, we assume 15% of LRI cases from GBD are severe CAP which would require Watch antibiotics⁽⁹⁾ (Figure 15B). We assume this proportion did not vary by CTA

for primary analyses. We use separate estimates for HAP that require Watch antibiotics (see section 1.1.2) and assume that all HAP cases are treated with Watch antibiotics.




Figure 15. Illustration of the subset of cases from GBD considered A) Upper UTI and B) severe LRI used for estimating Watch antibiotic use out of total cases. For UTI, in the primary analysis, the subset of cases was taken after adjusting the case counts (described in supplemental methods 1.2.2.4)

Other hospital infections requiring Watch antibiotics

For severe infections such as intra-abdominal infections (IAI), and necrotising fasciitis (NF), which are included in the AWARe Book as significant infections that may require Watch antibiotics but which do not have estimates in Global Burden of Disease (GBD), we approximated the burden of these infections using Global PPS data (see section 1.1.2 for IAI and below for NF). Using these approximated incidence estimates for total infections, we then adjust the cases to estimate the number of cases that would require a Watch antibiotic for IAI, and NF.

For IAI that could receive Watch antibiotics, for primary analyses, we assumed 80% of patients received one of the first-choice antibiotics in the AWARe Book – either amoxicillin/clavulanic acid (Access) or a third-generation cephalosporin (cefotaxime or ceftriaxone) (Watch) and that 75% of those received a third-generation cephalosporin (Watch). We assume that the remaining 20% of patients also received a Watch antibiotic giving a percentage of total IAI that received Watch antibiotics of 80% ($0.8 * 0.75 + 0.2$).

For severe skin and soft tissue infections (SSTIs) such as necrotising fasciitis (NF) where the AWARe Book recommends a Watch antibiotic (all other SSTI are recommended to receive Access), GBD estimates of cellulitis include the ICD-10 codes for NF thus these infections are already included in the total infection count for our analysis. There are no national estimates of necrotising fasciitis so we assume all NF cases would be hospitalised and derive estimates of NF cases using hospital data from global PPS using the same method as for IAI described in section 1.1.2. For estimating the subset of SSTIs that require Watch antibiotics, we assume that NF accounts for 5% of hospitalised SSTIs^(68,69). Using this percentage, we scale the total SSTIs reported in Versporten et al⁽¹¹⁾ to estimate the number of cases that could be NF and then take the ratio of these cases to reported sepsis cases in gPPS (ratio = 0.2 NF cases to sepsis). This ratio was multiplied by the GBD estimate of total sepsis cases in each CTA to get an estimate of NF cases in each CTA. We did not adjust for length of stay in PPS as this information was unavailable. We use hospitalised SSTI data for estimating the cases of NF based on reported data in gPPS rather than adjusting 5% of all cellulitis SSTIs as this would over-inflate the number of NF cases due to the high number of mild SSTIs included in the overall estimate from GBD.

1.2.3 Sensitivity analyses

Our primary analysis (scenario 1) used the adjusted case counts as described in the methods above to estimate optimal antibiotic levels required. We conducted three sensitivity analyses to explore the impact of our assumptions of case counts on expected antibiotic use and the impact of benchmark CTA selection. The four analysis scenarios are summarised in Table 7.

For scenario 2, we estimate an upper level of optimal Watch DID antibiotics. Given our case adjustments for suspected typhoid and estimates of proportion of cases of LRI, UTI and hospital infections that may require antibiotics primarily affect the estimates of Watch antibiotics, we look at higher estimates of suspected typhoid and higher estimates of upper UTI and severe LRI cases and HAIs. We use the same total infection incidence with inflated case counts as in the main scenario. For optimal Watch DID, we inflate suspected typhoid cases to be 25 times higher than the GBD estimated typhoid burden in CTAs where incidence was greater than 10 per 100,000 (Figure 13). We also use a higher DDD for typhoid of 15 DDD which is a treatment course of 7 days of azithromycin (instead of 10 DDD for ciprofloxacin or ceftriaxone) (Table 6). We assume that 30% of UTI cases are upper UTI cases in all clusters.⁽⁷⁰⁾ For LRI, in clusters 1, 2 and 3 we assume that 30% of LRI are severe^(71,72) while for cluster 4 assume 20% are severe.⁽⁷³⁾ We assumed 100% of IAI cases received a Watch antibiotic. For NF, we assume that 15% of hospitalised SSTIs⁽⁷⁴⁾ are NF and follow the same process to take the ratio (ratio = 0.5 NF to sepsis cases) and then multiply by the GBD sepsis cases to get the total cases of NF that would require Watch antibiotics.

For scenario 3, we estimate a lower bound of total and AWaRe antibiotic use by using the case counts as reported directly from GBD without any adjustments for suspected typhoid, or underestimates of UTI and cellulitis. We also exclude MDR/XDR TB from these estimates as TB treatments can be procured under different programs in some CTAs. For typhoid, we use 10 DDD which is the DDD for 10 days of ciprofloxacin or ceftriaxone. Total infection incidence is the sum of infection incidence as reported in GBD. We assume that 20% of UTI cases are upper UTI and that 15% of LRI cases are severe across all benchmark groups.

For scenario 4, we select a different benchmark CTA in benchmark group 3 by using Colombia which has a lower total DID than Morocco (as used in primary analyses) to compare the impact of benchmark CTA selection on estimates of total and AWaRe antibiotic use. We use the same infection parameters as in scenario 1 (primary analysis) and only change the benchmark CTA.

Table 7. Table of the analysis scenarios used for estimating expected total and AWaRe antibiotic use.

	Scenario 1	Scenario 2	Scenario 3	Scenario 4
Scenario description	Primary analysis	Sensitivity analysis 1 - Upper estimate of Watch ("high Watch" scenario)	Sensitivity analysis 2 - lower estimate of Total, Watch and Access ("unadjusted case counts, excl. TB" scenario)	Sensitivity analysis 3 - impact of benchmark CTA selection ("alternate benchmark CTA" scenario)
Antibiotic use data	MIDAS® dataset post imputation	MIDAS® dataset post imputation	MIDAS® dataset post imputation	MIDAS® dataset post imputation
Benchmark CTA	Clusters 1, 2, 3: Morocco Cluster 4: Switzerland	Clusters 1, 2, 3: Morocco Cluster 4: Switzerland	Clusters 1, 2, 3: Morocco Cluster 4: Switzerland	Clusters 1, 2, 3: Colombia Cluster 4: Switzerland
Total infection incidence	- GBD infection incidence per 100,000 people as reported (no adjustment) for LRI, URI, OM, syphilis, gonorrhoea, chlamydia, trichomoniasis, sepsis, MDR+XDR TB - Adjusted case counts for UTI and cellulitis for potential underestimation - HAP estimated from ECDC - IAI estimated using gPPS data	- GBD infection incidence per 100,000 people as reported for LRI, URI, OM, syphilis, gonorrhoea, chlamydia, trichomoniasis, sepsis, MDR+XDR TB - Adjusted case counts for UTI and cellulitis for potential underdiagnosis - HAP estimated from ECDC - IAI estimated using gPPS data	- GBD infection incidence per 100,000 people as reported (no adjustment) for LRI, URI, OM, syphilis, gonorrhoea, chlamydia, trichomoniasis, sepsis, MDR+XDR TB - No additional hospital infections estimated from gPPS	- GBD infection incidence per 100,000 people as reported (no adjustment) for LRI, URI, OM, syphilis, gonorrhoea, chlamydia, trichomoniasis, sepsis, MDR+XDR TB - Adjusted case counts for UTI and cellulitis for potential underestimation - HAP estimated from ECDC - IAI estimated using gPPS data
Watch scenario	- Adjusted case counts for UTI and cellulitis for potential underestimation - Inflated typhoid cases 10x GBD where incidence was >50 per 100,000 cases 20% of adjusted UTI cases assumed to be upper UTI across all CTAs 15% LRI cases considered severe CAP 80% of IAI cases get Watch 100% of HAP cases 5% of hospitalised SSTI in gPPS are necrotising fasciitis	- Adjusted case counts for UTI and cellulitis for potential underestimation - Inflated typhoid 25x GBD where incidence was >10 per 100,000; used higher DDD of 15 DDD per treatment course (azithromycin course) 30% of adjusted UTI cases assumed to be upper UTI 30% of LRI cases considered severe CAP in clusters 1, 2, 3 (predominantly LMIC), 20% in cluster 4 (predominantly HIC) 100% of IAI cases 100% of HAP cases 15% of hospitalised SSTI in gPPS are necrotising fasciitis	- Case counts as reported in GBD for all infections (no adjustments for potential underestimation); - No typhoid inflation for suspected typhoid 20% of UTI assumed to be upper UTI 15% of LRI cases assumed to be severe - No additional hospital Watch infections from gPPS or ECDC - Excludes MDR/XDR TB	- Adjusted case counts for UTI and cellulitis for potential underestimation - Inflated typhoid cases 10x GBD where incidence was >50 per 100,000 cases 20% of adjusted UTI cases assumed to be upper UTI across all CTAs 15% LRI cases considered severe CAP 80% of IAI cases get Watch 100% of HAP cases 5% of hospitalised SSTI in gPPS are necrotising fasciitis
Reserve scenario	Ratio of cases GNB and GPB/MDR&XDR TB to Reserve DDD by coverage category	Ratio of cases GNB and GPB/MDR&XDR TB to Reserve DDD by coverage category	Ratio of cases GNB and GPB/MDR&XDR TB to Reserve DDD by coverage category	Ratio of cases GNB and GPB/MDR&XDR TB to Reserve DDD by coverage category
Access scenario	Difference between estimated total DDD and estimated Watch + Reserve	Difference between estimated total DDD and estimated Watch + Reserve	Difference between estimated total DDD and estimated Watch + Reserve	Difference between estimated total DDD and estimated Watch + Reserve

CAP = community acquired pneumonia; CTA = countries, territories and areas; DDD = defined daily dose; ECDC = European Centre for Disease Prevention and Control; GBD = Global Burden of Disease; GNB = Gram-negative bacteria; GPB = Gram-positive bacteria; gPPS = Global Point Prevalence Survey; HAP = Hospital acquired pneumonia; HIC = high income CTAs; IAI = intra-abdominal infection; LMIC = lower and middle income CTAs; LRI = lower respiratory infection; MDR TB = multidrug resistant tuberculosis; OM = Otitis media; URI = upper respiratory infection; UTI = urinary tract infection; XDR TB = extensively drug resistant tuberculosis

Table 8. Summary table of the variables included in the different stages of the analysis workflow from imputation through estimates of optimal antibiotic levels.

	Modelling stage	Imputation		Bayesian model			Clustering analysis	Benchmark CTA selection	Estimating optimal antibiotic use			
	Antibiotic data	MIDAS® use (with Not recommended)	MIDAS® antibiotic use (with re-classified Not recommended)	MIDAS® antibiotic use (with re-classified Not recommended)			N/A	IQVIA MIDAS® use (with Not recommended)	Total DID	Reserve	Watch	Access ¹
				Access DID	Watch DID	Reserve DID		Total DID, percent Access, DID Not recommended				
Category of Covariate	Covariate											
Population age	Proportion of population 0-4											
	Proportion of population 5-14											
	Proportion of population 15-64											
	Proportion of population 65-74											
	Proportion of population 75+											
	Proportion of population living in rural areas											
	Isometric log-ratio population age group 1 ²											
	Isometric log-ratio population age group 2											
	Isometric log-ratio population age group 3											
	Isometric log-ratio population age group 4											
	GNI per capita											
Income	Proportion of population living below the \$2.15 poverty line											
Healthcare workforce	Doctors per 1000 people											
	Nurses & midwives per 1000 people											
	Pharmacists per 1000 people											
Healthcare access	UHC coverage index											
	Population-weighted travel time to healthcare facilities											
Infection prevention	Rotavirus vaccination coverage proportion											
	PCV vaccination coverage proportion											
	Proportion of population with access to safe sanitation											

	Modelling stage	Imputation		Bayesian model			Clustering analysis	Benchmark CTA selection	Estimating optimal antibiotic use			
		MIDAS® use (with Not recommended)	MIDAS® antibiotic use (with re-classified Not recommended)	MIDAS® antibiotic use (with re-classified Not recommended)			N/A	IQVIA MIDAS® use (with Not recommended)	Total DID	Reserve	Watch	Access¹
	Antibiotic data			Access DID	Watch DID	Reserve DID		Total DID, percent Access, DID Not recommended				
Comorbidities & other clinical risk factors	Proportion of population with 1+ relevant comorbidity											
	Malaria incidence³											
	Burns and wounds from road traffic accidents and fires incidence											
	Protein energy malnutrition prevalence											
Infection incidence (used as per 100,000 people; except used as cases for estimating expected Watch antibiotics)⁴	Lower respiratory infection incidence											
	Upper respiratory infection incidence											
	Otitis media incidence											
	Gonorrhoea incidence											
	Chlamydia incidence											
	Syphilis incidence											
	Bacterial STI incidence (sum of gonorrhoea, chlamydia, syphilis)											
	Trichomoniasis incidence											
	Cellulitis incidence											
	Dysentery incidence (Shigella spp., non-typhoidal Salmonella spp., Enterotoxigenic E. coli, Campylobacter spp.)											
	Diarrhoea incidence											
	Typhoid incidence											
	Cholera incidence											
	UTI incidence											
	Sepsis incidence	Correlated with UHC, MRSA, dysentery	Correlated with UHC, MRSA, dysentery									
	MDR and XDR TB incidence											

	Modelling stage	Imputation		Bayesian model			Clustering analysis	Benchmark CTA selection	Estimating optimal antibiotic use			
	Antibiotic data	MIDAS® use (with Not recommended)	MIDAS® antibiotic use (with re-classified Not recommended)	MIDAS® antibiotic use (with re-classified Not recommended)			N/A	IQVIA MIDAS® use (with Not recommended)	Total DID	Reserve	Watch	Access ¹
				Access DID	Watch DID	Reserve DID						
Antibiotic Resistance								Total DID, percent Access, DID Not recommended				
	HAP incidence ⁵											
	IAI incidence ⁵											
	Necrotising fasciitis incidence ⁵											
	Total infection incidence											
	ESBL sepsis incidence											
	Carbapenem-resistant Acinetobacter baumannii sepsis incidence											
	CR-Pseudomonas aeruginosa sepsis incidence											
	CR-Enterobacterales sepsis incidence											
	CR-organisms sepsis incidence (sum of CRAB, CRPA, CRE)											
	MRSA sepsis incidence											
	Vancomycin resistant S. aureus sepsis incidence											
	Vancomycin resistant Enterococcus faecium sepsis incidence											
	Vancomycin-resistant organism sepsis incidence (sum of VRSA, VR-E.faecium)											
Aggregate infection estimates	Infection mortality rate (excludes TB)	Correlated with dysentery incidence	Correlated with dysentery incidence									
	Total infection incidence											

¹Note: Access is the difference between estimated Total DID and Reserve & Watch therefore not explicitly calculated with variables

²Note highly correlated with other population age group ratios so only used one

³Note: Malaria excluded from clustering because incidence was heavily zero skewed and in trials this was a very discriminative variable likely due to few CTAs having high incidence

⁴Note where infections are not listed individually as used in a step, they are all included in the total infection incidence which is used for benchmarking & total DID estimation

⁵HAP/IAI/Necrotising fasciitis incidences are derived using ECDC, Global PPS data and GBD data therefore are not included in sensitivity analysis scenario 3 which uses GBD data as is

2 SUPPLEMENTAL RESULTS

2.1 ANTIBIOTIC USE REGRESSION MODEL




Figure 16. Results of antibiotic use regression model showing the distribution of the posterior draws and 95%CrI for Access, Watch and Reserve antibiotic use. DID = defined daily doses (DDD)/1000 inhabitants/year. GNI = gross national income; UHC = universal health coverage; PCV = pneumococcal vaccine; LRI = lower respiratory infection; URI = upper respiratory infection; UTI = urinary tract infection; STI = sexually transmitted infection; MDR & XDR TB = multidrug resistant and extensively drug resistant tuberculosis; ESBL = extended spectrum beta-lactamase producing *Enterobacterales*; MRSA = methicillin-resistant *staphylococcus aureus*; CRO = carbapenem resistant organism; VRO = vancomycin-resistant organism

Table 9. Model estimates from the Bayesian multivariate model for AWaRe antibiotic use modelled using IQVIA MIDAS® data for 67 CTAs.

AWaRe Antibiotic Use	Variable	Estimate (95% CI)
Access	Intercept	8.4 (8.26, 8.57)
	GNI per capita	-0.01 (-0.08, 0.03)
	Population age group	-0.01 (-0.12, 0.03)
	UHC index	-0.01 (-0.11, 0.06)
	Travel time to healthcare facilities	-0.01 (-0.13, 0.05)
	PCV vaccine coverage	-0.01 (-0.07, 0.03)
	Rotavirus vaccine coverage	-0.01 (-0.08, 0.03)
	Proportion of population living in rural areas	0.01 (-0.03, 0.13)
	Proportion of population with comorbidities	-0.01 (-0.1, 0.04)
	URI incidence (per 100k)	0 (-0.05, 0.05)
	LRI incidence (per 100k)	0 (-0.09, 0.05)
	Typhoid incidence (per 100k)	-0.01 (-0.11, 0.04)
	Dysentery incidence (per 100k)	0.01 (-0.06, 0.16)
	UTI incidence (per 100k)	-0.02 (-0.14, 0.02)
	Burns and wounds incidence (per 100k)	0 (-0.07, 0.03)
	Cellulitis incidence (per 100k)	0.01 (-0.02, 0.07)
	Bacterial STI incidence (per 100k)	-0.01 (-0.08, 0.03)
Watch	MRSA incidence (per 100k)	-0.02 (-0.2, 0.04)
	ESBL incidence (per 100k)	-0.02 (-0.17, 0.04)
	Intercept	8.03 (7.61, 8.28)
	GNI per capita	-0.05 (-0.2, 0.02)
	Population age group	0.02 (-0.04, 0.17)
	UHC index	-0.01 (-0.18, 0.11)
	Travel time to healthcare facilities	0.01 (-0.1, 0.16)
	PCV vaccine coverage	0.03 (-0.04, 0.16)
	Rotavirus vaccine coverage	-0.01 (-0.11, 0.05)
	Proportion of population living in rural areas	0.04 (-0.04, 0.22)
	Proportion of population with comorbidities	-0.03 (-0.18, 0.04)
	LRI incidence (per 100k)	-0.03 (-0.25, 0.06)
	Typhoid incidence (per 100k)	0.01 (-0.08, 0.16)
	Dysentery incidence (per 100k)	-0.01 (-0.24, 0.15)
	Burns and wounds incidence (per 100k)	-0.01 (-0.09, 0.06)
	Cellulitis incidence (per 100k)	-0.04 (-0.13, 0.02)
	Sepsis incidence (per 100k)	-0.16 (-1.21, 0.09)
Reserve	UTI incidence (per 100k)	0 (-0.06, 0.08)
	MDR & XDR TB incidence (per 100k)	-0.01 (-0.15, 0.07)
	MRSA incidence (per 100k)	0 (-0.16, 0.15)
	ESBL incidence (per 100k)	0.14 (-0.03, 0.61)
	Intercept	2.9 (2.45, 3.36)
	GNI per capita	0.06 (-0.08, 0.39)
	Population age group	0.02 (-0.13, 0.27)
	UHC index	0.01 (-0.27, 0.4)
	Proportion of population living in rural areas	0.15 (-0.07, 0.72)
	Proportion of population with comorbidities	0.05 (-0.14, 0.41)
	LRI incidence (per 100k)	0.02 (-0.17, 0.27)
	Burns and wounds incidence (per 100k)	-0.08 (-0.37, 0.06)
	Cellulitis incidence (per 100k)	0.02 (-0.07, 0.17)
	Typhoid incidence (per 100k)	-0.02 (-0.37, 0.22)
	Sepsis incidence (per 100k)	0.03 (-0.35, 0.67)
	MDR & XDR TB incidence (per 100k)	0 (-0.2, 0.24)
	ESBL incidence (per 100k)	0.33 (-0.05, 1.08)
	CRO incidence (per 100k)	0.07 (-0.12, 0.44)
	VRO incidence (per 100k)	0 (-0.31, 0.31)

*Note: Estimates are on the DDD/1000 inhabitants/year scale not the DDD/1000 inhabitants/day (DID) scale. GNI = gross national income; UHC = universal health coverage; PCV = pneumococcal conjugate vaccine; URI = upper respiratory infection; LRI = lower respiratory infection; STI = sexually transmitted infection; UTI = urinary tract infection; MDR & XDR TB = multi-drug resistant and extremely-drug resistant tuberculosis; MRSA = methicillin-resistant *Staphylococcus aureus*; ESBL = extended-spectrum beta-lactamase; CRO = carbapenem resistant organism; VRO = vancomycin resistant organism

2.2 OPTIMAL AWARE ANTIBIOTIC USE BENCHMARKING

2.2.1 Clustering analysis

Discriminative power of variables (4 clusters)




Figure 17. Discriminative power of the variables included in the four groups cluster model. Negative bars indicate the variable was not discriminative and was not used by the model.




Figure 18. Distribution of covariates by cluster for the four-group cluster model. GNI = gross national income, UHC = universal health coverage, LRI = lower respiratory tract infection, MDR & XDR TB = multi-drug resistant and extremely-drug resistant tuberculosis, URTI = upper respiratory tract infection, UTI = urinary tract infection, CR = carbapenem resistant, ESBL = extended-spectrum beta-lactamase, MRSA = methicillin-resistant *Staphylococcus aureus*, VR- *E. faecium* = vancomycin-resistant *Enterococcus faecium*, VR-*S. aureus* = vancomycin-resistant *Staphylococcus aureus*, Prop = proportion, pop = population, PCV = pneumococcal conjugate vaccine




Figure 19. Comparison of cluster assignments to World Bank Income Groups.




Figure 20. Comparison of cluster assignments to WHO regions .

2.2.2 Benchmark CTA selection

Based on our criteria for selecting benchmark CTAs of low total DID with low infection mortality and at least 60% Access antibiotic use (the highest percentage Access where possible) and with low use of “Not recommended” antibiotics, ideally 0, we identified a clear benchmark CTA in cluster 4 (Switzerland). There were no suitable benchmark CTAs in clusters 1 and 2 as no CTAs in cluster 1 had antibiotic data in MIDAS and cluster 2 CTAs had higher infection mortality than CTAs in cluster 3 and low use of Access antibiotics. There were two possible CTAs that could be benchmark CTAs in cluster 3 (which would also be minimum benchmark CTAs for clusters 1 and 2): Morocco and Colombia with slight differences between them (Figure 21). We use Morocco as the benchmark CTA in primary analyses and scenarios 2 and 3 and we used Colombia in scenario 4 to demonstrate the influence of the chosen benchmark CTA on the estimates of expected optimal antibiotic use. We do not use Colombia as the benchmark CTA in primary analyses because they also report data to GLASS AMU which shows higher DID than in MIDAS (19.8 vs. 12.9(95%CI: 11.4-14.5)) and an unusually high use of parenteral antibiotics (23.8% vs. median 5.6%).⁽⁷⁵⁾ Table 10 summarises the characteristics of the chosen benchmark CTAs.




Figure 21. Infection deaths per 100,000 people and Total DID by cluster for CTAs with data available in IQVIA MIDAS® showing percentage Access antibiotics (size) and Healthcare Access and Quality Index (HAQI) (colour) with potential benchmark CTA codes highlighted in red (MAR (Morocco), COL (Colombia) in benchmark group 3 and CHE (Switzerland) in benchmark group 4). Source: Total DID based on IQVIA MIDAS® data for 2019, reflecting estimates of real-world activity. Copyright IQVIA. All Rights Reserved

Table 10. Table of characteristics for considered benchmark CTAs. Benchmark CTA selected from cluster 3 is used as the benchmark CTA to estimate minimum antibiotic need in clusters 1 and 2. Colombia is used only in a sensitivity analysis (scenario 4).

Clusters	CTA	Total DID (median)*	Infection deaths per 100,000 (median)	Access percent (median)*	Not Recommended DID (median)*	HAQI (mean)
Cluster 3	Morocco	16.6	103.9	71%	1.1	48.5
Cluster 4	Switzerland	11.0	72.3	61%	0.05	92.6
Cluster 3 (sensitivity analyses – scenario 4)	Colombia	12.9	84.2	64%	0.03	61.1

*Source: Total DID based on IQVIA MIDAS® data for 2019, reflecting estimates of real-world activity. Copyright IQVIA. All Rights Reserved

2.2.3 Estimated expected antibiotic use




Figure 22. Distribution of the 1000 draws of estimated expected Total, Access, Watch and Reserve (AWaRe) antibiotic use by cluster for primary analyses. Note: x-axis scales are different between the AWaRe categories.

2.2.4 Actual vs. estimated optimal antibiotic use




Figure 23. Median observed (IQVIA MIDAS®) vs. median estimated expected antibiotic use by AWaRe category and benchmark group for primary analyses for CTAs in IQVIA MIDAS® with observed antibiotic use data available. Dashed line indicates where observed = expected. Source: Actual DID based on IQVIA MIDAS® data for 2019, reflecting estimates of real-world activity. Copyright IQVIA. All Rights Reserved

2.3 SENSITIVITY ANALYSES

2.3.1 Global antibiotic use

Table 11. Estimated expected global antibiotic use for Total, Access, Watch and Reserve in billions of defined daily doses (DDD) and DDD/1000 inhabitants/day (DID), and estimated expected global percentage of Access antibiotic use for each analysis scenario.

Expected Antibiotic Use	Scenario 1 (Primary analysis)	Scenario 2 (High Watch)	Scenario 3 (Unadjusted cases & excl. TB)	Scenario 4 (Alternate benchmark CTA)
Total DDD (billions)	43 (35.4, 57.7)	43 (35.4, 57.7)	42.8 (35.2, 57.4)	31 (25.5, 44.3)
Access DDD (billions)	32.9 (25.2, 47.3)	28.5 (20.7, 43.1)	36.3 (28.6, 50.7)	20.9 (15.1, 34.1)
Watch DDD (billions)	8.9 (8.4, 9.5)	13.3 (12.5, 14.1)	6.2 (5.8, 6.7)	8.9 (8.4, 9.5)
Reserve DDD (billions)	1.2 (0.6, 2.3)	1.2 (0.6, 2.3)	0.3 (0.2, 0.6)	1.2 (0.6, 2.3)
Total DID	15.2 (12.5, 20)	15.3 (12.5, 20)	15.2 (12.5, 20)	11 (9, 16)
Access DID	11.7 (8.9, 17)	10.1 (7.3, 15)	12.9 (10.1, 18)	7.4 (5.3, 12)
Watch DID	3.2 (3, 3)	4.7 (4.4, 5)	2.2 (2.1, 2)	3.2 (3, 3)
Reserve DID	0.4 (0.2, 1)	0.4 (0.2, 1)	0.1 (0.1, 0)	0.4 (0.2, 1)
Access %	76 (71, 83)	66 (58, 75)	85 (81, 89)	67 (59, 77)

2.3.2 CTA-level scenario comparisons




Figure 24. Estimated optimal Total defined daily doses/1000 inhabitants/year (DID) by CTA and cluster assignment for each analysis scenario. Scenario 1 = primary analysis, Scenario 2 = high watch scenario, Scenario 3 = unadjusted cases & excl. TB, Scenario 4 = alternate benchmark CTA




Figure 25. Estimated optimal Access defined daily doses/1000 inhabitants/year (DID) by CTA and cluster assignment for each analysis scenario. Scenario 1 = primary analysis, Scenario 2 = high watch scenario, Scenario 3 = unadjusted cases & excl. TB, Scenario 4 = alternate benchmark CTA




Figure 26. Estimated optimal Watch defined daily doses/1000 inhabitants/year (DID) by CTA and cluster assignment for each analysis scenario. Scenario 1 = primary analysis, Scenario 2 = high watch scenario, Scenario 3 = unadjusted cases & excl. TB, Scenario 4 = alternate benchmark CTA



Figure 27 Estimated optimal Reserve defined daily doses/1000 inhabitants/year (DID) by CTA and cluster assignment for each analysis scenario. Scenario 1 = primary analysis, Scenario 2 = high watch scenario, Scenario 3 = unadjusted cases & excl. TB, Scenario 4 = alternate benchmark CTA

Table 12. Estimated optimal total defined daily doses/1000 inhabitants/year (DID) and Access, Watch and Reserve DID for all four analysis scenarios. Scenario 1 = primary analysis, Scenario 2 = high watch scenario, Scenario 3 = unadjusted cases & excl. TB, Scenario 4 = alternate benchmark CTA

CTA Name	ISO3 Code	Cluster	WHO Region	Income Group	AWaRe Category	Scenario 1	Scenario 2	Scenario 3	Scenario 4
Afghanistan	AFG	Cluster 1	EMR	Low income	Total DID	9 (6.9, 12.8)	9 (6.9, 12.8)	8.7 (6.6, 12.4)	6.1 (4.5, 9.4)
Afghanistan	AFG	Cluster 1	EMR	Low income	Access DID	6.8 (4.6, 10.6)	6 (3.8, 9.8)	7.4 (5.3, 11)	3.9 (2.2, 7.1)
Afghanistan	AFG	Cluster 1	EMR	Low income	Watch DID	1.9 (1.6, 2.2)	2.6 (2.3, 3.1)	1.2 (1, 1.5)	1.9 (1.6, 2.2)
Afghanistan	AFG	Cluster 1	EMR	Low income	Reserve DID	0.3 (0.1, 1)	0.3 (0.1, 1)	0.1 (0, 0.2)	0.3 (0.1, 1)
Albania	ALB	Cluster 4	EUR	Upper middle income	Total DID	7.7 (6.5, 8.9)	7.7 (6.5, 8.9)	7.6 (6.5, 8.9)	7.7 (6.5, 8.9)
Albania	ALB	Cluster 4	EUR	Upper middle income	Access DID	6.7 (5.7, 8)	6.5 (5.5, 7.8)	6.8 (5.7, 8.1)	6.7 (5.7, 8)
Albania	ALB	Cluster 4	EUR	Upper middle income	Watch DID	0.9 (0.8, 1.1)	1.1 (1, 1.3)	0.7 (0.6, 0.9)	0.9 (0.8, 1.1)
Albania	ALB	Cluster 4	EUR	Upper middle income	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0.1)	0 (0, 0)
Algeria	DZA	Cluster 3	AFR	Upper middle income	Total DID	14.4 (11, 20.5)	14.4 (11, 20.5)	14.4 (11, 20.6)	9.8 (7.3, 15)
Algeria	DZA	Cluster 3	AFR	Upper middle income	Access DID	12.9 (9.6, 19.2)	12.4 (9.1, 18.7)	13.2 (9.9, 19.5)	8.3 (5.9, 13.6)
Algeria	DZA	Cluster 3	AFR	Upper middle income	Watch DID	1.4 (1.2, 1.7)	1.9 (1.6, 2.2)	1.1 (0.9, 1.4)	1.4 (1.2, 1.7)
Algeria	DZA	Cluster 3	AFR	Upper middle income	Reserve DID	0.1 (0, 0.2)	0.1 (0, 0.2)	0 (0, 0.1)	0.1 (0, 0.2)
Angola	AGO	Cluster 1	AFR	Lower middle income	Total DID	13.1 (10.1, 18.8)	13.2 (10.2, 18.8)	12.8 (9.9, 18.3)	8.8 (6.7, 13.6)
Angola	AGO	Cluster 1	AFR	Lower middle income	Access DID	9.6 (6.4, 15.1)	8.6 (5.5, 14.2)	10.6 (7.5, 16.1)	5.4 (2.8, 10.2)
Angola	AGO	Cluster 1	AFR	Lower middle income	Watch DID	3.1 (2.6, 3.9)	4.1 (3.5, 5)	2.1 (1.7, 2.7)	3.1 (2.6, 3.9)
Angola	AGO	Cluster 1	AFR	Lower middle income	Reserve DID	0.3 (0.1, 1.4)	0.3 (0.1, 1.4)	0.1 (0, 0.3)	0.3 (0.1, 1.4)
Antigua and Barbuda	ATG	Cluster 3	AMR	High income	Total DID	15.2 (11.9, 21.4)	15.2 (11.9, 21.4)	15.4 (12, 21.7)	10.3 (7.9, 15.9)
Antigua and Barbuda	ATG	Cluster 3	AMR	High income	Access DID	13.6 (10.2, 19.8)	13.2 (9.8, 19.4)	14 (10.7, 20.4)	8.7 (6.3, 14.3)
Antigua and Barbuda	ATG	Cluster 3	AMR	High income	Watch DID	1.6 (1.4, 1.8)	2 (1.8, 2.2)	1.3 (1.1, 1.5)	1.6 (1.4, 1.8)
Antigua and Barbuda	ATG	Cluster 3	AMR	High income	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
Argentina	ARG	Cluster 3	AMR	Upper middle income	Total DID	19.6 (15.3, 27.6)	19.6 (15.3, 27.6)	19.9 (15.5, 28)	13.2 (9.9, 20.1)
Argentina	ARG	Cluster 3	AMR	Upper middle income	Access DID	18.4 (14.1, 26.5)	18 (13.7, 26.1)	18.9 (14.5, 27.1)	12 (8.8, 18.9)

Argentina	ARG	Cluster 3	AMR	Upper middle income	Watch DID	1.1 (1, 1.2)	1.5 (1.4, 1.7)	0.8 (0.7, 0.9)	1.1 (1, 1.2)
Argentina	ARG	Cluster 3	AMR	Upper middle income	Reserve DID	0 (0, 0.1)	0 (0, 0.1)	0.1 (0.1, 0.3)	0 (0, 0.1)
Armenia	ARM	Cluster 4	EUR	Upper middle income	Total DID	10 (8.7, 11.7)	10 (8.7, 11.7)	9.9 (8.6, 11.6)	10 (8.7, 11.7)
Armenia	ARM	Cluster 4	EUR	Upper middle income	Access DID	7.9 (6.5, 9.6)	7.6 (6.2, 9.3)	8.5 (7.2, 10.1)	7.9 (6.5, 9.6)
Armenia	ARM	Cluster 4	EUR	Upper middle income	Watch DID	1.7 (1.5, 2)	2.1 (1.9, 2.3)	1.4 (1.2, 1.6)	1.7 (1.5, 2)
Armenia	ARM	Cluster 4	EUR	Upper middle income	Reserve DID	0.3 (0.1, 0.9)	0.3 (0.1, 0.9)	0 (0, 0.1)	0.3 (0.1, 0.9)
Australia	AUS	Cluster 4	WPR	High income	Total DID	12.9 (11.2, 14.9)	12.9 (11.2, 14.9)	12.9 (11.2, 14.9)	12.9 (11.2, 14.9)
Australia	AUS	Cluster 4	WPR	High income	Access DID	12.1 (10.4, 14.1)	11.9 (10.2, 13.8)	12.3 (10.6, 14.2)	12.1 (10.4, 14.1)
Australia	AUS	Cluster 4	WPR	High income	Watch DID	0.8 (0.7, 0.8)	1 (0.9, 1.1)	0.6 (0.5, 0.7)	0.8 (0.7, 0.8)
Australia	AUS	Cluster 4	WPR	High income	Reserve DID	0 (0, 0)	0 (0, 0)	0.1 (0, 0.1)	0 (0, 0)
Austria	AUT	Cluster 4	EUR	High income	Total DID	10.8 (9.3, 12.4)	10.8 (9.3, 12.4)	10.8 (9.3, 12.5)	10.8 (9.3, 12.4)
Austria	AUT	Cluster 4	EUR	High income	Access DID	9.9 (8.5, 11.6)	9.7 (8.2, 11.3)	10.1 (8.6, 11.7)	9.9 (8.5, 11.6)
Austria	AUT	Cluster 4	EUR	High income	Watch DID	0.9 (0.8, 1)	1.1 (1, 1.3)	0.7 (0.6, 0.8)	0.9 (0.8, 1)
Austria	AUT	Cluster 4	EUR	High income	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
Azerbaijan	AZE	Cluster 2	EUR	Upper middle income	Total DID	10.1 (7.8, 14.4)	10.1 (7.8, 14.4)	10.1 (7.8, 14.5)	6.8 (5.2, 10.6)
Azerbaijan	AZE	Cluster 2	EUR	Upper middle income	Access DID	7 (4.5, 11.5)	6.6 (4.1, 11.1)	8.6 (6.3, 13)	3.8 (1.5, 7.5)
Azerbaijan	AZE	Cluster 2	EUR	Upper middle income	Watch DID	2 (1.8, 2.4)	2.5 (2.2, 2.8)	1.5 (1.3, 1.7)	2 (1.8, 2.4)
Azerbaijan	AZE	Cluster 2	EUR	Upper middle income	Reserve DID	0.9 (0.4, 2.2)	0.9 (0.4, 2.2)	0 (0, 0.1)	0.9 (0.4, 2.2)
Bahamas, The	BHS	Cluster 3	AMR	High income	Total DID	15.1 (11.8, 21.4)	15.1 (11.8, 21.4)	15.2 (11.9, 21.6)	10.2 (7.7, 15.7)
Bahamas, The	BHS	Cluster 3	AMR	High income	Access DID	13.6 (10.3, 19.9)	13.2 (9.9, 19.5)	14 (10.6, 20.4)	8.7 (6.2, 14.3)
Bahamas, The	BHS	Cluster 3	AMR	High income	Watch DID	1.5 (1.3, 1.7)	1.9 (1.7, 2.1)	1.2 (1, 1.4)	1.5 (1.3, 1.7)
Bahamas, The	BHS	Cluster 3	AMR	High income	Reserve DID	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.2)	0 (0, 0.1)
Bahrain	BHR	Cluster 3	EMR	High income	Total DID	13.5 (10.5, 19.2)	13.5 (10.5, 19.2)	13.5 (10.5, 19.3)	9.1 (6.9, 13.9)
Bahrain	BHR	Cluster 3	EMR	High income	Access DID	12.2 (9.3, 18)	11.9 (8.9, 17.6)	12.4 (9.5, 18.2)	7.9 (5.7, 12.8)
Bahrain	BHR	Cluster 3	EMR	High income	Watch DID	1.2 (1, 1.4)	1.5 (1.4, 1.8)	1 (0.8, 1.2)	1.2 (1, 1.4)

Bahrain	BHR	Cluster 3	EMR	High income	Reserve DID	0 (0, 0.1)	0 (0, 0.1)	0.1 (0, 0.1)	0 (0, 0.1)
Bangladesh	BGD	Cluster 2	SEAR	Lower middle income	Total DID	18.6 (14.4, 26.7)	18.6 (14.4, 26.7)	18.5 (14.2, 26.5)	12.6 (9.6, 19.4)
Bangladesh	BGD	Cluster 2	SEAR	Lower middle income	Access DID	14.1 (9.9, 21.9)	10.9 (6.6, 18.9)	15.8 (11.6, 23.8)	8.1 (5.1, 15)
Bangladesh	BGD	Cluster 2	SEAR	Lower middle income	Watch DID	4.1 (3.6, 4.8)	7.3 (6.4, 8.3)	2.5 (2.2, 3.1)	4.1 (3.6, 4.8)
Bangladesh	BGD	Cluster 2	SEAR	Lower middle income	Reserve DID	0.4 (0.1, 1)	0.4 (0.1, 1)	0.1 (0, 0.4)	0.4 (0.1, 1)
Barbados	BRB	Cluster 3	AMR	High income	Total DID	16.3 (12.7, 23.2)	16.3 (12.7, 23.3)	16.4 (12.8, 23.4)	11 (8.3, 17)
Barbados	BRB	Cluster 3	AMR	High income	Access DID	14.2 (10.6, 21)	13.6 (10, 20.4)	14.7 (11.1, 21.7)	8.8 (6.3, 15)
Barbados	BRB	Cluster 3	AMR	High income	Watch DID	2.1 (1.9, 2.4)	2.7 (2.4, 3)	1.7 (1.5, 1.9)	2.1 (1.9, 2.4)
Barbados	BRB	Cluster 3	AMR	High income	Reserve DID	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.3)	0 (0, 0.1)
Belarus	BLR	Cluster 4	EUR	Upper middle income	Total DID	10.5 (9, 12.1)	10.5 (9, 12.1)	10.5 (9, 12)	10.5 (9, 12.1)
Belarus	BLR	Cluster 4	EUR	Upper middle income	Access DID	8 (6.5, 9.8)	7.7 (6.2, 9.5)	9.3 (7.9, 10.9)	8 (6.5, 9.8)
Belarus	BLR	Cluster 4	EUR	Upper middle income	Watch DID	1.5 (1.4, 1.7)	1.8 (1.6, 2)	1.1 (1, 1.2)	1.5 (1.4, 1.7)
Belarus	BLR	Cluster 4	EUR	Upper middle income	Reserve DID	0.8 (0.5, 1.6)	0.8 (0.5, 1.6)	0 (0, 0.1)	0.8 (0.5, 1.6)
Belgium	BEL	Cluster 4	EUR	High income	Total DID	10.8 (9.4, 12.5)	10.8 (9.4, 12.5)	10.8 (9.4, 12.5)	10.8 (9.4, 12.5)
Belgium	BEL	Cluster 4	EUR	High income	Access DID	9.8 (8.4, 11.5)	9.5 (8.1, 11.2)	10 (8.6, 11.7)	9.8 (8.4, 11.5)
Belgium	BEL	Cluster 4	EUR	High income	Watch DID	1 (0.9, 1.2)	1.3 (1.2, 1.5)	0.8 (0.7, 0.9)	1 (0.9, 1.2)
Belgium	BEL	Cluster 4	EUR	High income	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0.1)	0 (0, 0)
Belize	BLZ	Cluster 2	AMR	Upper middle income	Total DID	18 (13.9, 26.2)	18 (13.9, 26.2)	18.1 (13.9, 26.3)	12.2 (9.3, 18.9)
Belize	BLZ	Cluster 2	AMR	Upper middle income	Access DID	16.3 (12.1, 24.3)	15.8 (11.7, 23.9)	16.7 (12.5, 24.9)	10.5 (7.6, 17.2)
Belize	BLZ	Cluster 2	AMR	Upper middle income	Watch DID	1.7 (1.5, 2)	2.2 (1.9, 2.4)	1.4 (1.2, 1.6)	1.7 (1.5, 2)
Belize	BLZ	Cluster 2	AMR	Upper middle income	Reserve DID	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)
Benin	BEN	Cluster 1	AFR	Lower middle income	Total DID	16.9 (13, 24)	17 (13, 24.1)	16.6 (12.6, 23.5)	11.4 (8.5, 17.5)
Benin	BEN	Cluster 1	AFR	Lower middle income	Access DID	11.1 (7, 18)	9.1 (4.9, 16.1)	12.1 (8, 18.8)	5.5 (2.4, 11.3)
Benin	BEN	Cluster 1	AFR	Lower middle income	Watch DID	5.6 (4.4, 7.5)	7.6 (6.3, 9.7)	4 (3, 5.9)	5.6 (4.4, 7.5)

Benin	BEN	Cluster 1	AFR	Lower middle income	Reserve DID	0.2 (0.1, 0.5)	0.2 (0.1, 0.5)	0.4 (0.1, 0.9)	0.2 (0.1, 0.5)
Bhutan	BTN	Cluster 2	SEAR	Lower middle income	Total DID	15.1 (11.8, 21.1)	15.2 (11.8, 21.1)	14.9 (11.6, 20.8)	10.3 (7.8, 15.7)
Bhutan	BTN	Cluster 2	SEAR	Lower middle income	Access DID	11.2 (7.6, 17.2)	8 (4.2, 13.8)	12.8 (9.3, 18.7)	6.2 (3.6, 11.8)
Bhutan	BTN	Cluster 2	SEAR	Lower middle income	Watch DID	3.7 (3.3, 4.2)	7 (6.1, 8.1)	2.1 (1.9, 2.5)	3.7 (3.3, 4.2)
Bhutan	BTN	Cluster 2	SEAR	Lower middle income	Reserve DID	0.3 (0.1, 1)	0.3 (0.1, 1)	0.1 (0, 0.3)	0.3 (0.1, 1)
Bolivia	BOL	Cluster 2	AMR	Lower middle income	Total DID	16.4 (12.6, 23.3)	16.4 (12.6, 23.3)	16.4 (12.6, 23.4)	11.1 (8.3, 16.8)
Bolivia	BOL	Cluster 2	AMR	Lower middle income	Access DID	14.4 (10.5, 21)	13.9 (10, 20.5)	15.1 (11.3, 22)	9.1 (6.2, 14.9)
Bolivia	BOL	Cluster 2	AMR	Lower middle income	Watch DID	1.7 (1.5, 1.9)	2.3 (2, 2.6)	1.2 (1.1, 1.4)	1.7 (1.5, 1.9)
Bolivia	BOL	Cluster 2	AMR	Lower middle income	Reserve DID	0.2 (0.1, 0.8)	0.2 (0.1, 0.8)	0.1 (0, 0.2)	0.2 (0.1, 0.8)
Bosnia and Herzegovina	BIH	Cluster 4	EUR	Upper middle income	Total DID	8 (7, 9.2)	8 (7, 9.2)	8 (6.9, 9.1)	8 (7, 9.2)
Bosnia and Herzegovina	BIH	Cluster 4	EUR	Upper middle income	Access DID	7.1 (6, 8.2)	6.9 (5.8, 8)	7.2 (6.1, 8.4)	7.1 (6, 8.2)
Bosnia and Herzegovina	BIH	Cluster 4	EUR	Upper middle income	Watch DID	1 (0.8, 1.1)	1.1 (1, 1.3)	0.8 (0.7, 0.9)	1 (0.8, 1.1)
Bosnia and Herzegovina	BIH	Cluster 4	EUR	Upper middle income	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0.1)	0 (0, 0)
Botswana	BWA	Cluster 2	AFR	Upper middle income	Total DID	17.6 (13.6, 24.9)	17.6 (13.6, 24.9)	17.5 (13.4, 24.7)	11.9 (9.1, 18.4)
Botswana	BWA	Cluster 2	AFR	Upper middle income	Access DID	13.1 (8.2, 20.8)	12.4 (7.5, 20.1)	14.7 (10.7, 22.1)	7.5 (3.4, 13.8)
Botswana	BWA	Cluster 2	AFR	Upper middle income	Watch DID	3.5 (3, 4.3)	4.2 (3.6, 5.1)	2.6 (2.2, 3.4)	3.5 (3, 4.3)
Botswana	BWA	Cluster 2	AFR	Upper middle income	Reserve DID	0.8 (0.2, 3.4)	0.8 (0.2, 3.4)	0.1 (0, 0.2)	0.8 (0.2, 3.4)
Brazil	BRA	Cluster 3	AMR	Upper middle income	Total DID	21.7 (16.6, 30.7)	21.7 (16.6, 30.8)	21.9 (16.8, 31.1)	14.7 (11.2, 22.6)
Brazil	BRA	Cluster 3	AMR	Upper middle income	Access DID	19.6 (14.5, 28.6)	19 (13.8, 28.1)	20.1 (14.9, 29.1)	12.6 (9.1, 20.6)
Brazil	BRA	Cluster 3	AMR	Upper middle income	Watch DID	2 (1.8, 2.2)	2.6 (2.4, 2.8)	1.6 (1.4, 1.8)	2 (1.8, 2.2)
Brazil	BRA	Cluster 3	AMR	Upper middle income	Reserve DID	0.1 (0.1, 0.3)	0.1 (0.1, 0.3)	0.3 (0.1, 0.5)	0.1 (0.1, 0.3)
Brunei Darussalam	BRN	Cluster 3	WPR	High income	Total DID	19.3 (14.9, 27.6)	19.3 (14.9, 27.5)	19.5 (15.1, 27.9)	13 (9.7, 20.1)

Brunei Darussalam	BRN	Cluster 3	WPR	High income	Access DID	18.5 (14.1, 26.8)	18.3 (13.9, 26.6)	18.9 (14.5, 27.3)	12.2 (9, 19.3)
Brunei Darussalam	BRN	Cluster 3	WPR	High income	Watch DID	0.7 (0.7, 0.8)	1 (0.9, 1.1)	0.5 (0.5, 0.6)	0.7 (0.7, 0.8)
Brunei Darussalam	BRN	Cluster 3	WPR	High income	Reserve DID	0 (0, 0.1)	0 (0, 0.1)	0.1 (0.1, 0.2)	0 (0, 0.1)
Bulgaria	BGR	Cluster 4	EUR	Upper middle income	Total DID	7.7 (6.7, 8.9)	7.8 (6.7, 8.9)	7.7 (6.6, 8.9)	7.7 (6.7, 8.9)
Bulgaria	BGR	Cluster 4	EUR	Upper middle income	Access DID	6.7 (5.6, 7.8)	6.5 (5.4, 7.6)	6.9 (5.8, 8)	6.7 (5.6, 7.8)
Bulgaria	BGR	Cluster 4	EUR	Upper middle income	Watch DID	1 (0.9, 1.2)	1.2 (1.1, 1.4)	0.8 (0.7, 0.9)	1 (0.9, 1.2)
Bulgaria	BGR	Cluster 4	EUR	Upper middle income	Reserve DID	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)
Burkina Faso	BFA	Cluster 1	AFR	Low income	Total DID	18.3 (14.1, 25.9)	18.4 (14.2, 26)	17.8 (13.7, 25.3)	12.4 (9.3, 19.1)
Burkina Faso	BFA	Cluster 1	AFR	Low income	Access DID	11.3 (7, 18.8)	6.4 (1.8, 14.1)	13.5 (9, 20.8)	5.3 (1.9, 11.8)
Burkina Faso	BFA	Cluster 1	AFR	Low income	Watch DID	6.7 (5.6, 8)	11.8 (10, 13.8)	3.8 (3.1, 4.9)	6.7 (5.6, 8)
Burkina Faso	BFA	Cluster 1	AFR	Low income	Reserve DID	0.4 (0.1, 0.9)	0.4 (0.1, 0.9)	0.5 (0.2, 1.6)	0.4 (0.1, 0.9)
Burundi	BDI	Cluster 1	AFR	Low income	Total DID	21.8 (16.8, 30.8)	21.8 (16.8, 30.8)	21.5 (16.5, 30.5)	14.7 (11.1, 22.9)
Burundi	BDI	Cluster 1	AFR	Low income	Access DID	14.6 (9.2, 23.8)	12.8 (7.5, 22)	16.4 (11.3, 25.5)	7.6 (3.3, 16.2)
Burundi	BDI	Cluster 1	AFR	Low income	Watch DID	6.4 (5.3, 8.3)	8.3 (7.1, 10.2)	4.9 (3.9, 6.7)	6.4 (5.3, 8.3)
Burundi	BDI	Cluster 1	AFR	Low income	Reserve DID	0.5 (0.2, 2.1)	0.5 (0.2, 2.1)	0.1 (0, 0.3)	0.5 (0.2, 2.1)
Cabo Verde	CPV	Cluster 2	AFR	Lower middle income	Total DID	13.7 (10.5, 19.8)	13.7 (10.5, 19.9)	13.8 (10.5, 19.9)	9.3 (7.1, 14.5)
Cabo Verde	CPV	Cluster 2	AFR	Lower middle income	Access DID	10.4 (7.2, 16.7)	9.3 (6.1, 15.5)	11.2 (8, 17.5)	5.9 (3.6, 11)
Cabo Verde	CPV	Cluster 2	AFR	Lower middle income	Watch DID	3.1 (2.5, 4.1)	4.2 (3.6, 5.2)	2.5 (1.9, 3.4)	3.1 (2.5, 4.1)
Cabo Verde	CPV	Cluster 2	AFR	Lower middle income	Reserve DID	0.1 (0, 0.5)	0.1 (0, 0.5)	0 (0, 0.1)	0.1 (0, 0.5)
Cambodia	KHM	Cluster 2	WPR	Lower middle income	Total DID	15.1 (11.6, 21.2)	15.1 (11.6, 21.2)	14.9 (11.4, 20.9)	10.2 (7.7, 15.5)
Cambodia	KHM	Cluster 2	WPR	Lower middle income	Access DID	12.2 (8.5, 18.4)	10.3 (6.7, 16.6)	13.1 (9.6, 19.2)	7.3 (4.8, 12.8)
Cambodia	KHM	Cluster 2	WPR	Lower middle income	Watch DID	2.7 (2.4, 3.1)	4.6 (4.1, 5.3)	1.6 (1.4, 2)	2.7 (2.4, 3.1)
Cambodia	KHM	Cluster 2	WPR	Lower middle income	Reserve DID	0.1 (0.1, 0.5)	0.1 (0.1, 0.5)	0.1 (0.1, 0.3)	0.1 (0.1, 0.5)
Cameroon	CMR	Cluster 1	AFR	Lower middle income	Total DID	23.3 (18, 32.6)	23.3 (18, 32.7)	23 (17.7, 32.3)	15.7 (11.9, 24.3)

Cameroon	CMR	Cluster 1	AFR	Lower middle income	Access DID	16.8 (11.2, 26.1)	14.9 (9.1, 24.1)	18.3 (12.8, 27.5)	9.2 (5.1, 17.9)
Cameroon	CMR	Cluster 1	AFR	Lower middle income	Watch DID	6.2 (5, 8)	8.3 (6.9, 10.2)	4.6 (3.5, 6.3)	6.2 (5, 8)
Cameroon	CMR	Cluster 1	AFR	Lower middle income	Reserve DID	0.2 (0.1, 0.6)	0.2 (0.1, 0.6)	0.1 (0, 0.3)	0.2 (0.1, 0.6)
Canada	CAN	Cluster 4	AMR	High income	Total DID	16.9 (14.5, 19.4)	16.9 (14.5, 19.4)	16.8 (14.5, 19.4)	16.9 (14.5, 19.4)
Canada	CAN	Cluster 4	AMR	High income	Access DID	16.1 (13.7, 18.6)	15.8 (13.4, 18.3)	16.2 (13.8, 18.7)	16.1 (13.7, 18.6)
Canada	CAN	Cluster 4	AMR	High income	Watch DID	0.8 (0.7, 0.9)	1.1 (1, 1.2)	0.6 (0.5, 0.6)	0.8 (0.7, 0.9)
Canada	CAN	Cluster 4	AMR	High income	Reserve DID	0 (0, 0)	0 (0, 0)	0.1 (0, 0.2)	0 (0, 0)
Central African Republic	CAF	Cluster 1	AFR	Low income	Total DID	25.5 (19.5, 36.2)	25.5 (19.5, 36.2)	25.1 (19.2, 35.8)	17.1 (13.1, 26.9)
Central African Republic	CAF	Cluster 1	AFR	Low income	Access DID	19.1 (12.9, 29.7)	17.7 (11.4, 28.2)	20.6 (14.7, 31)	10.8 (6.4, 20.5)
Central African Republic	CAF	Cluster 1	AFR	Low income	Watch DID	5.6 (4.3, 7.9)	7 (5.7, 9.4)	4 (2.9, 6.4)	5.6 (4.3, 7.9)
Central African Republic	CAF	Cluster 1	AFR	Low income	Reserve DID	0.5 (0.2, 1.9)	0.5 (0.2, 1.9)	0.3 (0.1, 0.8)	0.5 (0.2, 1.9)
Chad	TCD	Cluster 1	AFR	Low income	Total DID	19.2 (14.7, 27.6)	19.3 (14.8, 27.7)	18.7 (14.3, 26.9)	13 (9.8, 19.9)
Chad	TCD	Cluster 1	AFR	Low income	Access DID	10.3 (5.6, 18.1)	7.8 (3.1, 15.9)	12 (7.3, 19.6)	4.1 (0.1, 10.7)
Chad	TCD	Cluster 1	AFR	Low income	Watch DID	8.4 (6.8, 11.4)	11 (9.1, 14.1)	6.2 (4.7, 9.1)	8.4 (6.8, 11.4)
Chad	TCD	Cluster 1	AFR	Low income	Reserve DID	0.4 (0.1, 1.2)	0.4 (0.1, 1.2)	0.5 (0.2, 1.4)	0.4 (0.1, 1.2)
Chile	CHL	Cluster 3	AMR	High income	Total DID	18.5 (14.3, 26.1)	18.5 (14.3, 26.1)	18.7 (14.5, 26.4)	12.4 (9.3, 19.4)
Chile	CHL	Cluster 3	AMR	High income	Access DID	17.6 (13.5, 25.1)	17.2 (13.2, 24.8)	17.9 (13.7, 25.6)	11.5 (8.4, 18.5)
Chile	CHL	Cluster 3	AMR	High income	Watch DID	0.8 (0.8, 0.9)	1.2 (1.1, 1.3)	0.6 (0.6, 0.7)	0.8 (0.8, 0.9)
Chile	CHL	Cluster 3	AMR	High income	Reserve DID	0 (0, 0.1)	0 (0, 0.1)	0.1 (0.1, 0.3)	0 (0, 0.1)
China	CHN	Cluster 3	WPR	Upper middle income	Total DID	11.6 (9, 16.3)	11.6 (9, 16.3)	11.7 (9, 16.4)	7.8 (6, 12.1)
China	CHN	Cluster 3	WPR	Upper middle income	Access DID	10.3 (7.7, 15.2)	10 (7.4, 14.9)	10.8 (8.2, 15.6)	6.5 (4.7, 10.9)
China	CHN	Cluster 3	WPR	Upper middle income	Watch DID	1.1 (1, 1.3)	1.4 (1.3, 1.6)	0.8 (0.7, 1)	1.1 (1, 1.3)
China	CHN	Cluster 3	WPR	Upper middle income	Reserve DID	0.1 (0, 0.5)	0.1 (0, 0.5)	0 (0, 0)	0.1 (0, 0.5)
Colombia	COL	Cluster 3	AMR	Upper middle income	Total DID	19 (14.5, 27.3)	19 (14.5, 27.3)	19.2 (14.6, 27.6)	12.9 (10.4, 19.3)

Colombia	COL	Cluster 3	AMR	Upper middle income	Access DID	17.5 (13.1, 25.8)	17.2 (12.7, 25.4)	18 (13.5, 26.4)	11.5 (8.9, 17.9)
Colombia	COL	Cluster 3	AMR	Upper middle income	Watch DID	1.4 (1.2, 1.6)	1.7 (1.5, 2)	1.1 (1, 1.4)	1.4 (1.2, 1.6)
Colombia	COL	Cluster 3	AMR	Upper middle income	Reserve DID	0.1 (0, 0.2)	0.1 (0, 0.2)	0.1 (0, 0.2)	0.1 (0, 0.2)
Comoros	COM	Cluster 1	AFR	Lower middle income	Total DID	16.5 (12.6, 23.5)	16.5 (12.6, 23.5)	16.3 (12.5, 23.3)	11.1 (8.4, 16.8)
Comoros	COM	Cluster 1	AFR	Lower middle income	Access DID	10.5 (5.6, 18.2)	9.2 (4.1, 16.9)	12.7 (8.8, 19.8)	5.2 (1, 10.9)
Comoros	COM	Cluster 1	AFR	Lower middle income	Watch DID	4.6 (3.9, 5.9)	6 (5.2, 7.3)	3.5 (2.8, 4.7)	4.6 (3.9, 5.9)
Comoros	COM	Cluster 1	AFR	Lower middle income	Reserve DID	1.1 (0.3, 4.6)	1.1 (0.3, 4.6)	0.1 (0, 0.2)	1.1 (0.3, 4.6)
Congo, Dem. Rep.	COD	Cluster 1	AFR	Low income	Total DID	19.1 (14.6, 27.1)	19.2 (14.6, 27.2)	18.9 (14.3, 26.8)	12.9 (9.7, 19.6)
Congo, Dem. Rep.	COD	Cluster 1	AFR	Low income	Access DID	14.9 (10.4, 23)	13.8 (9.2, 21.8)	16.2 (11.8, 24)	8.8 (5.2, 15.7)
Congo, Dem. Rep.	COD	Cluster 1	AFR	Low income	Watch DID	3.7 (2.9, 4.6)	4.8 (4, 6)	2.4 (1.9, 3.3)	3.7 (2.9, 4.6)
Congo, Dem. Rep.	COD	Cluster 1	AFR	Low income	Reserve DID	0.4 (0.1, 1.5)	0.4 (0.1, 1.5)	0.1 (0.1, 0.4)	0.4 (0.1, 1.5)
Congo, Rep.	COG	Cluster 1	AFR	Lower middle income	Total DID	18.7 (14.4, 26.2)	18.7 (14.5, 26.3)	18.4 (14.2, 26)	12.5 (9.3, 19.6)
Congo, Rep.	COG	Cluster 1	AFR	Lower middle income	Access DID	14.9 (10.6, 22.5)	14 (9.7, 21.6)	15.8 (11.5, 23.3)	8.9 (5.5, 16)
Congo, Rep.	COG	Cluster 1	AFR	Lower middle income	Watch DID	3.3 (2.7, 4.4)	4.3 (3.6, 5.3)	2.4 (1.8, 3.4)	3.3 (2.7, 4.4)
Congo, Rep.	COG	Cluster 1	AFR	Lower middle income	Reserve DID	0.3 (0.1, 1.1)	0.3 (0.1, 1.1)	0.1 (0, 0.3)	0.3 (0.1, 1.1)
Costa Rica	CRI	Cluster 3	AMR	Upper middle income	Total DID	15 (11.6, 21.9)	15 (11.6, 21.9)	15.2 (11.7, 22.1)	10.2 (7.7, 15.8)
Costa Rica	CRI	Cluster 3	AMR	Upper middle income	Access DID	13.5 (10, 20.4)	13.2 (9.8, 20.2)	13.8 (10.3, 20.9)	8.6 (6.1, 14.2)
Costa Rica	CRI	Cluster 3	AMR	Upper middle income	Watch DID	1.5 (1.3, 1.8)	1.8 (1.6, 2.1)	1.4 (1.2, 1.7)	1.5 (1.3, 1.8)
Costa Rica	CRI	Cluster 3	AMR	Upper middle income	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0.1)	0 (0, 0)
Cote d'Ivoire	CIV	Cluster 1	AFR	Lower middle income	Total DID	18.2 (13.9, 25.4)	18.2 (13.9, 25.5)	17.9 (13.6, 25)	12.1 (9.2, 18.9)
Cote d'Ivoire	CIV	Cluster 1	AFR	Lower middle income	Access DID	12.6 (8.3, 19.7)	10.9 (6.6, 18)	13.9 (9.7, 21)	6.8 (3.6, 13.7)
Cote d'Ivoire	CIV	Cluster 1	AFR	Lower middle income	Watch DID	5.1 (4.2, 6.5)	6.9 (5.8, 8.3)	3.7 (2.8, 5)	5.1 (4.2, 6.5)
Cote d'Ivoire	CIV	Cluster 1	AFR	Lower middle income	Reserve DID	0.3 (0.1, 0.9)	0.3 (0.1, 0.9)	0.1 (0, 0.4)	0.3 (0.1, 0.9)

Croatia	HRV	Cluster 4	EUR	High income	Total DID	8.2 (7.1, 9.6)	8.2 (7.1, 9.6)	8.2 (7.1, 9.6)	8.2 (7.1, 9.6)
Croatia	HRV	Cluster 4	EUR	High income	Access DID	7.2 (6.1, 8.5)	6.9 (5.8, 8.3)	7.3 (6.2, 8.7)	7.2 (6.1, 8.5)
Croatia	HRV	Cluster 4	EUR	High income	Watch DID	1.1 (0.9, 1.2)	1.3 (1.2, 1.5)	0.9 (0.7, 1)	1.1 (0.9, 1.2)
Croatia	HRV	Cluster 4	EUR	High income	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0.1)	0 (0, 0)
Cuba	CUB	Cluster 3	AMR	Upper middle income	Total DID	15.3 (11.8, 21.5)	15.3 (11.8, 21.5)	15.5 (11.9, 21.8)	10.3 (7.9, 16.1)
Cuba	CUB	Cluster 3	AMR	Upper middle income	Access DID	13.7 (10.2, 19.9)	13.2 (9.7, 19.4)	14.2 (10.6, 20.5)	8.7 (6.2, 14.5)
Cuba	CUB	Cluster 3	AMR	Upper middle income	Watch DID	1.6 (1.4, 1.8)	2.1 (1.9, 2.3)	1.3 (1.2, 1.5)	1.6 (1.4, 1.8)
Cuba	CUB	Cluster 3	AMR	Upper middle income	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0.1)	0 (0, 0)
Cyprus	CYP	Cluster 4	EUR	High income	Total DID	11.8 (10.3, 13.6)	11.8 (10.3, 13.6)	11.8 (10.3, 13.6)	11.8 (10.3, 13.6)
Cyprus	CYP	Cluster 4	EUR	High income	Access DID	10.9 (9.4, 12.7)	10.7 (9.2, 12.5)	11 (9.5, 12.8)	10.9 (9.4, 12.7)
Cyprus	CYP	Cluster 4	EUR	High income	Watch DID	0.9 (0.8, 1)	1.1 (1, 1.2)	0.7 (0.7, 0.8)	0.9 (0.8, 1)
Cyprus	CYP	Cluster 4	EUR	High income	Reserve DID	0 (0, 0)	0 (0, 0)	0.1 (0, 0.2)	0 (0, 0)
Czechia	CZE	Cluster 4	EUR	High income	Total DID	7.9 (6.9, 9.1)	7.9 (6.9, 9.1)	7.9 (6.8, 9.1)	7.9 (6.9, 9.1)
Czechia	CZE	Cluster 4	EUR	High income	Access DID	6.9 (5.8, 8)	6.6 (5.6, 7.8)	7.1 (6, 8.2)	6.9 (5.8, 8)
Czechia	CZE	Cluster 4	EUR	High income	Watch DID	1 (0.9, 1.2)	1.3 (1.1, 1.4)	0.8 (0.7, 0.9)	1 (0.9, 1.2)
Czechia	CZE	Cluster 4	EUR	High income	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0.1)	0 (0, 0)
Denmark	DNK	Cluster 4	EUR	High income	Total DID	11 (9.5, 12.7)	11 (9.5, 12.7)	11 (9.5, 12.7)	11 (9.5, 12.7)
Denmark	DNK	Cluster 4	EUR	High income	Access DID	9.6 (8.2, 11.3)	9.4 (7.9, 11.1)	9.8 (8.3, 11.5)	9.6 (8.2, 11.3)
Denmark	DNK	Cluster 4	EUR	High income	Watch DID	1.3 (1.2, 1.4)	1.6 (1.5, 1.8)	1.1 (1, 1.2)	1.3 (1.2, 1.4)
Denmark	DNK	Cluster 4	EUR	High income	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0.1)	0 (0, 0)
Djibouti	DJI	Cluster 2	EMR	Lower middle income	Total DID	21.1 (16.2, 30.6)	21.1 (16.2, 30.6)	20.9 (16.1, 30.4)	14.3 (10.8, 21.8)
Djibouti	DJI	Cluster 2	EMR	Lower middle income	Access DID	14.7 (9.5, 24.6)	13.2 (8, 23.2)	16.6 (11.7, 26.4)	7.9 (3.8, 15.5)
Djibouti	DJI	Cluster 2	EMR	Lower middle income	Watch DID	5.2 (4.3, 6.6)	6.8 (5.8, 8.2)	3.9 (3.2, 5.3)	5.2 (4.3, 6.6)
Djibouti	DJI	Cluster 2	EMR	Lower middle income	Reserve DID	1 (0.4, 2.3)	1 (0.4, 2.3)	0.2 (0.1, 0.7)	1 (0.4, 2.3)
Dominican Republic	DOM	Cluster 3	AMR	Upper middle income	Total DID	15.5 (11.9, 21.5)	15.5 (11.9, 21.5)	15.5 (11.9, 21.6)	10.5 (7.8, 16.3)
Dominican Republic	DOM	Cluster 3	AMR	Upper middle income	Access DID	13.6 (10, 19.8)	13.1 (9.5, 19.4)	14.1 (10.5, 20.3)	8.6 (5.9, 14.5)
Dominican Republic	DOM	Cluster 3	AMR	Upper middle income	Watch DID	1.8 (1.5, 2.1)	2.3 (2, 2.7)	1.3 (1.2, 1.6)	1.8 (1.5, 2.1)

Dominican Republic	DOM	Cluster 3	AMR	Upper middle income	Reserve DID	0 (0, 0.1)	0 (0, 0.1)	0.1 (0, 0.3)	0 (0, 0.1)
Ecuador	ECU	Cluster 3	AMR	Upper middle income	Total DID	18 (14.1, 25.7)	18 (14.1, 25.7)	18.2 (14.2, 26)	12.2 (9.2, 18.4)
Ecuador	ECU	Cluster 3	AMR	Upper middle income	Access DID	16.1 (12, 23.8)	15.6 (11.4, 23.3)	16.7 (12.6, 24.4)	10.3 (7.2, 16.5)
Ecuador	ECU	Cluster 3	AMR	Upper middle income	Watch DID	1.7 (1.5, 1.9)	2.3 (2, 2.5)	1.4 (1.2, 1.6)	1.7 (1.5, 1.9)
Ecuador	ECU	Cluster 3	AMR	Upper middle income	Reserve DID	0.1 (0.1, 0.5)	0.1 (0.1, 0.5)	0.1 (0, 0.2)	0.1 (0.1, 0.5)
Egypt, Arab Rep.	EGY	Cluster 2	EMR	Lower middle income	Total DID	13.4 (10.3, 18.9)	13.4 (10.3, 18.9)	13.3 (10.2, 18.8)	9 (6.8, 14.1)
Egypt, Arab Rep.	EGY	Cluster 2	EMR	Lower middle income	Access DID	11.5 (8.4, 17.2)	11 (7.8, 16.6)	11.9 (8.7, 17.5)	7.2 (5, 12.2)
Egypt, Arab Rep.	EGY	Cluster 2	EMR	Lower middle income	Watch DID	1.8 (1.6, 2)	2.3 (2.1, 2.6)	1.4 (1.2, 1.5)	1.8 (1.6, 2)
Egypt, Arab Rep.	EGY	Cluster 2	EMR	Lower middle income	Reserve DID	0.1 (0, 0.1)	0.1 (0, 0.1)	0.1 (0, 0.2)	0.1 (0, 0.1)
El Salvador	SLV	Cluster 3	AMR	Upper middle income	Total DID	17 (13, 24.2)	17 (13.1, 24.2)	17.2 (13.2, 24.5)	11.5 (8.7, 17.6)
El Salvador	SLV	Cluster 3	AMR	Upper middle income	Access DID	15.3 (11.4, 22.5)	14.9 (11, 22.2)	15.8 (11.8, 23.1)	9.8 (7, 16)
El Salvador	SLV	Cluster 3	AMR	Upper middle income	Watch DID	1.6 (1.4, 1.9)	2 (1.8, 2.3)	1.3 (1.2, 1.6)	1.6 (1.4, 1.9)
El Salvador	SLV	Cluster 3	AMR	Upper middle income	Reserve DID	0.1 (0, 0.2)	0.1 (0, 0.2)	0.1 (0, 0.1)	0.1 (0, 0.2)
Equatorial Guinea	GNQ	Cluster 1	AFR	Upper middle income	Total DID	17.7 (13.6, 25.7)	17.8 (13.6, 25.7)	17.5 (13.3, 25.4)	12 (8.9, 18.5)
Equatorial Guinea	GNQ	Cluster 1	AFR	Upper middle income	Access DID	14.4 (10.1, 22.4)	13.6 (9.1, 21.5)	15.2 (10.9, 23.1)	8.7 (5.5, 15.2)
Equatorial Guinea	GNQ	Cluster 1	AFR	Upper middle income	Watch DID	3 (2.3, 4.1)	3.9 (3, 5.2)	2.1 (1.6, 2.9)	3 (2.3, 4.1)
Equatorial Guinea	GNQ	Cluster 1	AFR	Upper middle income	Reserve DID	0.2 (0.1, 0.7)	0.2 (0.1, 0.7)	0.1 (0, 0.5)	0.2 (0.1, 0.7)
Eritrea	ERI	Cluster 1	AFR	Low income	Total DID	36.5 (28, 51.3)	36.6 (28.1, 51.4)	36.4 (27.9, 51.2)	24.6 (18.6, 38.6)
Eritrea	ERI	Cluster 1	AFR	Low income	Access DID	22.7 (13.5, 38.1)	19.7 (10.5, 35.2)	26.6 (18.3, 42.2)	10.9 (2.8, 24.3)
Eritrea	ERI	Cluster 1	AFR	Low income	Watch DID	11.8 (9.8, 15.2)	14.8 (12.6, 18.4)	9.3 (7.4, 12.8)	11.8 (9.8, 15.2)
Eritrea	ERI	Cluster 1	AFR	Low income	Reserve DID	1.5 (0.4, 6.1)	1.5 (0.4, 6.1)	0.2 (0.1, 0.4)	1.5 (0.4, 6.1)
Estonia	EST	Cluster 4	EUR	High income	Total DID	10.1 (8.7, 11.8)	10.1 (8.8, 11.8)	10.1 (8.7, 11.8)	10.1 (8.7, 11.8)
Estonia	EST	Cluster 4	EUR	High income	Access DID	8.6 (7.2, 10.3)	8.3 (6.9, 10)	9 (7.6, 10.7)	8.6 (7.2, 10.3)
Estonia	EST	Cluster 4	EUR	High income	Watch DID	1.3 (1.2, 1.5)	1.6 (1.5, 1.8)	1.1 (1, 1.2)	1.3 (1.2, 1.5)

Estonia	EST	Cluster 4	EUR	High income	Reserve DID	0.2 (0.1, 0.4)	0.2 (0.1, 0.4)	0 (0, 0)	0.2 (0.1, 0.4)
Eswatini	SWZ	Cluster 2	AFR	Lower middle income	Total DID	16.6 (12.8, 23.4)	16.6 (12.8, 23.4)	16.4 (12.5, 23)	11.2 (8.6, 17.6)
Eswatini	SWZ	Cluster 2	AFR	Lower middle income	Access DID	9.4 (2.7, 16.6)	8.6 (1.9, 15.9)	13 (9.1, 19.6)	4.1 (-2.9, 10.7)
Eswatini	SWZ	Cluster 2	AFR	Lower middle income	Watch DID	4.6 (3.7, 5.8)	5.3 (4.4, 6.6)	3.2 (2.6, 4.3)	4.6 (3.7, 5.8)
Eswatini	SWZ	Cluster 2	AFR	Lower middle income	Reserve DID	2.5 (0.8, 8.1)	2.5 (0.8, 8.1)	0.1 (0, 0.3)	2.5 (0.8, 8.1)
Ethiopia	ETH	Cluster 1	AFR	Low income	Total DID	14.8 (11.4, 21)	14.9 (11.4, 21.1)	14.5 (11.1, 20.7)	10 (7.6, 15.5)
Ethiopia	ETH	Cluster 1	AFR	Low income	Access DID	8.6 (4.8, 15)	6.8 (3, 13.2)	9.8 (6.3, 16)	3.7 (0.6, 9.2)
Ethiopia	ETH	Cluster 1	AFR	Low income	Watch DID	5.7 (4.5, 8)	7.5 (6.2, 9.9)	4.5 (3.3, 6.9)	5.7 (4.5, 8)
Ethiopia	ETH	Cluster 1	AFR	Low income	Reserve DID	0.3 (0.1, 1.2)	0.3 (0.1, 1.2)	0.1 (0, 0.2)	0.3 (0.1, 1.2)
Fiji	FJI	Cluster 2	WPR	Upper middle income	Total DID	19.7 (15.2, 28.5)	19.7 (15.2, 28.5)	19.7 (15.2, 28.6)	13.4 (10.1, 20.4)
Fiji	FJI	Cluster 2	WPR	Upper middle income	Access DID	17.3 (12.8, 26.1)	16.4 (11.8, 25.3)	17.9 (13.4, 26.8)	11 (7.6, 18.2)
Fiji	FJI	Cluster 2	WPR	Upper middle income	Watch DID	2.4 (2, 2.8)	3.2 (2.8, 3.8)	1.7 (1.4, 2.2)	2.4 (2, 2.8)
Fiji	FJI	Cluster 2	WPR	Upper middle income	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0.1)	0 (0, 0)
Finland	FIN	Cluster 4	EUR	High income	Total DID	10.6 (9.3, 12.3)	10.6 (9.3, 12.2)	10.6 (9.3, 12.3)	10.6 (9.3, 12.3)
Finland	FIN	Cluster 4	EUR	High income	Access DID	9.7 (8.4, 11.5)	9.5 (8.2, 11.2)	9.9 (8.6, 11.6)	9.7 (8.4, 11.5)
Finland	FIN	Cluster 4	EUR	High income	Watch DID	0.8 (0.8, 0.9)	1.1 (1, 1.2)	0.7 (0.6, 0.7)	0.8 (0.8, 0.9)
Finland	FIN	Cluster 4	EUR	High income	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
France	FRA	Cluster 4	EUR	High income	Total DID	10.7 (9.3, 12.4)	10.7 (9.3, 12.4)	10.7 (9.3, 12.3)	10.7 (9.3, 12.4)
France	FRA	Cluster 4	EUR	High income	Access DID	9.7 (8.2, 11.3)	9.4 (8, 11.1)	9.8 (8.4, 11.5)	9.7 (8.2, 11.3)
France	FRA	Cluster 4	EUR	High income	Watch DID	1 (0.9, 1.2)	1.3 (1.2, 1.5)	0.9 (0.8, 1)	1 (0.9, 1.2)
France	FRA	Cluster 4	EUR	High income	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
Gabon	GAB	Cluster 2	AFR	Upper middle income	Total DID	16.4 (12.5, 23)	16.4 (12.6, 23)	16.3 (12.4, 22.9)	11.1 (8.3, 17.2)
Gabon	GAB	Cluster 2	AFR	Upper middle income	Access DID	13.8 (9.9, 20.3)	13.1 (9.2, 19.6)	14.4 (10.6, 21)	8.4 (5.6, 14.5)
Gabon	GAB	Cluster 2	AFR	Upper middle income	Watch DID	2.3 (1.9, 3)	3 (2.6, 3.7)	1.7 (1.3, 2.3)	2.3 (1.9, 3)
Gabon	GAB	Cluster 2	AFR	Upper middle income	Reserve DID	0.2 (0.1, 0.9)	0.2 (0.1, 0.9)	0.1 (0, 0.4)	0.2 (0.1, 0.9)
Gambia, The	GMB	Cluster 1	AFR	Low income	Total DID	13.9 (10.8, 19.9)	14 (10.8, 19.9)	13.6 (10.5, 19.4)	9.4 (7.2, 14.4)

Gambia, The	GMB	Cluster 1	AFR	Low income	Access DID	9.2 (5.9, 14.8)	7.7 (4.4, 13.3)	10 (6.9, 15.6)	4.6 (2.2, 9.8)
Gambia, The	GMB	Cluster 1	AFR	Low income	Watch DID	4.5 (3.7, 5.8)	6 (5.1, 7.4)	3.3 (2.5, 4.6)	4.5 (3.7, 5.8)
Gambia, The	GMB	Cluster 1	AFR	Low income	Reserve DID	0.2 (0.1, 0.8)	0.2 (0.1, 0.8)	0.2 (0.1, 0.6)	0.2 (0.1, 0.8)
Georgia	GEO	Cluster 4	EUR	Upper middle income	Total DID	6.9 (6, 8)	6.9 (6, 8)	6.9 (6, 7.9)	6.9 (6, 8)
Georgia	GEO	Cluster 4	EUR	Upper middle income	Access DID	4.3 (3.1, 5.5)	4 (2.8, 5.2)	5.6 (4.7, 6.7)	4.3 (3.1, 5.5)
Georgia	GEO	Cluster 4	EUR	Upper middle income	Watch DID	1.7 (1.5, 1.9)	2 (1.8, 2.2)	1.2 (1.1, 1.4)	1.7 (1.5, 1.9)
Georgia	GEO	Cluster 4	EUR	Upper middle income	Reserve DID	0.9 (0.5, 1.8)	0.9 (0.5, 1.8)	0 (0, 0.1)	0.9 (0.5, 1.8)
Germany	DEU	Cluster 4	EUR	High income	Total DID	10.9 (9.5, 12.6)	10.9 (9.5, 12.6)	10.9 (9.5, 12.6)	10.9 (9.5, 12.6)
Germany	DEU	Cluster 4	EUR	High income	Access DID	9.9 (8.5, 11.6)	9.6 (8.2, 11.3)	10.1 (8.7, 11.8)	9.9 (8.5, 11.6)
Germany	DEU	Cluster 4	EUR	High income	Watch DID	0.9 (0.9, 1)	1.3 (1.1, 1.4)	0.7 (0.7, 0.8)	0.9 (0.9, 1)
Germany	DEU	Cluster 4	EUR	High income	Reserve DID	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)
Ghana	GHA	Cluster 1	AFR	Lower middle income	Total DID	16.4 (12.6, 22.6)	16.4 (12.6, 22.7)	16.1 (12.3, 22.3)	10.9 (8.4, 16.9)
Ghana	GHA	Cluster 1	AFR	Lower middle income	Access DID	10.6 (6.7, 16.9)	8.3 (4.4, 14.8)	11.9 (8.1, 18.1)	5.2 (2.4, 11.1)
Ghana	GHA	Cluster 1	AFR	Lower middle income	Watch DID	5.4 (4.5, 7)	7.7 (6.6, 9.4)	3.8 (3, 5.4)	5.4 (4.5, 7)
Ghana	GHA	Cluster 1	AFR	Lower middle income	Reserve DID	0.3 (0.1, 0.9)	0.3 (0.1, 0.9)	0.2 (0.1, 0.5)	0.3 (0.1, 0.9)
Greece	GRC	Cluster 4	EUR	High income	Total DID	10 (8.7, 11.7)	10 (8.7, 11.7)	10 (8.7, 11.7)	10 (8.7, 11.7)
Greece	GRC	Cluster 4	EUR	High income	Access DID	9.2 (7.9, 10.9)	8.9 (7.6, 10.7)	9.3 (8, 11)	9.2 (7.9, 10.9)
Greece	GRC	Cluster 4	EUR	High income	Watch DID	0.8 (0.8, 0.9)	1.1 (1, 1.2)	0.6 (0.6, 0.7)	0.8 (0.8, 0.9)
Greece	GRC	Cluster 4	EUR	High income	Reserve DID	0 (0, 0.1)	0 (0, 0.1)	0.1 (0, 0.2)	0 (0, 0.1)
Grenada	GRD	Cluster 3	AMR	Upper middle income	Total DID	13.8 (10.7, 19.2)	13.8 (10.7, 19.3)	13.8 (10.7, 19.3)	9.3 (7.1, 14.5)
Grenada	GRD	Cluster 3	AMR	Upper middle income	Access DID	12.2 (9, 17.7)	11.8 (8.6, 17.2)	12.6 (9.4, 18)	7.6 (5.4, 12.6)
Grenada	GRD	Cluster 3	AMR	Upper middle income	Watch DID	1.6 (1.4, 1.8)	2 (1.8, 2.3)	1.2 (1.1, 1.5)	1.6 (1.4, 1.8)
Grenada	GRD	Cluster 3	AMR	Upper middle income	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
Guatemala	GTM	Cluster 2	AMR	Upper middle income	Total DID	15.1 (11.6, 21.5)	15.1 (11.6, 21.5)	15 (11.5, 21.4)	10.2 (7.7, 15.6)
Guatemala	GTM	Cluster 2	AMR	Upper middle income	Access DID	12.9 (9.4, 19.4)	12.2 (8.6, 18.6)	13.3 (9.8, 19.7)	8 (5.5, 13.5)

Guatemala	GTM	Cluster 2	AMR	Upper middle income	Watch DID	2.1 (1.8, 2.5)	2.9 (2.5, 3.4)	1.5 (1.3, 1.9)	2.1 (1.8, 2.5)
Guatemala	GTM	Cluster 2	AMR	Upper middle income	Reserve DID	0.1 (0, 0.2)	0.1 (0, 0.2)	0.1 (0.1, 0.3)	0.1 (0, 0.2)
Guinea	GIN	Cluster 1	AFR	Low income	Total DID	15.8 (12.2, 22.3)	15.8 (12.2, 22.3)	15.4 (11.8, 21.8)	10.6 (8, 16.3)
Guinea	GIN	Cluster 1	AFR	Low income	Access DID	9.7 (6, 16.3)	7.7 (4, 14.4)	11 (7.3, 17.3)	4.6 (1.7, 10.2)
Guinea	GIN	Cluster 1	AFR	Low income	Watch DID	5.8 (4.7, 7.5)	7.8 (6.5, 9.6)	4.1 (3.1, 5.8)	5.8 (4.7, 7.5)
Guinea	GIN	Cluster 1	AFR	Low income	Reserve DID	0.2 (0.1, 0.6)	0.2 (0.1, 0.6)	0.1 (0.1, 0.4)	0.2 (0.1, 0.6)
Guinea-Bissau	GNB	Cluster 1	AFR	Low income	Total DID	16.3 (12.3, 23.3)	16.4 (12.4, 23.3)	16 (12.1, 22.9)	11 (8.3, 17.1)
Guinea-Bissau	GNB	Cluster 1	AFR	Low income	Access DID	11.4 (7.5, 18.1)	10.4 (6.5, 17.1)	12.1 (8.3, 18.7)	6.1 (3.2, 12.2)
Guinea-Bissau	GNB	Cluster 1	AFR	Low income	Watch DID	4.5 (3.5, 6.2)	5.6 (4.5, 7.3)	3.5 (2.6, 5.1)	4.5 (3.5, 6.2)
Guinea-Bissau	GNB	Cluster 1	AFR	Low income	Reserve DID	0.2 (0.1, 0.8)	0.2 (0.1, 0.8)	0.3 (0.1, 0.9)	0.2 (0.1, 0.8)
Guyana	GUY	Cluster 3	AMR	Upper middle income	Total DID	16.1 (12.2, 22.7)	16.1 (12.2, 22.7)	16.2 (12.3, 22.8)	10.8 (8.1, 16.6)
Guyana	GUY	Cluster 3	AMR	Upper middle income	Access DID	14.4 (10.6, 21.1)	13.8 (9.9, 20.3)	14.8 (11, 21.5)	9.2 (6.5, 15)
Guyana	GUY	Cluster 3	AMR	Upper middle income	Watch DID	1.6 (1.4, 1.8)	2.3 (2.1, 2.5)	1.2 (1.1, 1.4)	1.6 (1.4, 1.8)
Guyana	GUY	Cluster 3	AMR	Upper middle income	Reserve DID	0 (0, 0.1)	0 (0, 0.1)	0.1 (0, 0.2)	0 (0, 0.1)
Haiti	HTI	Cluster 2	AMR	Lower middle income	Total DID	22.7 (17.4, 32.3)	22.7 (17.4, 32.3)	22.6 (17.2, 32.1)	15.3 (11.5, 23.6)
Haiti	HTI	Cluster 2	AMR	Lower middle income	Access DID	20.4 (15, 29.9)	19.4 (14, 28.8)	21 (15.6, 30.5)	12.9 (9.2, 21.4)
Haiti	HTI	Cluster 2	AMR	Lower middle income	Watch DID	2.3 (2, 2.7)	3.3 (2.8, 3.8)	1.5 (1.3, 1.7)	2.3 (2, 2.7)
Haiti	HTI	Cluster 2	AMR	Lower middle income	Reserve DID	0.1 (0, 0.1)	0.1 (0, 0.1)	0.1 (0, 0.4)	0.1 (0, 0.1)
Honduras	HND	Cluster 2	AMR	Lower middle income	Total DID	17.6 (13.8, 25.4)	17.6 (13.8, 25.4)	17.6 (13.7, 25.4)	11.8 (9, 18.6)
Honduras	HND	Cluster 2	AMR	Lower middle income	Access DID	15.5 (11.6, 23.4)	15.1 (11.2, 23)	15.9 (11.9, 23.8)	9.9 (6.9, 16.6)
Honduras	HND	Cluster 2	AMR	Lower middle income	Watch DID	1.9 (1.7, 2.4)	2.3 (2, 2.7)	1.6 (1.3, 2)	1.9 (1.7, 2.4)
Honduras	HND	Cluster 2	AMR	Lower middle income	Reserve DID	0.1 (0, 0.2)	0.1 (0, 0.2)	0 (0, 0.1)	0.1 (0, 0.2)
Hungary	HUN	Cluster 4	EUR	High income	Total DID	7.8 (6.8, 9)	7.8 (6.8, 9)	7.7 (6.7, 9)	7.8 (6.8, 9)
Hungary	HUN	Cluster 4	EUR	High income	Access DID	6.8 (5.8, 8)	6.6 (5.6, 7.8)	6.9 (6, 8.1)	6.8 (5.8, 8)
Hungary	HUN	Cluster 4	EUR	High income	Watch DID	1 (0.8, 1.1)	1.2 (1, 1.3)	0.8 (0.7, 0.9)	1 (0.8, 1.1)

Hungary	HUN	Cluster 4	EUR	High income	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0.1)	0 (0, 0)
Iceland	ISL	Cluster 4	EUR	High income	Total DID	10.8 (9.4, 12.5)	10.8 (9.4, 12.5)	10.8 (9.4, 12.5)	10.8 (9.4, 12.5)
Iceland	ISL	Cluster 4	EUR	High income	Access DID	9.9 (8.4, 11.5)	9.7 (8.2, 11.3)	10 (8.6, 11.6)	9.9 (8.4, 11.5)
Iceland	ISL	Cluster 4	EUR	High income	Watch DID	1 (0.8, 1.1)	1.2 (1, 1.4)	0.8 (0.7, 1)	1 (0.8, 1.1)
Iceland	ISL	Cluster 4	EUR	High income	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
India	IND	Cluster 2	SEAR	Lower middle income	Total DID	14.7 (11.4, 20.7)	14.7 (11.4, 20.8)	14.5 (11.2, 20.5)	9.9 (7.5, 15.5)
India	IND	Cluster 2	SEAR	Lower middle income	Access DID	7.6 (3.8, 13.7)	3.4 (-0.8, 9.5)	10.5 (7, 16.3)	2.8 (-0.1, 8.2)
India	IND	Cluster 2	SEAR	Lower middle income	Watch DID	6 (5.3, 7)	10.3 (8.9, 11.7)	3.9 (3.3, 4.9)	6 (5.3, 7)
India	IND	Cluster 2	SEAR	Lower middle income	Reserve DID	1 (0.4, 2.8)	1 (0.4, 2.8)	0.2 (0.1, 0.4)	1 (0.4, 2.8)
Indonesia	IDN	Cluster 2	SEAR	Upper middle income	Total DID	19.7 (15.4, 27.7)	19.7 (15.4, 27.7)	19.6 (15.3, 27.7)	13.4 (10.1, 20.6)
Indonesia	IDN	Cluster 2	SEAR	Upper middle income	Access DID	16.5 (12.2, 24.6)	14.6 (10.3, 22.8)	17.6 (13.2, 25.6)	10.2 (7, 17.5)
Indonesia	IDN	Cluster 2	SEAR	Upper middle income	Watch DID	3 (2.7, 3.6)	5 (4.4, 5.7)	2 (1.7, 2.5)	3 (2.7, 3.6)
Indonesia	IDN	Cluster 2	SEAR	Upper middle income	Reserve DID	0.1 (0, 0.2)	0.1 (0, 0.2)	0 (0, 0.1)	0.1 (0, 0.2)
Iran, Islamic Rep.	IRN	Cluster 3	EMR	Lower middle income	Total DID	14.3 (11, 20.4)	14.3 (11, 20.3)	14.4 (11.1, 20.5)	9.7 (7.3, 15)
Iran, Islamic Rep.	IRN	Cluster 3	EMR	Lower middle income	Access DID	12.6 (9.4, 18.6)	12.2 (8.9, 18.2)	12.9 (9.6, 19)	8 (5.7, 13.2)
Iran, Islamic Rep.	IRN	Cluster 3	EMR	Lower middle income	Watch DID	1.6 (1.3, 2.1)	2.1 (1.7, 2.5)	1.4 (1.1, 1.9)	1.6 (1.3, 2.1)
Iran, Islamic Rep.	IRN	Cluster 3	EMR	Lower middle income	Reserve DID	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)
Iraq	IRQ	Cluster 2	EMR	Upper middle income	Total DID	14.2 (10.9, 20.1)	14.3 (10.9, 20.1)	14.2 (10.8, 20.1)	9.6 (7.2, 14.6)
Iraq	IRQ	Cluster 2	EMR	Upper middle income	Access DID	12.5 (9.1, 18.2)	11.9 (8.6, 17.6)	12.8 (9.5, 18.6)	7.8 (5.4, 12.8)
Iraq	IRQ	Cluster 2	EMR	Upper middle income	Watch DID	1.7 (1.4, 2.1)	2.2 (1.9, 2.7)	1.2 (1, 1.6)	1.7 (1.4, 2.1)
Iraq	IRQ	Cluster 2	EMR	Upper middle income	Reserve DID	0.1 (0, 0.2)	0.1 (0, 0.2)	0.1 (0, 0.3)	0.1 (0, 0.2)
Ireland	IRL	Cluster 4	EUR	High income	Total DID	11.3 (9.9, 13.1)	11.3 (9.9, 13.1)	11.3 (9.8, 13.1)	11.3 (9.9, 13.1)
Ireland	IRL	Cluster 4	EUR	High income	Access DID	10.4 (8.9, 12.2)	10.1 (8.7, 12)	10.4 (9, 12.3)	10.4 (8.9, 12.2)
Ireland	IRL	Cluster 4	EUR	High income	Watch DID	0.9 (0.8, 1)	1.1 (1, 1.3)	0.8 (0.7, 0.9)	0.9 (0.8, 1)
Ireland	IRL	Cluster 4	EUR	High income	Reserve DID	0 (0, 0)	0 (0, 0)	0.1 (0, 0.1)	0 (0, 0)

Israel	ISR	Cluster 3	EUR	High income	Total DID	17.6 (13.4, 24.9)	17.6 (13.4, 24.9)	17.8 (13.5, 25.4)	11.8 (9, 18.4)
Israel	ISR	Cluster 3	EUR	High income	Access DID	16.7 (12.4, 24)	16.4 (12.1, 23.7)	17.1 (12.8, 24.6)	11 (8.1, 17.6)
Israel	ISR	Cluster 3	EUR	High income	Watch DID	0.8 (0.7, 0.9)	1.1 (1, 1.2)	0.7 (0.6, 0.8)	0.8 (0.7, 0.9)
Israel	ISR	Cluster 3	EUR	High income	Reserve DID	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)
Italy	ITA	Cluster 4	EUR	High income	Total DID	10.7 (9.3, 12.3)	10.7 (9.3, 12.3)	10.7 (9.3, 12.3)	10.7 (9.3, 12.3)
Italy	ITA	Cluster 4	EUR	High income	Access DID	10.1 (8.7, 11.6)	9.9 (8.4, 11.4)	10.2 (8.8, 11.8)	10.1 (8.7, 11.6)
Italy	ITA	Cluster 4	EUR	High income	Watch DID	0.6 (0.6, 0.7)	0.9 (0.8, 0.9)	0.5 (0.4, 0.5)	0.6 (0.6, 0.7)
Italy	ITA	Cluster 4	EUR	High income	Reserve DID	0 (0, 0.1)	0 (0, 0.1)	0.1 (0, 0.1)	0 (0, 0.1)
Jamaica	JAM	Cluster 3	AMR	Upper middle income	Total DID	16.3 (12.3, 23.4)	16.3 (12.3, 23.4)	16.2 (12.3, 23.4)	10.9 (8.3, 17)
Jamaica	JAM	Cluster 3	AMR	Upper middle income	Access DID	14.6 (10.7, 21.7)	14.2 (10.2, 21.3)	14.9 (10.9, 22.1)	9.3 (6.7, 15.3)
Jamaica	JAM	Cluster 3	AMR	Upper middle income	Watch DID	1.6 (1.5, 1.9)	2.1 (1.9, 2.3)	1.3 (1.1, 1.5)	1.6 (1.5, 1.9)
Jamaica	JAM	Cluster 3	AMR	Upper middle income	Reserve DID	0 (0, 0)	0 (0, 0)	0.1 (0, 0.2)	0 (0, 0)
Japan	JPN	Cluster 4	WPR	High income	Total DID	12.8 (11.2, 14.8)	12.8 (11.2, 14.9)	12.8 (11.1, 14.8)	12.8 (11.2, 14.8)
Japan	JPN	Cluster 4	WPR	High income	Access DID	11.8 (10.1, 13.8)	11.5 (9.8, 13.6)	12 (10.3, 14.1)	11.8 (10.1, 13.8)
Japan	JPN	Cluster 4	WPR	High income	Watch DID	1 (0.9, 1.2)	1.3 (1.2, 1.5)	0.8 (0.7, 0.9)	1 (0.9, 1.2)
Japan	JPN	Cluster 4	WPR	High income	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
Jordan	JOR	Cluster 3	EMR	Upper middle income	Total DID	12.5 (9.5, 18.1)	12.5 (9.5, 18.1)	12.7 (9.6, 18.3)	8.5 (6.3, 13.1)
Jordan	JOR	Cluster 3	EMR	Upper middle income	Access DID	11.4 (8.4, 16.9)	10.9 (8, 16.4)	11.7 (8.7, 17.3)	7.4 (5.1, 11.9)
Jordan	JOR	Cluster 3	EMR	Upper middle income	Watch DID	1.1 (1, 1.3)	1.6 (1.4, 1.8)	0.9 (0.8, 1.1)	1.1 (1, 1.3)
Jordan	JOR	Cluster 3	EMR	Upper middle income	Reserve DID	0 (0, 0.1)	0 (0, 0.1)	0.1 (0, 0.1)	0 (0, 0.1)
Kazakhstan	KAZ	Cluster 2	EUR	Upper middle income	Total DID	12.3 (9.4, 17.3)	12.3 (9.4, 17.3)	12.4 (9.5, 17.6)	8.3 (6.2, 12.7)
Kazakhstan	KAZ	Cluster 2	EUR	Upper middle income	Access DID	9.6 (6.7, 14.7)	9.3 (6.3, 14.3)	11.1 (8.2, 16.3)	5.6 (3.2, 10.2)
Kazakhstan	KAZ	Cluster 2	EUR	Upper middle income	Watch DID	1.7 (1.5, 1.9)	2 (1.8, 2.3)	1.2 (1.1, 1.5)	1.7 (1.5, 1.9)
Kazakhstan	KAZ	Cluster 2	EUR	Upper middle income	Reserve DID	1 (0.5, 1.9)	1 (0.5, 1.9)	0 (0, 0.1)	1 (0.5, 1.9)
Kenya	KEN	Cluster 1	AFR	Lower middle income	Total DID	23.9 (18.4, 34.2)	23.9 (18.4, 34.2)	23.7 (18.2, 34)	16.1 (12.1, 25.2)

Kenya	KEN	Cluster 1	AFR	Lower middle income	Access DID	16.5 (10.8, 26.7)	13.6 (7.7, 24)	18.2 (12.5, 28.4)	8.7 (4.6, 17.4)
Kenya	KEN	Cluster 1	AFR	Lower middle income	Watch DID	7.1 (6.2, 8.6)	10 (8.8, 11.6)	5.4 (4.5, 6.8)	7.1 (6.2, 8.6)
Kenya	KEN	Cluster 1	AFR	Lower middle income	Reserve DID	0.2 (0.1, 0.6)	0.2 (0.1, 0.6)	0.1 (0, 0.3)	0.2 (0.1, 0.6)
Kiribati	KIR	Cluster 2	WPR	Lower middle income	Total DID	20.3 (15.4, 29.3)	20.3 (15.4, 29.3)	20.2 (15.3, 29.2)	13.6 (10.2, 21.3)
Kiribati	KIR	Cluster 2	WPR	Lower middle income	Access DID	17.4 (12.5, 26.4)	16.4 (11.4, 25.3)	18.2 (13.4, 27.2)	10.8 (7.4, 18.4)
Kiribati	KIR	Cluster 2	WPR	Lower middle income	Watch DID	2.7 (2.3, 3.4)	3.8 (3.3, 4.5)	1.9 (1.5, 2.6)	2.7 (2.3, 3.4)
Kiribati	KIR	Cluster 2	WPR	Lower middle income	Reserve DID	0.1 (0, 0.3)	0.1 (0, 0.3)	0 (0, 0)	0.1 (0, 0.3)
Korea, Dem. People's Rep.	PRK	Cluster 2	SEAR	Low income	Total DID	11.5 (8.9, 16.3)	11.6 (8.9, 16.3)	11.7 (8.9, 16.4)	7.7 (5.9, 11.8)
Korea, Dem. People's Rep.	PRK	Cluster 2	SEAR	Low income	Access DID	8.8 (5.9, 13.7)	8.5 (5.5, 13.3)	10.4 (7.6, 15.2)	5 (2.6, 9.2)
Korea, Dem. People's Rep.	PRK	Cluster 2	SEAR	Low income	Watch DID	1.7 (1.5, 2)	2.1 (1.8, 2.4)	1.2 (1.1, 1.5)	1.7 (1.5, 2)
Korea, Dem. People's Rep.	PRK	Cluster 2	SEAR	Low income	Reserve DID	0.9 (0.4, 2.4)	0.9 (0.4, 2.4)	0 (0, 0.1)	0.9 (0.4, 2.4)
Korea, Rep.	KOR	Cluster 4	WPR	High income	Total DID	12.1 (10.4, 14.3)	12.1 (10.4, 14.3)	12.1 (10.4, 14.3)	12.1 (10.4, 14.3)
Korea, Rep.	KOR	Cluster 4	WPR	High income	Access DID	11.4 (9.7, 13.5)	11.2 (9.6, 13.4)	11.5 (9.9, 13.7)	11.4 (9.7, 13.5)
Korea, Rep.	KOR	Cluster 4	WPR	High income	Watch DID	0.6 (0.6, 0.7)	0.8 (0.7, 0.9)	0.5 (0.4, 0.5)	0.6 (0.6, 0.7)
Korea, Rep.	KOR	Cluster 4	WPR	High income	Reserve DID	0.1 (0, 0.2)	0.1 (0, 0.2)	0.1 (0, 0.2)	0.1 (0, 0.2)
Kuwait	KWT	Cluster 3	EMR	High income	Total DID	13.4 (10.2, 19.1)	13.4 (10.1, 19.1)	13.5 (10.3, 19.3)	9 (6.8, 14.1)
Kuwait	KWT	Cluster 3	EMR	High income	Access DID	12.1 (8.9, 17.8)	11.8 (8.5, 17.4)	12.4 (9.1, 18.2)	7.7 (5.4, 12.8)
Kuwait	KWT	Cluster 3	EMR	High income	Watch DID	1.2 (1.1, 1.5)	1.6 (1.4, 1.8)	1.1 (0.9, 1.3)	1.2 (1.1, 1.5)
Kuwait	KWT	Cluster 3	EMR	High income	Reserve DID	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0)	0 (0, 0.1)
Kyrgyz Republic	KGZ	Cluster 2	EUR	Lower middle income	Total DID	9.8 (7.5, 14.1)	9.8 (7.5, 14.1)	9.8 (7.5, 14.2)	6.6 (5, 10.2)
Kyrgyz Republic	KGZ	Cluster 2	EUR	Lower middle income	Access DID	6 (3, 10.4)	5.7 (2.6, 10.1)	8.5 (6.1, 12.7)	2.9 (0.2, 6.6)
Kyrgyz Republic	KGZ	Cluster 2	EUR	Lower middle income	Watch DID	2 (1.7, 2.3)	2.4 (2.1, 2.7)	1.3 (1.1, 1.6)	2 (1.7, 2.3)
Kyrgyz Republic	KGZ	Cluster 2	EUR	Lower middle income	Reserve DID	1.7 (0.8, 3.9)	1.7 (0.8, 3.9)	0 (0, 0.1)	1.7 (0.8, 3.9)
Lao PDR	LAO	Cluster 2	WPR	Lower middle income	Total DID	17.7 (13.3, 25.2)	17.7 (13.3, 25.3)	17.5 (13.2, 25.1)	11.9 (9, 18.7)

Lao PDR	LAO	Cluster 2	WPR	Lower middle income	Access DID	14.6 (10.4, 22.1)	12.6 (8.3, 20.3)	15.6 (11.4, 23.1)	8.9 (5.8, 15.4)
Lao PDR	LAO	Cluster 2	WPR	Lower middle income	Watch DID	3 (2.7, 3.5)	5 (4.4, 5.8)	1.9 (1.6, 2.3)	3 (2.7, 3.5)
Lao PDR	LAO	Cluster 2	WPR	Lower middle income	Reserve DID	0 (0, 0.2)	0 (0, 0.2)	0.1 (0, 0.1)	0 (0, 0.2)
Latvia	LVA	Cluster 4	EUR	High income	Total DID	10.2 (8.9, 11.7)	10.2 (8.9, 11.7)	10.2 (8.9, 11.7)	10.2 (8.9, 11.7)
Latvia	LVA	Cluster 4	EUR	High income	Access DID	8.6 (7.3, 10.2)	8.3 (7, 9.9)	9 (7.7, 10.6)	8.6 (7.3, 10.2)
Latvia	LVA	Cluster 4	EUR	High income	Watch DID	1.4 (1.3, 1.6)	1.7 (1.6, 1.9)	1.1 (1, 1.2)	1.4 (1.3, 1.6)
Latvia	LVA	Cluster 4	EUR	High income	Reserve DID	0.2 (0.1, 0.4)	0.2 (0.1, 0.4)	0.1 (0, 0.1)	0.2 (0.1, 0.4)
Lebanon	LBN	Cluster 3	EMR	Upper middle income	Total DID	13.2 (9.9, 18.5)	13.2 (9.9, 18.5)	13.3 (10, 18.7)	8.9 (6.6, 13.7)
Lebanon	LBN	Cluster 3	EMR	Upper middle income	Access DID	11.7 (8.5, 17.1)	11.2 (8, 16.7)	12.1 (8.8, 17.6)	7.4 (5.1, 12.3)
Lebanon	LBN	Cluster 3	EMR	Upper middle income	Watch DID	1.4 (1.2, 1.7)	1.9 (1.6, 2.2)	1.1 (0.9, 1.5)	1.4 (1.2, 1.7)
Lebanon	LBN	Cluster 3	EMR	Upper middle income	Reserve DID	0 (0, 0.1)	0 (0, 0.1)	0.1 (0, 0.2)	0 (0, 0.1)
Lesotho	LSO	Cluster 2	AFR	Lower middle income	Total DID	16.4 (12.8, 23.3)	16.5 (12.8, 23.4)	16.2 (12.5, 22.9)	11.1 (8.4, 17.2)
Lesotho	LSO	Cluster 2	AFR	Lower middle income	Access DID	10.6 (6.3, 17.6)	9.7 (5.5, 16.8)	12.9 (9.3, 19.8)	5.3 (1.4, 11.3)
Lesotho	LSO	Cluster 2	AFR	Lower middle income	Watch DID	4.1 (3.5, 5)	4.9 (4.2, 5.9)	2.9 (2.4, 3.7)	4.1 (3.5, 5)
Lesotho	LSO	Cluster 2	AFR	Lower middle income	Reserve DID	1.5 (0.5, 4.3)	1.5 (0.5, 4.3)	0.3 (0.1, 0.8)	1.5 (0.5, 4.3)
Liberia	LBR	Cluster 1	AFR	Low income	Total DID	20.9 (16, 29.6)	20.9 (16.1, 29.7)	20.6 (15.8, 29.2)	14.1 (10.7, 21.7)
Liberia	LBR	Cluster 1	AFR	Low income	Access DID	13.6 (8.6, 21.8)	11.8 (6.8, 20)	14.8 (9.9, 22.9)	6.8 (3, 14.6)
Liberia	LBR	Cluster 1	AFR	Low income	Watch DID	7 (5.5, 9.5)	8.8 (7.2, 11.3)	5.6 (4.2, 8.1)	7 (5.5, 9.5)
Liberia	LBR	Cluster 1	AFR	Low income	Reserve DID	0.2 (0, 0.6)	0.2 (0, 0.6)	0.1 (0, 0.3)	0.2 (0, 0.6)
Libya	LBY	Cluster 3	EMR	Upper middle income	Total DID	14 (10.5, 19.8)	14 (10.5, 19.8)	14.1 (10.6, 20)	9.4 (7.1, 14.5)
Libya	LBY	Cluster 3	EMR	Upper middle income	Access DID	12.5 (9.1, 18.3)	12.1 (8.7, 17.9)	12.9 (9.5, 18.8)	7.9 (5.7, 13)
Libya	LBY	Cluster 3	EMR	Upper middle income	Watch DID	1.4 (1.2, 1.6)	1.8 (1.6, 2.1)	1.1 (1, 1.3)	1.4 (1.2, 1.6)
Libya	LBY	Cluster 3	EMR	Upper middle income	Reserve DID	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)
Lithuania	LTU	Cluster 4	EUR	High income	Total DID	10.3 (8.9, 11.7)	10.3 (8.9, 11.7)	10.2 (8.9, 11.7)	10.3 (8.9, 11.7)
Lithuania	LTU	Cluster 4	EUR	High income	Access DID	8.1 (6.7, 9.7)	7.8 (6.4, 9.4)	9 (7.6, 10.6)	8.1 (6.7, 9.7)

Lithuania	LTU	Cluster 4	EUR	High income	Watch DID	1.5 (1.4, 1.7)	1.9 (1.7, 2)	1.1 (1, 1.3)	1.5 (1.4, 1.7)
Lithuania	LTU	Cluster 4	EUR	High income	Reserve DID	0.6 (0.3, 1.1)	0.6 (0.3, 1.1)	0.1 (0, 0.1)	0.6 (0.3, 1.1)
Luxembourg	LUX	Cluster 4	EUR	High income	Total DID	10.9 (9.4, 12.7)	10.9 (9.4, 12.7)	10.9 (9.3, 12.7)	10.9 (9.4, 12.7)
Luxembourg	LUX	Cluster 4	EUR	High income	Access DID	10.1 (8.5, 11.9)	9.9 (8.3, 11.6)	10.3 (8.7, 12)	10.1 (8.5, 11.9)
Luxembourg	LUX	Cluster 4	EUR	High income	Watch DID	0.8 (0.7, 0.9)	1.1 (0.9, 1.2)	0.6 (0.6, 0.7)	0.8 (0.7, 0.9)
Luxembourg	LUX	Cluster 4	EUR	High income	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
Madagascar	MDG	Cluster 1	AFR	Low income	Total DID	19.5 (15.1, 27.9)	19.6 (15.1, 28)	19.2 (14.8, 27.6)	13.2 (10, 20.6)
Madagascar	MDG	Cluster 1	AFR	Low income	Access DID	11.9 (7.5, 20)	10.1 (5.8, 18.4)	13.4 (9.1, 21.4)	5.7 (2.2, 12.6)
Madagascar	MDG	Cluster 1	AFR	Low income	Watch DID	7 (5.7, 9.3)	8.8 (7.3, 11.2)	5.5 (4.3, 7.8)	7 (5.7, 9.3)
Madagascar	MDG	Cluster 1	AFR	Low income	Reserve DID	0.3 (0.1, 1.1)	0.3 (0.1, 1.1)	0.1 (0, 0.3)	0.3 (0.1, 1.1)
Malawi	MWI	Cluster 1	AFR	Low income	Total DID	20.2 (15.6, 29.4)	20.2 (15.6, 29.4)	20 (15.4, 29.2)	13.8 (10.4, 21)
Malawi	MWI	Cluster 1	AFR	Low income	Access DID	14.8 (10.2, 23.8)	13.7 (9.1, 22.7)	15.7 (11.2, 24.7)	8.3 (4.6, 15.6)
Malawi	MWI	Cluster 1	AFR	Low income	Watch DID	5 (4.1, 6.8)	6.1 (5.1, 7.9)	4 (3.2, 5.7)	5 (4.1, 6.8)
Malawi	MWI	Cluster 1	AFR	Low income	Reserve DID	0.3 (0.1, 0.9)	0.3 (0.1, 0.9)	0.1 (0, 0.2)	0.3 (0.1, 0.9)
Malaysia	MYS	Cluster 2	WPR	Upper middle income	Total DID	15.8 (12.2, 22.6)	15.8 (12.2, 22.6)	15.9 (12.3, 22.7)	10.7 (8, 16.3)
Malaysia	MYS	Cluster 2	WPR	Upper middle income	Access DID	13.3 (9.7, 20.1)	12.1 (8.5, 18.6)	14.1 (10.5, 21)	8.2 (5.6, 13.8)
Malaysia	MYS	Cluster 2	WPR	Upper middle income	Watch DID	2.4 (2.1, 2.8)	3.7 (3.3, 4.2)	1.7 (1.5, 2.1)	2.4 (2.1, 2.8)
Malaysia	MYS	Cluster 2	WPR	Upper middle income	Reserve DID	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)
Maldives	MDV	Cluster 2	SEAR	Upper middle income	Total DID	16.7 (12.8, 23.6)	16.7 (12.8, 23.6)	16.9 (13, 23.9)	11.3 (8.4, 17.7)
Maldives	MDV	Cluster 2	SEAR	Upper middle income	Access DID	14.6 (10.8, 21.5)	13.4 (9.6, 20.3)	15.3 (11.5, 22.3)	9.2 (6.3, 15.7)
Maldives	MDV	Cluster 2	SEAR	Upper middle income	Watch DID	2.1 (1.8, 2.4)	3.2 (2.8, 3.8)	1.6 (1.3, 1.9)	2.1 (1.8, 2.4)
Maldives	MDV	Cluster 2	SEAR	Upper middle income	Reserve DID	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0)	0 (0, 0.1)
Mali	MLI	Cluster 1	AFR	Low income	Total DID	16.3 (12.5, 23)	16.4 (12.6, 23.2)	15.7 (12, 22.3)	11 (8.4, 16.8)
Mali	MLI	Cluster 1	AFR	Low income	Access DID	8.4 (4.6, 15)	6.1 (2, 12.7)	9.7 (6, 16.3)	3.1 (-0.1, 9.2)
Mali	MLI	Cluster 1	AFR	Low income	Watch DID	7.4 (6.1, 9.3)	9.9 (8.2, 12.1)	5.2 (4.2, 7)	7.4 (6.1, 9.3)
Mali	MLI	Cluster 1	AFR	Low income	Reserve DID	0.3 (0.1, 1)	0.3 (0.1, 1)	0.6 (0.2, 1.8)	0.3 (0.1, 1)
Malta	MLT	Cluster 4	EUR	High income	Total DID	9.2 (8, 10.6)	9.2 (8, 10.6)	9.2 (8, 10.6)	9.2 (8, 10.6)

Malta	MLT	Cluster 4	EUR	High income	Access DID	8.4 (7.2, 9.8)	8.2 (7, 9.6)	8.6 (7.4, 10)	8.4 (7.2, 9.8)
Malta	MLT	Cluster 4	EUR	High income	Watch DID	0.7 (0.7, 0.8)	1 (0.9, 1.1)	0.6 (0.5, 0.6)	0.7 (0.7, 0.8)
Malta	MLT	Cluster 4	EUR	High income	Reserve DID	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)
Mauritania	MRT	Cluster 1	AFR	Lower middle income	Total DID	13.2 (10.1, 19.1)	13.3 (10.2, 19.1)	12.9 (9.9, 18.7)	9 (6.7, 13.7)
Mauritania	MRT	Cluster 1	AFR	Lower middle income	Access DID	7 (3.6, 12.6)	5.5 (1.9, 10.9)	7.9 (4.5, 13.3)	2.7 (-0.1, 7.8)
Mauritania	MRT	Cluster 1	AFR	Lower middle income	Watch DID	6 (4.7, 8.6)	7.6 (6.3, 10.3)	4.8 (3.5, 7.4)	6 (4.7, 8.6)
Mauritania	MRT	Cluster 1	AFR	Lower middle income	Reserve DID	0.1 (0, 0.4)	0.1 (0, 0.4)	0.2 (0.1, 0.6)	0.1 (0, 0.4)
Mauritius	MUS	Cluster 3	AFR	Upper middle income	Total DID	15 (11.7, 20.8)	15 (11.7, 20.8)	15.2 (11.8, 21)	10.1 (7.7, 15.5)
Mauritius	MUS	Cluster 3	AFR	Upper middle income	Access DID	13.5 (10.1, 19.2)	12.9 (9.5, 18.6)	13.9 (10.5, 19.7)	8.5 (6.1, 13.9)
Mauritius	MUS	Cluster 3	AFR	Upper middle income	Watch DID	1.6 (1.4, 1.8)	2.2 (2, 2.4)	1.2 (1.1, 1.4)	1.6 (1.4, 1.8)
Mauritius	MUS	Cluster 3	AFR	Upper middle income	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0.1)	0 (0, 0)
Mexico	MEX	Cluster 3	AMR	Upper middle income	Total DID	17.9 (13.7, 25.5)	17.9 (13.7, 25.5)	18.1 (13.9, 25.8)	12 (9.1, 18.7)
Mexico	MEX	Cluster 3	AMR	Upper middle income	Access DID	16.3 (12.2, 24)	15.7 (11.6, 23.4)	16.7 (12.5, 24.6)	10.4 (7.5, 17.1)
Mexico	MEX	Cluster 3	AMR	Upper middle income	Watch DID	1.5 (1.4, 1.7)	2.1 (1.9, 2.3)	1.2 (1.1, 1.4)	1.5 (1.4, 1.7)
Mexico	MEX	Cluster 3	AMR	Upper middle income	Reserve DID	0.1 (0, 0.1)	0.1 (0, 0.1)	0.1 (0, 0.2)	0.1 (0, 0.1)
Micronesia, Fed. Sts.	FSM	Cluster 2	WPR	Lower middle income	Total DID	18.3 (14.1, 25.9)	18.3 (14.1, 25.9)	18.3 (14, 25.9)	12.3 (9.2, 19.2)
Micronesia, Fed. Sts.	FSM	Cluster 2	WPR	Lower middle income	Access DID	16.3 (12, 24)	15.4 (11.1, 23.1)	16.9 (12.7, 24.6)	10.3 (7.2, 17.3)
Micronesia, Fed. Sts.	FSM	Cluster 2	WPR	Lower middle income	Watch DID	1.9 (1.7, 2.4)	2.9 (2.5, 3.4)	1.4 (1.1, 1.8)	1.9 (1.7, 2.4)
Micronesia, Fed. Sts.	FSM	Cluster 2	WPR	Lower middle income	Reserve DID	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0)	0 (0, 0.1)
Moldova	MDA	Cluster 4	EUR	Upper middle income	Total DID	14.3 (12.4, 16.6)	14.3 (12.4, 16.6)	14.2 (12.3, 16.6)	14.3 (12.4, 16.6)
Moldova	MDA	Cluster 4	EUR	Upper middle income	Access DID	8.6 (5.4, 11.4)	8.1 (4.9, 10.9)	12.5 (10.6, 14.8)	8.6 (5.4, 11.4)
Moldova	MDA	Cluster 4	EUR	Upper middle income	Watch DID	2.7 (2.4, 3)	3.2 (2.9, 3.5)	1.6 (1.4, 1.9)	2.7 (2.4, 3)
Moldova	MDA	Cluster 4	EUR	Upper middle income	Reserve DID	3 (1.5, 5.5)	3 (1.5, 5.5)	0.1 (0, 0.2)	3 (1.5, 5.5)

Mongolia	MNG	Cluster 2	WPR	Lower middle income	Total DID	10.5 (8, 14.9)	10.5 (8, 14.9)	10.6 (8.1, 15)	7.1 (5.4, 10.9)
Mongolia	MNG	Cluster 2	WPR	Lower middle income	Access DID	8 (5.5, 12.5)	7.7 (5.1, 12.2)	9.3 (6.9, 13.8)	4.6 (2.5, 8.4)
Mongolia	MNG	Cluster 2	WPR	Lower middle income	Watch DID	1.6 (1.4, 2)	2 (1.7, 2.3)	1.2 (1, 1.4)	1.6 (1.4, 2)
Mongolia	MNG	Cluster 2	WPR	Lower middle income	Reserve DID	0.7 (0.3, 2.1)	0.7 (0.3, 2.1)	0 (0, 0.1)	0.7 (0.3, 2.1)
Montenegro	MNE	Cluster 4	EUR	Upper middle income	Total DID	8.1 (6.9, 9.4)	8.1 (7, 9.4)	8.1 (6.9, 9.4)	8.1 (6.9, 9.4)
Montenegro	MNE	Cluster 4	EUR	Upper middle income	Access DID	7.2 (6, 8.5)	7 (5.9, 8.3)	7.3 (6.2, 8.6)	7.2 (6, 8.5)
Montenegro	MNE	Cluster 4	EUR	Upper middle income	Watch DID	0.9 (0.8, 1)	1.1 (1, 1.2)	0.8 (0.7, 0.9)	0.9 (0.8, 1)
Montenegro	MNE	Cluster 4	EUR	Upper middle income	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
Morocco	MAR	Cluster 3	EMR	Lower middle income	Total DID	16.6 (14, 22.9)	16.6 (14, 22.9)	16.6 (14, 22.9)	11.4 (8.5, 17.3)
Morocco	MAR	Cluster 3	EMR	Lower middle income	Access DID	14.9 (12.4, 21.2)	14.4 (11.8, 20.7)	15.3 (12.8, 21.7)	9.7 (6.8, 15.7)
Morocco	MAR	Cluster 3	EMR	Lower middle income	Watch DID	1.5 (1.4, 1.8)	2.1 (1.9, 2.3)	1.2 (1, 1.4)	1.5 (1.4, 1.8)
Morocco	MAR	Cluster 3	EMR	Lower middle income	Reserve DID	0.1 (0, 0.3)	0.1 (0, 0.3)	0 (0, 0.1)	0.1 (0, 0.3)
Mozambique	MOZ	Cluster 1	AFR	Low income	Total DID	16 (12.3, 22.8)	16 (12.3, 22.9)	15.6 (12, 22.4)	10.7 (8.1, 17)
Mozambique	MOZ	Cluster 1	AFR	Low income	Access DID	10.3 (6.3, 17.3)	8.6 (4.5, 15.6)	12.4 (8.8, 19.2)	5 (1.9, 10.9)
Mozambique	MOZ	Cluster 1	AFR	Low income	Watch DID	4.5 (3.9, 5.5)	6.3 (5.5, 7.4)	3 (2.5, 3.9)	4.5 (3.9, 5.5)
Mozambique	MOZ	Cluster 1	AFR	Low income	Reserve DID	1 (0.4, 2.6)	1 (0.4, 2.6)	0.1 (0.1, 0.3)	1 (0.4, 2.6)
Myanmar	MMR	Cluster 2	SEAR	Lower middle income	Total DID	14.2 (10.9, 20.2)	14.2 (10.9, 20.3)	14.1 (10.7, 20.1)	9.7 (7.2, 14.8)
Myanmar	MMR	Cluster 2	SEAR	Lower middle income	Access DID	10.4 (6.8, 16.4)	8.5 (4.9, 14.6)	12.1 (8.8, 18)	5.9 (3.1, 11.1)
Myanmar	MMR	Cluster 2	SEAR	Lower middle income	Watch DID	3.1 (2.8, 3.5)	5 (4.4, 5.7)	1.9 (1.7, 2.3)	3.1 (2.8, 3.5)
Myanmar	MMR	Cluster 2	SEAR	Lower middle income	Reserve DID	0.7 (0.3, 1.6)	0.7 (0.3, 1.6)	0.1 (0, 0.1)	0.7 (0.3, 1.6)
Namibia	NAM	Cluster 2	AFR	Upper middle income	Total DID	18 (14, 25.6)	18 (14, 25.6)	17.8 (13.8, 25.4)	12.2 (9.2, 18.9)
Namibia	NAM	Cluster 2	AFR	Upper middle income	Access DID	12.5 (8.1, 20)	11.8 (7.4, 19.3)	14.6 (10.5, 22.1)	6.7 (3.2, 13.3)
Namibia	NAM	Cluster 2	AFR	Upper middle income	Watch DID	4.1 (3.5, 5)	4.8 (4.1, 5.8)	3.1 (2.6, 4)	4.1 (3.5, 5)

Namibia	NAM	Cluster 2	AFR	Upper middle income	Reserve DID	1.3 (0.5, 3)	1.3 (0.5, 3)	0.1 (0, 0.3)	1.3 (0.5, 3)
Nepal	NPL	Cluster 2	SEAR	Lower middle income	Total DID	17.9 (13.9, 25.4)	17.9 (13.9, 25.4)	17.8 (13.8, 25.2)	12 (9.2, 18.8)
Nepal	NPL	Cluster 2	SEAR	Lower middle income	Access DID	12.8 (8.8, 20.4)	8.9 (4.7, 16.6)	15 (11.1, 22.3)	7 (4, 13.8)
Nepal	NPL	Cluster 2	SEAR	Lower middle income	Watch DID	4.4 (3.9, 5.2)	8.4 (7.3, 9.7)	2.5 (2.1, 3.2)	4.4 (3.9, 5.2)
Nepal	NPL	Cluster 2	SEAR	Lower middle income	Reserve DID	0.5 (0.2, 1.2)	0.5 (0.2, 1.2)	0.1 (0, 0.2)	0.5 (0.2, 1.2)
Netherlands	NLD	Cluster 4	EUR	High income	Total DID	10.7 (9.2, 12.4)	10.7 (9.2, 12.4)	10.6 (9.2, 12.4)	10.7 (9.2, 12.4)
Netherlands	NLD	Cluster 4	EUR	High income	Access DID	9.6 (8.1, 11.3)	9.3 (7.8, 11.1)	9.8 (8.3, 11.5)	9.6 (8.1, 11.3)
Netherlands	NLD	Cluster 4	EUR	High income	Watch DID	1.1 (0.9, 1.2)	1.4 (1.2, 1.5)	0.8 (0.8, 1)	1.1 (0.9, 1.2)
Netherlands	NLD	Cluster 4	EUR	High income	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
New Zealand	NZL	Cluster 4	WPR	High income	Total DID	14.3 (12.5, 16.4)	14.3 (12.5, 16.4)	14.3 (12.5, 16.4)	14.3 (12.5, 16.4)
New Zealand	NZL	Cluster 4	WPR	High income	Access DID	13.3 (11.5, 15.4)	13 (11.2, 15.1)	13.4 (11.6, 15.5)	13.3 (11.5, 15.4)
New Zealand	NZL	Cluster 4	WPR	High income	Watch DID	1 (0.9, 1.1)	1.3 (1.2, 1.4)	0.8 (0.8, 0.9)	1 (0.9, 1.1)
New Zealand	NZL	Cluster 4	WPR	High income	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0.1)	0 (0, 0)
Nicaragua	NIC	Cluster 3	AMR	Lower middle income	Total DID	14.9 (11.5, 21)	14.9 (11.5, 21)	14.8 (11.4, 21)	10 (7.6, 15.7)
Nicaragua	NIC	Cluster 3	AMR	Lower middle income	Access DID	13.4 (10, 19.5)	13 (9.6, 19.1)	13.7 (10.3, 19.8)	8.5 (6.1, 14.1)
Nicaragua	NIC	Cluster 3	AMR	Lower middle income	Watch DID	1.4 (1.3, 1.7)	1.8 (1.6, 2)	1.1 (1, 1.3)	1.4 (1.3, 1.7)
Nicaragua	NIC	Cluster 3	AMR	Lower middle income	Reserve DID	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)
Niger	NER	Cluster 1	AFR	Low income	Total DID	17.4 (13.2, 25)	17.5 (13.3, 25.1)	16.9 (12.7, 24.4)	11.7 (8.9, 18)
Niger	NER	Cluster 1	AFR	Low income	Access DID	9 (4.6, 16.5)	6.7 (2.1, 14.2)	10.4 (6, 17.6)	3.4 (-0.1, 9.4)
Niger	NER	Cluster 1	AFR	Low income	Watch DID	7.8 (6.2, 10.6)	10.3 (8.4, 13.1)	5.7 (4.3, 8.3)	7.8 (6.2, 10.6)
Niger	NER	Cluster 1	AFR	Low income	Reserve DID	0.3 (0.1, 0.9)	0.3 (0.1, 0.9)	0.5 (0.2, 1.6)	0.3 (0.1, 0.9)
Nigeria	NGA	Cluster 1	AFR	Lower middle income	Total DID	20.4 (15.7, 28.9)	20.4 (15.8, 29.1)	19.9 (15.3, 28.4)	13.7 (10.4, 21.1)
Nigeria	NGA	Cluster 1	AFR	Lower middle income	Access DID	11.5 (6.7, 19.8)	9.2 (4.2, 17.5)	13.5 (8.8, 21.6)	5.1 (0.9, 12.6)
Nigeria	NGA	Cluster 1	AFR	Lower middle income	Watch DID	8.1 (6.2, 11.3)	10.5 (8.3, 13.8)	5.8 (4.1, 8.9)	8.1 (6.2, 11.3)
Nigeria	NGA	Cluster 1	AFR	Lower middle income	Reserve DID	0.5 (0.2, 1.3)	0.5 (0.2, 1.3)	0.3 (0.1, 0.9)	0.5 (0.2, 1.3)

North Macedonia	MKD	Cluster 4	EUR	Upper middle income	Total DID	9.4 (8.2, 10.9)	9.4 (8.2, 10.9)	9.4 (8.1, 10.9)	9.4 (8.2, 10.9)
North Macedonia	MKD	Cluster 4	EUR	Upper middle income	Access DID	8.3 (7.1, 9.8)	8.1 (6.9, 9.6)	8.4 (7.2, 10)	8.3 (7.1, 9.8)
North Macedonia	MKD	Cluster 4	EUR	Upper middle income	Watch DID	1.1 (0.9, 1.2)	1.3 (1.1, 1.4)	0.9 (0.8, 1.1)	1.1 (0.9, 1.2)
North Macedonia	MKD	Cluster 4	EUR	Upper middle income	Reserve DID	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)
Norway	NOR	Cluster 4	EUR	High income	Total DID	11.7 (10.2, 13.5)	11.7 (10.2, 13.5)	11.7 (10.2, 13.5)	11.7 (10.2, 13.5)
Norway	NOR	Cluster 4	EUR	High income	Access DID	10.6 (9, 12.4)	10.3 (8.7, 12.1)	10.8 (9.2, 12.6)	10.6 (9, 12.4)
Norway	NOR	Cluster 4	EUR	High income	Watch DID	1.1 (1, 1.2)	1.4 (1.3, 1.6)	0.9 (0.8, 1)	1.1 (1, 1.2)
Norway	NOR	Cluster 4	EUR	High income	Reserve DID	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)
Oman	OMN	Cluster 3	EMR	High income	Total DID	13.1 (10, 18.7)	13.1 (10, 18.7)	13.3 (10.1, 19)	8.9 (6.7, 13.7)
Oman	OMN	Cluster 3	EMR	High income	Access DID	11.9 (8.7, 17.4)	11.5 (8.4, 17.1)	12.1 (9, 17.8)	7.6 (5.4, 12.6)
Oman	OMN	Cluster 3	EMR	High income	Watch DID	1.2 (1, 1.5)	1.6 (1.4, 1.9)	1.1 (0.9, 1.3)	1.2 (1, 1.5)
Oman	OMN	Cluster 3	EMR	High income	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0.1)	0 (0, 0)
Pakistan	PAK	Cluster 2	EMR	Lower middle income	Total DID	19.9 (15.2, 28)	19.9 (15.2, 28)	19.8 (15.1, 28)	13.5 (10.1, 20.6)
Pakistan	PAK	Cluster 2	EMR	Lower middle income	Access DID	13.2 (8.5, 21.6)	9.6 (4.7, 18)	15.6 (10.9, 24)	6.8 (3.2, 14.4)
Pakistan	PAK	Cluster 2	EMR	Lower middle income	Watch DID	5.9 (5.2, 7)	9.5 (8.4, 11.1)	4 (3.4, 5)	5.9 (5.2, 7)
Pakistan	PAK	Cluster 2	EMR	Lower middle income	Reserve DID	0.6 (0.3, 1.7)	0.6 (0.3, 1.7)	0.1 (0, 0.3)	0.6 (0.3, 1.7)
Panama	PAN	Cluster 3	AMR	High income	Total DID	16.4 (12.6, 23.3)	16.4 (12.6, 23.3)	16.6 (12.7, 23.5)	11.2 (8.4, 17.3)
Panama	PAN	Cluster 3	AMR	High income	Access DID	14.5 (10.7, 21.4)	14.1 (10.3, 21)	14.9 (11.1, 21.9)	9.3 (6.5, 15.4)
Panama	PAN	Cluster 3	AMR	High income	Watch DID	1.9 (1.6, 2.3)	2.2 (2, 2.6)	1.5 (1.3, 1.9)	1.9 (1.6, 2.3)
Panama	PAN	Cluster 3	AMR	High income	Reserve DID	0.1 (0, 0.2)	0.1 (0, 0.2)	0 (0, 0.1)	0.1 (0, 0.2)
Papua New Guinea	PNG	Cluster 2	WPR	Lower middle income	Total DID	24.3 (18.6, 33.9)	24.3 (18.7, 34)	24.2 (18.5, 33.7)	16.4 (12.2, 25.1)
Papua New Guinea	PNG	Cluster 2	WPR	Lower middle income	Access DID	18.1 (12.6, 27.9)	14 (8, 24)	20.3 (15, 30.1)	10.3 (6, 19)
Papua New Guinea	PNG	Cluster 2	WPR	Lower middle income	Watch DID	5.7 (4.9, 7)	9.8 (8.3, 12)	3.6 (2.9, 4.8)	5.7 (4.9, 7)
Papua New Guinea	PNG	Cluster 2	WPR	Lower middle income	Reserve DID	0.3 (0.1, 0.8)	0.3 (0.1, 0.8)	0 (0, 0.1)	0.3 (0.1, 0.8)
Paraguay	PRY	Cluster 3	AMR	Upper middle income	Total DID	22.8 (17.8, 32.4)	22.8 (17.8, 32.4)	23 (17.9, 32.7)	15.4 (11.6, 24.1)

Paraguay	PRY	Cluster 3	AMR	Upper middle income	Access DID	20.9 (15.9, 30.6)	20.4 (15.4, 30)	21.4 (16.2, 31.1)	13.5 (9.7, 22.2)
Paraguay	PRY	Cluster 3	AMR	Upper middle income	Watch DID	1.8 (1.6, 2)	2.3 (2.1, 2.6)	1.4 (1.3, 1.7)	1.8 (1.6, 2)
Paraguay	PRY	Cluster 3	AMR	Upper middle income	Reserve DID	0.1 (0, 0.3)	0.1 (0, 0.3)	0.2 (0.1, 0.4)	0.1 (0, 0.3)
Peru	PER	Cluster 2	AMR	Upper middle income	Total DID	20.5 (16, 28.7)	20.5 (16, 28.7)	20.6 (16.1, 28.9)	13.9 (10.3, 21.7)
Peru	PER	Cluster 2	AMR	Upper middle income	Access DID	17.7 (13.3, 25.9)	17 (12.5, 25.2)	18.7 (14.2, 27)	11.1 (7.5, 19)
Peru	PER	Cluster 2	AMR	Upper middle income	Watch DID	2.3 (2.1, 2.6)	2.9 (2.7, 3.3)	1.8 (1.6, 2)	2.3 (2.1, 2.6)
Peru	PER	Cluster 2	AMR	Upper middle income	Reserve DID	0.4 (0.2, 0.9)	0.4 (0.2, 0.9)	0.1 (0, 0.3)	0.4 (0.2, 0.9)
Philippines	PHL	Cluster 2	WPR	Lower middle income	Total DID	20 (15.5, 27.9)	20 (15.5, 28)	20 (15.4, 27.9)	13.4 (10.1, 21.1)
Philippines	PHL	Cluster 2	WPR	Lower middle income	Access DID	16.5 (11.9, 24.8)	14.8 (10.2, 23.2)	18.2 (13.5, 26.2)	9.9 (6.5, 17.5)
Philippines	PHL	Cluster 2	WPR	Lower middle income	Watch DID	2.9 (2.5, 3.3)	4.6 (4, 5.1)	1.8 (1.5, 2.1)	2.9 (2.5, 3.3)
Philippines	PHL	Cluster 2	WPR	Lower middle income	Reserve DID	0.5 (0.2, 1.5)	0.5 (0.2, 1.5)	0.1 (0, 0.1)	0.5 (0.2, 1.5)
Poland	POL	Cluster 4	EUR	High income	Total DID	8.4 (7.3, 9.7)	8.4 (7.3, 9.7)	8.4 (7.3, 9.7)	8.4 (7.3, 9.7)
Poland	POL	Cluster 4	EUR	High income	Access DID	7.4 (6.3, 8.7)	7.2 (6.1, 8.5)	7.6 (6.4, 8.8)	7.4 (6.3, 8.7)
Poland	POL	Cluster 4	EUR	High income	Watch DID	1 (0.9, 1.1)	1.2 (1, 1.3)	0.8 (0.7, 0.9)	1 (0.9, 1.1)
Poland	POL	Cluster 4	EUR	High income	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0.1)	0 (0, 0)
Portugal	PRT	Cluster 4	EUR	High income	Total DID	10.6 (9.3, 12.4)	10.6 (9.3, 12.4)	10.6 (9.3, 12.3)	10.6 (9.3, 12.4)
Portugal	PRT	Cluster 4	EUR	High income	Access DID	9.7 (8.3, 11.4)	9.4 (8, 11.1)	9.9 (8.5, 11.6)	9.7 (8.3, 11.4)
Portugal	PRT	Cluster 4	EUR	High income	Watch DID	0.9 (0.8, 1)	1.2 (1.1, 1.4)	0.6 (0.6, 0.7)	0.9 (0.8, 1)
Portugal	PRT	Cluster 4	EUR	High income	Reserve DID	0 (0, 0.1)	0 (0, 0.1)	0.1 (0, 0.1)	0 (0, 0.1)
Puerto Rico	PRI	Cluster 3	AMR	High income	Total DID	15.6 (12.3, 22)	15.6 (12.4, 22)	15.7 (12.4, 22.1)	10.6 (8.1, 16.3)
Puerto Rico	PRI	Cluster 3	AMR	High income	Access DID	13.8 (10.5, 20.2)	13.3 (9.9, 19.7)	14.2 (10.9, 20.6)	8.8 (6.3, 14.5)
Puerto Rico	PRI	Cluster 3	AMR	High income	Watch DID	1.8 (1.6, 2)	2.3 (2.1, 2.6)	1.4 (1.2, 1.6)	1.8 (1.6, 2)
Puerto Rico	PRI	Cluster 3	AMR	High income	Reserve DID	0 (0, 0.1)	0 (0, 0.1)	0.1 (0, 0.2)	0 (0, 0.1)
Qatar	QAT	Cluster 3	EMR	High income	Total DID	13.6 (10.3, 19.2)	13.6 (10.3, 19.2)	13.7 (10.4, 19.5)	9.1 (6.9, 14.2)
Qatar	QAT	Cluster 3	EMR	High income	Access DID	12.4 (9.1, 18.1)	12 (8.8, 17.7)	12.6 (9.3, 18.4)	7.9 (5.7, 13.1)
Qatar	QAT	Cluster 3	EMR	High income	Watch DID	1.1 (0.9, 1.4)	1.4 (1.2, 1.7)	1 (0.9, 1.3)	1.1 (0.9, 1.4)

Qatar	QAT	Cluster 3	EMR	High income	Reserve DID	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)
Romania	ROU	Cluster 4	EUR	High income	Total DID	7.8 (6.8, 9.1)	7.8 (6.8, 9.1)	7.8 (6.8, 9)	7.8 (6.8, 9.1)
Romania	ROU	Cluster 4	EUR	High income	Access DID	6.7 (5.6, 7.8)	6.4 (5.3, 7.6)	7 (5.9, 8.1)	6.7 (5.6, 7.8)
Romania	ROU	Cluster 4	EUR	High income	Watch DID	1.1 (0.9, 1.2)	1.3 (1.2, 1.4)	0.8 (0.7, 0.9)	1.1 (0.9, 1.2)
Romania	ROU	Cluster 4	EUR	High income	Reserve DID	0.1 (0.1, 0.3)	0.1 (0.1, 0.3)	0.1 (0, 0.2)	0.1 (0.1, 0.3)
Russian Federation	RUS	Cluster 4	EUR	Upper middle income	Total DID	11.2 (9.7, 13)	11.2 (9.7, 13)	11.2 (9.7, 13)	11.2 (9.7, 13)
Russian Federation	RUS	Cluster 4	EUR	Upper middle income	Access DID	7.8 (5.8, 9.8)	7.5 (5.4, 9.4)	9.9 (8.5, 11.7)	7.8 (5.8, 9.8)
Russian Federation	RUS	Cluster 4	EUR	Upper middle income	Watch DID	1.8 (1.6, 2)	2.2 (2, 2.4)	1.2 (1.1, 1.4)	1.8 (1.6, 2)
Russian Federation	RUS	Cluster 4	EUR	Upper middle income	Reserve DID	1.5 (0.7, 2.9)	1.5 (0.7, 2.9)	0 (0, 0.1)	1.5 (0.7, 2.9)
Rwanda	RWA	Cluster 1	AFR	Low income	Total DID	19.7 (15.2, 28)	19.7 (15.2, 28)	19.4 (15, 27.8)	13.3 (10.1, 20.4)
Rwanda	RWA	Cluster 1	AFR	Low income	Access DID	14.6 (10.1, 23.1)	13.1 (8.6, 21.6)	15.8 (11.4, 24.1)	8.3 (4.9, 15.2)
Rwanda	RWA	Cluster 1	AFR	Low income	Watch DID	4.7 (3.9, 6)	6.2 (5.4, 7.6)	3.5 (2.8, 4.7)	4.7 (3.9, 6)
Rwanda	RWA	Cluster 1	AFR	Low income	Reserve DID	0.3 (0.1, 0.8)	0.3 (0.1, 0.8)	0.1 (0, 0.2)	0.3 (0.1, 0.8)
Samoa	WSM	Cluster 2	WPR	Upper middle income	Total DID	21.1 (15.9, 29.8)	21.1 (15.9, 29.8)	21.2 (15.9, 29.9)	14.1 (10.7, 21.8)
Samoa	WSM	Cluster 2	WPR	Upper middle income	Access DID	18.6 (13.2, 27.2)	17.7 (12.4, 26.4)	19.2 (13.8, 27.8)	11.6 (8.2, 19.2)
Samoa	WSM	Cluster 2	WPR	Upper middle income	Watch DID	2.5 (2, 3.3)	3.3 (2.8, 4.1)	1.9 (1.5, 2.7)	2.5 (2, 3.3)
Samoa	WSM	Cluster 2	WPR	Upper middle income	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
Sao Tome and Principe	STP	Cluster 2	AFR	Lower middle income	Total DID	14.7 (11.4, 20.9)	14.8 (11.4, 20.9)	14.6 (11.2, 20.7)	9.9 (7.5, 15.5)
Sao Tome and Principe	STP	Cluster 2	AFR	Lower middle income	Access DID	11.4 (7.8, 17.4)	10.1 (6.6, 16.1)	12.2 (8.7, 18.2)	6.5 (4.1, 12.3)
Sao Tome and Principe	STP	Cluster 2	AFR	Lower middle income	Watch DID	3.2 (2.7, 4.1)	4.5 (3.8, 5.4)	2.3 (1.8, 3.2)	3.2 (2.7, 4.1)
Sao Tome and Principe	STP	Cluster 2	AFR	Lower middle income	Reserve DID	0.1 (0, 0.5)	0.1 (0, 0.5)	0 (0, 0)	0.1 (0, 0.5)
Saudi Arabia	SAU	Cluster 3	EMR	High income	Total DID	14.1 (10.6, 19.8)	14.1 (10.6, 19.8)	14.2 (10.7, 20)	9.5 (7.2, 14.7)
Saudi Arabia	SAU	Cluster 3	EMR	High income	Access DID	12.4 (8.9, 18)	12 (8.5, 17.6)	12.8 (9.2, 18.5)	7.9 (5.5, 13.1)
Saudi Arabia	SAU	Cluster 3	EMR	High income	Watch DID	1.5 (1.3, 1.9)	2 (1.7, 2.3)	1.3 (1.1, 1.7)	1.5 (1.3, 1.9)
Saudi Arabia	SAU	Cluster 3	EMR	High income	Reserve DID	0.1 (0, 0.3)	0.1 (0, 0.3)	0.1 (0, 0.1)	0.1 (0, 0.3)

Senegal	SEN	Cluster 1	AFR	Lower middle income	Total DID	15.7 (11.9, 22)	15.7 (11.9, 22.1)	15.4 (11.6, 21.8)	10.6 (7.8, 16.2)
Senegal	SEN	Cluster 1	AFR	Lower middle income	Access DID	8.5 (4.8, 14.8)	7.1 (3.3, 13.2)	9.4 (5.7, 15.6)	3.4 (0.6, 9.4)
Senegal	SEN	Cluster 1	AFR	Lower middle income	Watch DID	6.7 (5.1, 9.7)	8.2 (6.6, 11.2)	5.6 (4, 8.5)	6.7 (5.1, 9.7)
Senegal	SEN	Cluster 1	AFR	Lower middle income	Reserve DID	0.2 (0.1, 0.4)	0.2 (0.1, 0.4)	0.2 (0.1, 0.5)	0.2 (0.1, 0.4)
Serbia	SRB	Cluster 4	EUR	Upper middle income	Total DID	10.2 (8.8, 11.8)	10.2 (8.8, 11.8)	10.2 (8.8, 11.8)	10.2 (8.8, 11.8)
Serbia	SRB	Cluster 4	EUR	Upper middle income	Access DID	9 (7.6, 10.6)	8.7 (7.3, 10.3)	9.1 (7.8, 10.8)	9 (7.6, 10.6)
Serbia	SRB	Cluster 4	EUR	Upper middle income	Watch DID	1.2 (1.1, 1.4)	1.5 (1.3, 1.7)	1 (0.8, 1.2)	1.2 (1.1, 1.4)
Serbia	SRB	Cluster 4	EUR	Upper middle income	Reserve DID	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)
Seychelles	SYC	Cluster 2	AFR	High income	Total DID	16.8 (13.2, 23.5)	16.8 (13.2, 23.5)	16.9 (13.2, 23.7)	11.3 (8.6, 17.8)
Seychelles	SYC	Cluster 2	AFR	High income	Access DID	14.4 (10.7, 21.3)	13 (9.3, 19.8)	15.3 (11.6, 22.2)	9 (6.3, 15.4)
Seychelles	SYC	Cluster 2	AFR	High income	Watch DID	2.3 (2.1, 2.6)	3.8 (3.4, 4.2)	1.5 (1.3, 1.8)	2.3 (2.1, 2.6)
Seychelles	SYC	Cluster 2	AFR	High income	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
Sierra Leone	SLE	Cluster 1	AFR	Low income	Total DID	16.8 (12.9, 24.1)	16.9 (12.9, 24.2)	16.3 (12.5, 23.4)	11.3 (8.7, 17.6)
Sierra Leone	SLE	Cluster 1	AFR	Low income	Access DID	9.3 (5.3, 16.4)	7.1 (3, 14.2)	10.9 (7.1, 17.8)	3.9 (0.8, 9.9)
Sierra Leone	SLE	Cluster 1	AFR	Low income	Watch DID	7.1 (5.8, 9)	9.4 (7.8, 11.5)	5.1 (4, 6.8)	7.1 (5.8, 9)
Sierra Leone	SLE	Cluster 1	AFR	Low income	Reserve DID	0.3 (0.1, 1.2)	0.3 (0.1, 1.2)	0.2 (0.1, 0.6)	0.3 (0.1, 1.2)
Singapore	SGP	Cluster 4	WPR	High income	Total DID	12.6 (10.8, 14.6)	12.6 (10.8, 14.6)	12.6 (10.8, 14.6)	12.6 (10.8, 14.6)
Singapore	SGP	Cluster 4	WPR	High income	Access DID	11.8 (10, 13.9)	11.6 (9.8, 13.7)	12 (10.2, 14.1)	11.8 (10, 13.9)
Singapore	SGP	Cluster 4	WPR	High income	Watch DID	0.7 (0.6, 0.8)	0.9 (0.8, 1.1)	0.5 (0.5, 0.6)	0.7 (0.6, 0.8)
Singapore	SGP	Cluster 4	WPR	High income	Reserve DID	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)
Slovak Republic	SVK	Cluster 4	EUR	High income	Total DID	8 (6.9, 9.3)	8 (6.9, 9.3)	7.9 (6.8, 9.2)	8 (6.9, 9.3)
Slovak Republic	SVK	Cluster 4	EUR	High income	Access DID	6.9 (5.8, 8.2)	6.7 (5.6, 8)	7.1 (5.9, 8.3)	6.9 (5.8, 8.2)
Slovak Republic	SVK	Cluster 4	EUR	High income	Watch DID	1 (0.9, 1.2)	1.2 (1.1, 1.4)	0.8 (0.7, 0.9)	1 (0.9, 1.2)
Slovak Republic	SVK	Cluster 4	EUR	High income	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0.1)	0 (0, 0)
Slovenia	SVN	Cluster 4	EUR	High income	Total DID	7.7 (6.7, 8.9)	7.7 (6.7, 8.9)	7.7 (6.7, 8.8)	7.7 (6.7, 8.9)
Slovenia	SVN	Cluster 4	EUR	High income	Access DID	6.8 (5.8, 7.9)	6.6 (5.6, 7.7)	6.9 (5.9, 8.1)	6.8 (5.8, 7.9)
Slovenia	SVN	Cluster 4	EUR	High income	Watch DID	0.9 (0.8, 1)	1.1 (1, 1.2)	0.7 (0.6, 0.8)	0.9 (0.8, 1)

Slovenia	SVN	Cluster 4	EUR	High income	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
Solomon Islands	SLB	Cluster 2	WPR	Lower middle income	Total DID	21.3 (16.3, 30)	21.3 (16.3, 30)	21.2 (16.1, 29.9)	14.3 (10.7, 22.4)
Solomon Islands	SLB	Cluster 2	WPR	Lower middle income	Access DID	18.5 (13.5, 27.3)	17.2 (12.1, 25.9)	19.3 (14.3, 28)	11.6 (8, 19.7)
Solomon Islands	SLB	Cluster 2	WPR	Lower middle income	Watch DID	2.6 (2.3, 3.2)	4 (3.5, 4.8)	1.7 (1.4, 2.3)	2.6 (2.3, 3.2)
Solomon Islands	SLB	Cluster 2	WPR	Lower middle income	Reserve DID	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0)	0 (0, 0.1)
Somalia	SOM	Cluster 1	EMR	Low income	Total DID	25.8 (19.9, 37.1)	25.9 (19.9, 37.1)	25.6 (19.6, 36.7)	17.4 (13.1, 27.4)
Somalia	SOM	Cluster 1	EMR	Low income	Access DID	16.5 (8.5, 27.6)	14.2 (6.2, 25.3)	20.3 (14.2, 30.8)	8 (1.2, 17.9)
Somalia	SOM	Cluster 1	EMR	Low income	Watch DID	7.1 (6, 9)	9.4 (8.1, 11.3)	5.1 (4.1, 6.9)	7.1 (6, 9)
Somalia	SOM	Cluster 1	EMR	Low income	Reserve DID	2 (0.6, 7)	2 (0.6, 7)	0.2 (0.1, 0.4)	2 (0.6, 7)
South Africa	ZAF	Cluster 2	AFR	Upper middle income	Total DID	23.3 (18.1, 32.9)	23.4 (18.1, 32.9)	23.3 (18.1, 32.9)	15.8 (12, 24.2)
South Africa	ZAF	Cluster 2	AFR	Upper middle income	Access DID	17.6 (12.2, 27.5)	16.8 (11.4, 26.7)	19.4 (14.1, 28.9)	10.1 (5.9, 18.7)
South Africa	ZAF	Cluster 2	AFR	Upper middle income	Watch DID	4.8 (4.1, 5.8)	5.6 (4.9, 6.6)	3.8 (3.2, 4.9)	4.8 (4.1, 5.8)
South Africa	ZAF	Cluster 2	AFR	Upper middle income	Reserve DID	0.8 (0.3, 2.2)	0.8 (0.3, 2.2)	0.1 (0, 0.2)	0.8 (0.3, 2.2)
South Sudan	SSD	Cluster 1	AFR	Low income	Total DID	19 (14.6, 27.1)	19.1 (14.7, 27.2)	18.6 (14.2, 26.5)	12.9 (9.9, 19.9)
South Sudan	SSD	Cluster 1	AFR	Low income	Access DID	10.4 (5.5, 18.6)	8.4 (3.5, 16.8)	12.5 (8, 20.5)	4.2 (0.2, 11.6)
South Sudan	SSD	Cluster 1	AFR	Low income	Watch DID	7.7 (6.3, 10)	9.7 (8.1, 12.1)	5.8 (4.5, 7.9)	7.7 (6.3, 10)
South Sudan	SSD	Cluster 1	AFR	Low income	Reserve DID	0.7 (0.2, 2.6)	0.7 (0.2, 2.6)	0.2 (0.1, 0.6)	0.7 (0.2, 2.6)
Spain	ESP	Cluster 4	EUR	High income	Total DID	10.5 (8.9, 12)	10.5 (8.9, 12)	10.4 (8.9, 12)	10.5 (8.9, 12)
Spain	ESP	Cluster 4	EUR	High income	Access DID	9.5 (8, 11.1)	9.3 (7.7, 10.8)	9.7 (8.2, 11.3)	9.5 (8, 11.1)
Spain	ESP	Cluster 4	EUR	High income	Watch DID	0.9 (0.8, 1)	1.2 (1.1, 1.3)	0.7 (0.6, 0.7)	0.9 (0.8, 1)
Spain	ESP	Cluster 4	EUR	High income	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
Sri Lanka	LKA	Cluster 2	SEAR	Upper middle income	Total DID	15.9 (12.2, 22.7)	15.9 (12.2, 22.7)	16 (12.2, 22.8)	10.8 (8, 16.6)
Sri Lanka	LKA	Cluster 2	SEAR	Upper middle income	Access DID	13.8 (10.2, 20.6)	12.6 (8.9, 19.5)	14.5 (10.8, 21.3)	8.7 (5.9, 14.6)
Sri Lanka	LKA	Cluster 2	SEAR	Upper middle income	Watch DID	2.1 (1.8, 2.4)	3.3 (2.9, 3.8)	1.4 (1.2, 1.7)	2.1 (1.8, 2.4)
Sri Lanka	LKA	Cluster 2	SEAR	Upper middle income	Reserve DID	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)
St. Lucia	LCA	Cluster 3	AMR	Upper middle income	Total DID	15.5 (12, 21.8)	15.5 (12, 21.8)	15.5 (12, 21.8)	10.5 (8, 16.2)

St. Lucia	LCA	Cluster 3	AMR	Upper middle income	Access DID	13.8 (10.3, 20.1)	13.3 (9.9, 19.7)	14.1 (10.7, 20.5)	8.7 (6.3, 14.6)
St. Lucia	LCA	Cluster 3	AMR	Upper middle income	Watch DID	1.7 (1.6, 1.9)	2.2 (2, 2.4)	1.4 (1.2, 1.6)	1.7 (1.6, 1.9)
St. Lucia	LCA	Cluster 3	AMR	Upper middle income	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
St. Vincent and the Grenadines	VCT	Cluster 3	AMR	Upper middle income	Total DID	17.6 (13.5, 24.6)	17.6 (13.5, 24.6)	17.6 (13.5, 24.7)	11.9 (9, 18.3)
St. Vincent and the Grenadines	VCT	Cluster 3	AMR	Upper middle income	Access DID	15.7 (11.6, 22.7)	15.2 (11.1, 22.2)	16.2 (12, 23.3)	10 (7.2, 16.4)
St. Vincent and the Grenadines	VCT	Cluster 3	AMR	Upper middle income	Watch DID	1.8 (1.7, 2.1)	2.4 (2.1, 2.6)	1.4 (1.2, 1.6)	1.8 (1.7, 2.1)
St. Vincent and the Grenadines	VCT	Cluster 3	AMR	Upper middle income	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
Sudan	SDN	Cluster 1	EMR	Low income	Total DID	15.1 (11.9, 21.6)	15.2 (11.9, 21.6)	14.9 (11.6, 21.3)	10.3 (7.8, 16)
Sudan	SDN	Cluster 1	EMR	Low income	Access DID	12.3 (8.9, 18.7)	11.5 (8, 17.9)	12.7 (9.3, 19)	7.5 (4.7, 13)
Sudan	SDN	Cluster 1	EMR	Low income	Watch DID	2.7 (2.2, 3.6)	3.6 (2.9, 4.5)	2 (1.6, 2.7)	2.7 (2.2, 3.6)
Sudan	SDN	Cluster 1	EMR	Low income	Reserve DID	0.1 (0, 0.3)	0.1 (0, 0.3)	0.2 (0.1, 0.8)	0.1 (0, 0.3)
Suriname	SUR	Cluster 3	AMR	Upper middle income	Total DID	15.9 (12.3, 22.6)	15.9 (12.3, 22.6)	15.9 (12.3, 22.6)	10.7 (8.2, 16.8)
Suriname	SUR	Cluster 3	AMR	Upper middle income	Access DID	14.1 (10.5, 20.8)	13.7 (10, 20.4)	14.5 (10.9, 21.2)	9 (6.4, 15)
Suriname	SUR	Cluster 3	AMR	Upper middle income	Watch DID	1.7 (1.5, 1.9)	2.2 (1.9, 2.5)	1.2 (1.1, 1.5)	1.7 (1.5, 1.9)
Suriname	SUR	Cluster 3	AMR	Upper middle income	Reserve DID	0 (0, 0.1)	0 (0, 0.1)	0.1 (0, 0.3)	0 (0, 0.1)
Sweden	SWE	Cluster 4	EUR	High income	Total DID	11.7 (10.1, 13.5)	11.7 (10.1, 13.5)	11.7 (10.1, 13.5)	11.7 (10.1, 13.5)
Sweden	SWE	Cluster 4	EUR	High income	Access DID	10.3 (8.8, 12.1)	10 (8.5, 11.8)	10.5 (8.9, 12.3)	10.3 (8.8, 12.1)
Sweden	SWE	Cluster 4	EUR	High income	Watch DID	1.4 (1.2, 1.5)	1.6 (1.5, 1.8)	1.2 (1, 1.3)	1.4 (1.2, 1.5)
Sweden	SWE	Cluster 4	EUR	High income	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
Switzerland	CHE	Cluster 4	EUR	High income	Total DID	11 (11, 11)	11 (11, 11)	11 (11, 11)	11 (11, 11)
Switzerland	CHE	Cluster 4	EUR	High income	Access DID	10 (9.8, 10.1)	9.7 (9.6, 9.9)	10.1 (10, 10.2)	10 (9.8, 10.1)
Switzerland	CHE	Cluster 4	EUR	High income	Watch DID	1 (0.9, 1.1)	1.3 (1.1, 1.4)	0.9 (0.8, 1)	1 (0.9, 1.1)
Switzerland	CHE	Cluster 4	EUR	High income	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
Syrian Arab Republic	SYR	Cluster 2	EMR	Low income	Total DID	9.8 (7.5, 13.8)	9.8 (7.5, 13.9)	9.6 (7.3, 13.7)	6.6 (5, 10.1)
Syrian Arab Republic	SYR	Cluster 2	EMR	Low income	Access DID	8.1 (5.8, 12.3)	7.5 (5.1, 11.8)	8.5 (6.2, 12.5)	4.9 (3.2, 8.6)
Syrian Arab Republic	SYR	Cluster 2	EMR	Low income	Watch DID	1.6 (1.1, 2.3)	2.1 (1.5, 3.2)	1 (0.8, 1.3)	1.6 (1.1, 2.3)

Syrian Arab Republic	SYR	Cluster 2	EMR	Low income	Reserve DID	0 (0, 0.1)	0 (0, 0.1)	0.1 (0, 0.4)	0 (0, 0.1)
Taiwan	TWN	Cluster 3	WPR	High income	Total DID	11.1 (8.6, 15.7)	11.1 (8.6, 15.7)	11 (8.5, 15.6)	7.4 (5.7, 11.4)
Taiwan	TWN	Cluster 3	WPR	High income	Access DID	9.2 (6.7, 13.9)	8.7 (6.2, 13.4)	9.6 (7.1, 14.2)	5.6 (3.8, 9.6)
Taiwan	TWN	Cluster 3	WPR	High income	Watch DID	1.8 (1.6, 2)	2.2 (2, 2.5)	1.3 (1.1, 1.5)	1.8 (1.6, 2)
Taiwan	TWN	Cluster 3	WPR	High income	Reserve DID	0.1 (0, 0.3)	0.1 (0, 0.3)	0.1 (0, 0.1)	0.1 (0, 0.3)
Tajikistan	TJK	Cluster 2	EUR	Lower middle income	Total DID	9.6 (7.5, 13.6)	9.7 (7.5, 13.7)	9.6 (7.4, 13.5)	6.5 (4.9, 9.9)
Tajikistan	TJK	Cluster 2	EUR	Lower middle income	Access DID	6.4 (4, 10.4)	5.8 (3.4, 9.9)	7.7 (5.4, 11.6)	3.2 (1.3, 6.7)
Tajikistan	TJK	Cluster 2	EUR	Lower middle income	Watch DID	2.6 (2.1, 3.1)	3.1 (2.6, 3.8)	1.8 (1.5, 2.2)	2.6 (2.1, 3.1)
Tajikistan	TJK	Cluster 2	EUR	Lower middle income	Reserve DID	0.7 (0.3, 1.4)	0.7 (0.3, 1.4)	0.1 (0, 0.2)	0.7 (0.3, 1.4)
Tanzania	TZA	Cluster 1	AFR	Lower middle income	Total DID	19.1 (14.6, 26.8)	19.1 (14.7, 26.8)	18.9 (14.4, 26.5)	12.8 (9.7, 19.8)
Tanzania	TZA	Cluster 1	AFR	Lower middle income	Access DID	13 (8.5, 20.6)	11 (6.4, 18.6)	14.3 (9.9, 21.8)	6.8 (3.6, 14)
Tanzania	TZA	Cluster 1	AFR	Lower middle income	Watch DID	5.6 (4.7, 7.2)	7.7 (6.7, 9.4)	4.3 (3.4, 5.8)	5.6 (4.7, 7.2)
Tanzania	TZA	Cluster 1	AFR	Lower middle income	Reserve DID	0.2 (0.1, 0.9)	0.2 (0.1, 0.9)	0.1 (0, 0.2)	0.2 (0.1, 0.9)
Thailand	THA	Cluster 2	SEAR	Upper middle income	Total DID	20.1 (15.6, 28.2)	20.1 (15.6, 28.2)	20.1 (15.6, 28.3)	13.6 (10.2, 20.6)
Thailand	THA	Cluster 2	SEAR	Upper middle income	Access DID	17.5 (12.9, 25.5)	16.3 (11.7, 24.5)	18.5 (13.8, 26.6)	11 (7.6, 18)
Thailand	THA	Cluster 2	SEAR	Upper middle income	Watch DID	2.3 (2.1, 2.6)	3.5 (3.1, 3.8)	1.6 (1.4, 1.8)	2.3 (2.1, 2.6)
Thailand	THA	Cluster 2	SEAR	Upper middle income	Reserve DID	0.2 (0.1, 0.7)	0.2 (0.1, 0.7)	0.1 (0, 0.4)	0.2 (0.1, 0.7)
Timor-Leste	TLS	Cluster 2	SEAR	Lower middle income	Total DID	18 (13.7, 25.6)	18 (13.7, 25.6)	18 (13.5, 25.6)	12.1 (9.1, 18.6)
Timor-Leste	TLS	Cluster 2	SEAR	Lower middle income	Access DID	14.5 (10.2, 22.2)	12.2 (7.6, 19.8)	15.8 (11.5, 23.4)	8.7 (5.6, 15.2)
Timor-Leste	TLS	Cluster 2	SEAR	Lower middle income	Watch DID	3.3 (2.9, 3.9)	5.7 (4.9, 6.6)	2 (1.7, 2.5)	3.3 (2.9, 3.9)
Timor-Leste	TLS	Cluster 2	SEAR	Lower middle income	Reserve DID	0.1 (0, 0.4)	0.1 (0, 0.4)	0 (0, 0.2)	0.1 (0, 0.4)
Togo	TGO	Cluster 1	AFR	Low income	Total DID	18 (13.9, 25.5)	18.1 (13.9, 25.5)	17.7 (13.6, 25)	12.3 (9.2, 19.1)
Togo	TGO	Cluster 1	AFR	Low income	Access DID	11.9 (7.8, 19.2)	10.2 (6, 17.5)	13 (8.8, 20.1)	6.1 (2.7, 13)
Togo	TGO	Cluster 1	AFR	Low income	Watch DID	5.7 (4.6, 7.7)	7.4 (6.2, 9.5)	4.3 (3.3, 6.3)	5.7 (4.6, 7.7)
Togo	TGO	Cluster 1	AFR	Low income	Reserve DID	0.3 (0.1, 0.8)	0.3 (0.1, 0.8)	0.3 (0.1, 0.7)	0.3 (0.1, 0.8)

Tonga	TON	Cluster 2	WPR	Upper middle income	Total DID	21.6 (16.5, 30.5)	21.6 (16.5, 30.5)	21.7 (16.6, 30.7)	14.5 (10.8, 22.7)
Tonga	TON	Cluster 2	WPR	Upper middle income	Access DID	18.9 (13.8, 27.9)	17.9 (12.9, 26.9)	19.6 (14.5, 28.7)	11.9 (8.1, 20.3)
Tonga	TON	Cluster 2	WPR	Upper middle income	Watch DID	2.6 (2.2, 3.4)	3.6 (3.1, 4.4)	2 (1.6, 2.8)	2.6 (2.2, 3.4)
Tonga	TON	Cluster 2	WPR	Upper middle income	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
Trinidad and Tobago	TTO	Cluster 3	AMR	High income	Total DID	14.3 (11.1, 20.5)	14.3 (11.1, 20.5)	14.5 (11.3, 20.8)	9.7 (7.3, 14.9)
Trinidad and Tobago	TTO	Cluster 3	AMR	High income	Access DID	13 (9.8, 19)	12.6 (9.5, 18.7)	13.3 (10.1, 19.6)	8.3 (6, 13.6)
Trinidad and Tobago	TTO	Cluster 3	AMR	High income	Watch DID	1.3 (1.2, 1.5)	1.7 (1.5, 1.9)	1.1 (1, 1.3)	1.3 (1.2, 1.5)
Trinidad and Tobago	TTO	Cluster 3	AMR	High income	Reserve DID	0 (0, 0.1)	0 (0, 0.1)	0.1 (0, 0.2)	0 (0, 0.1)
Tunisia	TUN	Cluster 3	EMR	Lower middle income	Total DID	13.4 (10.3, 18.9)	13.4 (10.3, 18.9)	13.5 (10.3, 19)	9 (6.8, 13.9)
Tunisia	TUN	Cluster 3	EMR	Lower middle income	Access DID	12 (8.9, 17.5)	11.6 (8.4, 17)	12.3 (9.1, 17.8)	7.5 (5.4, 12.4)
Tunisia	TUN	Cluster 3	EMR	Lower middle income	Watch DID	1.4 (1.2, 1.6)	1.8 (1.6, 2.1)	1.2 (1, 1.4)	1.4 (1.2, 1.6)
Tunisia	TUN	Cluster 3	EMR	Lower middle income	Reserve DID	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)
Türkiye	TUR	Cluster 3	EUR	Upper middle income	Total DID	18.4 (13.9, 25.8)	18.4 (13.9, 25.8)	18.6 (14, 26.2)	12.4 (9.4, 19.2)
Türkiye	TUR	Cluster 3	EUR	Upper middle income	Access DID	17 (12.5, 24.4)	16.6 (12, 24)	17.4 (12.8, 25)	11 (8, 17.8)
Türkiye	TUR	Cluster 3	EUR	Upper middle income	Watch DID	1.3 (1.2, 1.5)	1.8 (1.6, 2)	1.1 (1, 1.3)	1.3 (1.2, 1.5)
Türkiye	TUR	Cluster 3	EUR	Upper middle income	Reserve DID	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)
Türkmenistan	TKM	Cluster 2	EUR	Upper middle income	Total DID	8.7 (6.7, 12.5)	8.7 (6.7, 12.5)	8.7 (6.7, 12.5)	5.9 (4.5, 9.1)
Türkmenistan	TKM	Cluster 2	EUR	Upper middle income	Access DID	6.7 (4.6, 10.4)	6.4 (4.3, 10.1)	7.6 (5.6, 11.3)	3.9 (2.2, 7.1)
Türkmenistan	TKM	Cluster 2	EUR	Upper middle income	Watch DID	1.4 (1.3, 1.7)	1.8 (1.5, 2)	1.1 (0.9, 1.2)	1.4 (1.3, 1.7)
Türkmenistan	TKM	Cluster 2	EUR	Upper middle income	Reserve DID	0.5 (0.2, 1.2)	0.5 (0.2, 1.2)	0.1 (0, 0.1)	0.5 (0.2, 1.2)
Uganda	UGA	Cluster 1	AFR	Low income	Total DID	23.3 (17.8, 33.1)	23.3 (17.8, 33.1)	23.2 (17.7, 33.1)	15.8 (11.9, 24.1)
Uganda	UGA	Cluster 1	AFR	Low income	Access DID	18.2 (12.6, 27.8)	16.7 (11, 26.3)	19.6 (14.1, 29.1)	10.7 (6.3, 19)
Uganda	UGA	Cluster 1	AFR	Low income	Watch DID	4.7 (3.9, 6.1)	6.2 (5.3, 7.7)	3.5 (2.7, 4.9)	4.7 (3.9, 6.1)

Uganda	UGA	Cluster 1	AFR	Low income	Reserve DID	0.4 (0.1, 1.1)	0.4 (0.1, 1.1)	0.1 (0, 0.2)	0.4 (0.1, 1.1)
Ukraine	UKR	Cluster 4	EUR	Lower middle income	Total DID	10.8 (9.3, 12.4)	10.8 (9.3, 12.4)	10.8 (9.2, 12.3)	10.8 (9.3, 12.4)
Ukraine	UKR	Cluster 4	EUR	Lower middle income	Access DID	7.1 (4.8, 9)	6.8 (4.5, 8.7)	9.5 (8, 11.1)	7.1 (4.8, 9)
Ukraine	UKR	Cluster 4	EUR	Lower middle income	Watch DID	1.8 (1.6, 2.1)	2.2 (2, 2.4)	1.1 (1, 1.3)	1.8 (1.6, 2.1)
Ukraine	UKR	Cluster 4	EUR	Lower middle income	Reserve DID	1.8 (0.9, 3.5)	1.8 (0.9, 3.5)	0.1 (0, 0.2)	1.8 (0.9, 3.5)
United Arab Emirates	ARE	Cluster 3	EMR	High income	Total DID	13.5 (10.2, 19.1)	13.5 (10.2, 19.1)	13.7 (10.3, 19.4)	9.2 (6.8, 14.6)
United Arab Emirates	ARE	Cluster 3	EMR	High income	Access DID	12.4 (9.1, 18)	12 (8.8, 17.7)	12.6 (9.3, 18.4)	8 (5.6, 13.4)
United Arab Emirates	ARE	Cluster 3	EMR	High income	Watch DID	1.1 (1, 1.4)	1.4 (1.3, 1.7)	1 (0.8, 1.2)	1.1 (1, 1.4)
United Arab Emirates	ARE	Cluster 3	EMR	High income	Reserve DID	0 (0, 0.1)	0 (0, 0.1)	0.1 (0, 0.2)	0 (0, 0.1)
United Kingdom	GBR	Cluster 4	EUR	High income	Total DID	11.6 (10.1, 13.4)	11.6 (10.1, 13.4)	11.5 (10.1, 13.4)	11.6 (10.1, 13.4)
United Kingdom	GBR	Cluster 4	EUR	High income	Access DID	10.6 (9.1, 12.5)	10.3 (8.9, 12.2)	10.8 (9.3, 12.6)	10.6 (9.1, 12.5)
United Kingdom	GBR	Cluster 4	EUR	High income	Watch DID	0.9 (0.8, 1.1)	1.2 (1.1, 1.4)	0.7 (0.6, 0.7)	0.9 (0.8, 1.1)
United Kingdom	GBR	Cluster 4	EUR	High income	Reserve DID	0 (0, 0)	0 (0, 0)	0.1 (0, 0.2)	0 (0, 0)
United States	USA	Cluster 4	AMR	High income	Total DID	16.2 (14.1, 18.7)	16.2 (14.1, 18.7)	16.2 (14.1, 18.7)	16.2 (14.1, 18.7)
United States	USA	Cluster 4	AMR	High income	Access DID	15.2 (13.2, 17.8)	14.9 (12.9, 17.5)	15.3 (13.2, 17.9)	15.2 (13.2, 17.8)
United States	USA	Cluster 4	AMR	High income	Watch DID	0.9 (0.8, 0.9)	1.2 (1.1, 1.3)	0.6 (0.6, 0.7)	0.9 (0.8, 0.9)
United States	USA	Cluster 4	AMR	High income	Reserve DID	0 (0, 0.1)	0 (0, 0.1)	0.2 (0.1, 0.4)	0 (0, 0.1)
Uruguay	URY	Cluster 3	AMR	High income	Total DID	18.7 (14.4, 26.6)	18.7 (14.4, 26.6)	18.9 (14.6, 26.9)	12.6 (9.5, 19.5)
Uruguay	URY	Cluster 3	AMR	High income	Access DID	17.6 (13.3, 25.5)	17.2 (13, 25.1)	18 (13.7, 26)	11.5 (8.3, 18.4)
Uruguay	URY	Cluster 3	AMR	High income	Watch DID	1.1 (1, 1.2)	1.5 (1.3, 1.6)	0.7 (0.7, 0.8)	1.1 (1, 1.2)
Uruguay	URY	Cluster 3	AMR	High income	Reserve DID	0 (0, 0.1)	0 (0, 0.1)	0.1 (0.1, 0.3)	0 (0, 0.1)
Uzbekistan	UZB	Cluster 2	EUR	Lower middle income	Total DID	9.7 (7.5, 13.9)	9.7 (7.5, 13.9)	9.8 (7.5, 14)	6.5 (4.9, 10)
Uzbekistan	UZB	Cluster 2	EUR	Lower middle income	Access DID	6.8 (4.4, 11.2)	6.5 (4, 10.8)	8.4 (6.2, 12.7)	3.7 (1.8, 7.3)
Uzbekistan	UZB	Cluster 2	EUR	Lower middle income	Watch DID	1.8 (1.5, 2.1)	2.2 (1.9, 2.5)	1.3 (1.1, 1.5)	1.8 (1.5, 2.1)
Uzbekistan	UZB	Cluster 2	EUR	Lower middle income	Reserve DID	1 (0.4, 2.1)	1 (0.4, 2.1)	0 (0, 0.1)	1 (0.4, 2.1)

Vanuatu	VUT	Cluster 2	WPR	Lower middle income	Total DID	21.3 (16.3, 30)	21.3 (16.3, 30)	21.3 (16.2, 29.9)	14.4 (10.8, 22.2)
Vanuatu	VUT	Cluster 2	WPR	Lower middle income	Access DID	18.5 (13.4, 27.1)	17.3 (12.2, 25.8)	19.2 (14.1, 27.8)	11.5 (8, 19.2)
Vanuatu	VUT	Cluster 2	WPR	Lower middle income	Watch DID	2.8 (2.3, 3.5)	4 (3.5, 4.7)	2 (1.6, 2.7)	2.8 (2.3, 3.5)
Vanuatu	VUT	Cluster 2	WPR	Lower middle income	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
Venezuela, RB	VEN	Cluster 3	AMR	Lower middle income	Total DID	16.4 (12.6, 23.3)	16.4 (12.6, 23.3)	16.5 (12.7, 23.5)	11.1 (8.4, 17.2)
Venezuela, RB	VEN	Cluster 3	AMR	Lower middle income	Access DID	14.6 (10.7, 21.4)	14.2 (10.3, 21)	15.1 (11.1, 22)	9.3 (6.6, 15.4)
Venezuela, RB	VEN	Cluster 3	AMR	Lower middle income	Watch DID	1.8 (1.5, 2.1)	2.1 (1.9, 2.5)	1.4 (1.2, 1.7)	1.8 (1.5, 2.1)
Venezuela, RB	VEN	Cluster 3	AMR	Lower middle income	Reserve DID	0 (0, 0.1)	0 (0, 0.1)	0.1 (0, 0.1)	0 (0, 0.1)
Viet Nam	VNM	Cluster 2	WPR	Lower middle income	Total DID	14.2 (10.8, 19.9)	14.2 (10.8, 19.9)	14.2 (10.7, 19.9)	9.6 (7.3, 14.7)
Viet Nam	VNM	Cluster 2	WPR	Lower middle income	Access DID	11.7 (8.3, 17.5)	10.5 (7.1, 16.4)	12.8 (9.4, 18.6)	7 (4.6, 12.2)
Viet Nam	VNM	Cluster 2	WPR	Lower middle income	Watch DID	2.1 (1.8, 2.4)	3.2 (2.8, 3.7)	1.4 (1.2, 1.7)	2.1 (1.8, 2.4)
Viet Nam	VNM	Cluster 2	WPR	Lower middle income	Reserve DID	0.4 (0.2, 1.2)	0.4 (0.2, 1.2)	0 (0, 0.1)	0.4 (0.2, 1.2)
West Bank and Gaza	PSE	Cluster 3	EMR	Upper middle income	Total DID	15.7 (12.2, 22.6)	15.7 (12.2, 22.6)	15.9 (12.3, 22.9)	10.6 (7.8, 16.6)
West Bank and Gaza	PSE	Cluster 3	EMR	Upper middle income	Access DID	14.4 (10.9, 21.3)	13.9 (10.4, 20.8)	14.7 (11.1, 21.8)	9.2 (6.5, 15.3)
West Bank and Gaza	PSE	Cluster 3	EMR	Upper middle income	Watch DID	1.3 (1.1, 1.6)	1.8 (1.6, 2.1)	1.1 (0.9, 1.4)	1.3 (1.1, 1.6)
West Bank and Gaza	PSE	Cluster 3	EMR	Upper middle income	Reserve DID	0 (0, 0.1)	0 (0, 0.1)	0.1 (0, 0.1)	0 (0, 0.1)
Yemen, Rep.	YEM	Cluster 1	EMR	Low income	Total DID	18 (13.8, 25.7)	18 (13.8, 25.7)	17.8 (13.6, 25.5)	12.1 (9.1, 18.3)
Yemen, Rep.	YEM	Cluster 1	EMR	Low income	Access DID	15.1 (10.7, 22.8)	14.1 (9.8, 21.8)	15.6 (11.3, 23.2)	9.1 (6, 15.6)
Yemen, Rep.	YEM	Cluster 1	EMR	Low income	Watch DID	2.8 (2.3, 3.5)	3.7 (3.1, 4.5)	2 (1.7, 2.5)	2.8 (2.3, 3.5)
Yemen, Rep.	YEM	Cluster 1	EMR	Low income	Reserve DID	0.1 (0, 0.2)	0.1 (0, 0.2)	0.1 (0.1, 0.4)	0.1 (0, 0.2)
Zambia	ZMB	Cluster 1	AFR	Lower middle income	Total DID	23 (18.1, 32.7)	23.1 (18.1, 32.7)	22.9 (18, 32.6)	15.5 (11.8, 23.9)
Zambia	ZMB	Cluster 1	AFR	Lower middle income	Access DID	16.3 (11.1, 25.9)	14.9 (9.7, 24.4)	17.7 (12.6, 27.3)	8.8 (4.7, 17.3)
Zambia	ZMB	Cluster 1	AFR	Lower middle income	Watch DID	6.1 (5, 8)	7.6 (6.3, 9.5)	5 (3.8, 6.8)	6.1 (5, 8)

Zambia	ZMB	Cluster 1	AFR	Lower middle income	Reserve DID	0.5 (0.1, 1.7)	0.5 (0.1, 1.7)	0.1 (0, 0.3)	0.5 (0.1, 1.7)
Zimbabwe	ZWE	Cluster 1	AFR	Lower middle income	Total DID	19.7 (15.1, 28.1)	19.8 (15.1, 28.1)	19.6 (14.9, 27.9)	13.3 (10.1, 20.7)
Zimbabwe	ZWE	Cluster 1	AFR	Lower middle income	Access DID	15.6 (10.3, 23.8)	14.9 (9.5, 23.1)	17.3 (12.7, 25.7)	9.2 (4.9, 16.8)
Zimbabwe	ZWE	Cluster 1	AFR	Lower middle income	Watch DID	3.1 (2.7, 3.7)	3.9 (3.4, 4.5)	2.1 (1.7, 2.5)	3.1 (2.7, 3.7)
Zimbabwe	ZWE	Cluster 1	AFR	Lower middle income	Reserve DID	0.9 (0.2, 3.5)	0.9 (0.2, 3.5)	0.1 (0, 0.3)	0.9 (0.2, 3.5)

Table 13. Estimated optimal percentage Access for each analysis scenario. Scenario 1 = primary analysis, Scenario 2 = high watch scenario, Scenario 3 = unadjusted cases & excl. TB, Scenario 4 = alternate benchmark CTA

CTA Name	ISO3 Code	Cluster	% Access Scenario 1	% Access Scenario 2	% Access Scenario 3	% Access Scenario 4
Afghanistan	AFG	Cluster 1	76 (63.2, 84)	67.4 (53, 77.8)	85.5 (79.3, 90)	64.4 (46.2, 77.8)
Albania	ALB	Cluster 4	87.8 (85.1, 89.8)	85.4 (82.3, 87.7)	89.8 (87.4, 91.7)	87.8 (85.1, 89.8)
Algeria	DZA	Cluster 3	90 (86.1, 93.2)	86.7 (81.9, 90.8)	92.1 (88.8, 94.6)	85.3 (78.9, 90.6)
Angola	AGO	Cluster 1	73.5 (60.6, 81.8)	65.9 (51.8, 76.5)	82.7 (75.2, 88)	60.9 (39.7, 75.9)
Antigua and Barbuda	ATG	Cluster 3	89.6 (86.3, 92.8)	87 (82.9, 91)	91.6 (88.8, 94.2)	84.6 (79.4, 90.2)
Argentina	ARG	Cluster 3	94.1 (92, 95.9)	91.9 (89.2, 94.4)	95.4 (93.7, 96.8)	91.2 (88, 94.3)
Armenia	ARM	Cluster 4	79.3 (72.6, 83.4)	75.9 (69.1, 80.5)	85.8 (82.6, 88.4)	79.3 (72.6, 83.4)
Australia	AUS	Cluster 4	94 (92.8, 94.9)	91.9 (90.4, 93.2)	94.8 (93.8, 95.7)	94 (92.8, 94.9)
Austria	AUT	Cluster 4	91.9 (90.4, 93.1)	89.3 (87.3, 91)	93.1 (91.8, 94.2)	91.9 (90.4, 93.1)
Azerbaijan	AZE	Cluster 2	70.4 (53.2, 81.4)	66.1 (48.5, 78.5)	85.1 (79.7, 89.8)	56.7 (28.5, 73)
Bahamas, The	BHS	Cluster 3	90.1 (87, 93.1)	87.5 (83.8, 91.4)	91.9 (88.9, 94.5)	85.4 (80, 90.8)
Bahrain	BHR	Cluster 3	91.1 (87.9, 93.8)	88.3 (84.4, 91.8)	92.4 (89.5, 94.7)	86.6 (81.7, 91.3)
Bangladesh	BGD	Cluster 2	75.9 (67.6, 83.3)	58.6 (45.1, 71.8)	85.7 (80.3, 90.1)	64.2 (51.8, 77.2)
Barbados	BRB	Cluster 3	86.9 (82.7, 90.9)	83.4 (78.3, 88.5)	89.7 (86, 92.8)	80.5 (73.8, 87.4)
Belarus	BLR	Cluster 4	77.5 (69.7, 82.3)	74.6 (66.8, 79.8)	89.1 (86.9, 90.8)	77.5 (69.7, 82.3)
Belgium	BEL	Cluster 4	90.2 (88.3, 91.7)	87.5 (85.1, 89.4)	92.4 (91, 93.6)	90.2 (88.3, 91.7)
Belize	BLZ	Cluster 2	90.4 (87.3, 93.4)	88 (84.2, 91.7)	92.4 (89.8, 94.8)	85.8 (80.7, 90.8)
Benin	BEN	Cluster 1	65.7 (52.2, 77.1)	53.9 (37.2, 68.9)	73 (60.8, 82.3)	48.7 (27.1, 67.7)
Bhutan	BTN	Cluster 2	73.6 (64, 81.9)	52.1 (34.9, 66.7)	85.3 (80, 89.8)	60.7 (45.2, 74.9)
Bolivia	BOL	Cluster 2	88 (82.8, 91.9)	84.5 (78.3, 89.4)	92.1 (89.1, 94.5)	82.3 (73.9, 88.8)
Bosnia and Herzegovina	BIH	Cluster 4	87.9 (85.5, 90)	85.4 (82.7, 87.8)	90 (87.8, 91.7)	87.9 (85.5, 90)
Botswana	BWA	Cluster 2	75.3 (56.6, 83.9)	71.2 (51.6, 81)	84.3 (78, 89.4)	63.4 (35.1, 77.2)
Brazil	BRA	Cluster 3	90.3 (87, 93.3)	87.5 (83.4, 91.3)	91.5 (88.6, 94.2)	85.7 (80.8, 90.8)
Brunei Darussalam	BRN	Cluster 3	96 (94.6, 97.2)	94.7 (92.9, 96.4)	96.8 (95.6, 97.8)	94 (91.8, 96.1)
Bulgaria	BGR	Cluster 4	86.3 (83.3, 88.6)	83.5 (80.3, 86.1)	89.3 (86.9, 91.1)	86.3 (83.3, 88.6)
Burkina Faso	BFA	Cluster 1	61.4 (46.3, 73.2)	34.5 (11.8, 54.6)	75.6 (63.7, 83.4)	42.8 (20.1, 63.1)
Burundi	BDI	Cluster 1	67.7 (53.7, 78.6)	58.9 (42.5, 72)	76.6 (66.3, 84.5)	52.3 (28.9, 70.5)
Cabo Verde	CPV	Cluster 2	75.9 (67, 83.9)	68 (57.7, 78.3)	81.9 (73.9, 88.2)	64.4 (48.5, 77.5)
Cambodia	KHM	Cluster 2	80.9 (73.6, 86.7)	68.5 (57.3, 78)	88 (83.1, 91.8)	71.7 (60.4, 81.6)
Cameroon	CMR	Cluster 1	72.4 (60.6, 81.6)	63.5 (49.7, 75.1)	79.6 (69.4, 86.9)	58.7 (41, 74.7)
Canada	CAN	Cluster 4	95.2 (94.3, 96)	93.5 (92.4, 94.6)	96.2 (95.3, 96.8)	95.2 (94.3, 96)
Central African Republic	CAF	Cluster 1	75.7 (64.1, 84.3)	69.9 (56.8, 80.2)	82.5 (72.9, 88.5)	64.1 (46.5, 77.7)
Chad	TCD	Cluster 1	53.9 (34.7, 68.7)	40.8 (18.1, 58.9)	64.4 (46, 76)	31.6 (0.5, 56.3)
Chile	CHL	Cluster 3	95.2 (93.6, 96.6)	93.5 (91.5, 95.4)	95.8 (94.2, 97.1)	92.9 (90.3, 95.5)
China	CHN	Cluster 3	89.1 (84.4, 92.7)	86.6 (81.4, 90.8)	92.6 (90, 95)	84 (75.9, 90)
Colombia	COL	Cluster 3	92.2 (89.4, 94.8)	90.5 (87.3, 93.6)	93.7 (91.2, 95.7)	88.5 (84.8, 92.6)
Comoros	COM	Cluster 1	64.6 (39.8, 77.6)	56.5 (29.5, 71.4)	78 (68.2, 85.7)	47.8 (9.2, 67.5)
Congo, Dem. Rep.	COD	Cluster 1	78.4 (68, 86)	72.3 (60.6, 81.5)	86.2 (79.5, 91)	68 (51.4, 80.3)
Congo, Rep.	COG	Cluster 1	80.5 (70.7, 86.7)	75.4 (64.6, 83)	86.3 (79.1, 90.7)	71.1 (56.6, 81.7)
Costa Rica	CRI	Cluster 3	89.7 (85.8, 93)	87.8 (83.4, 91.7)	90.8 (87.3, 93.7)	84.5 (78.3, 90.3)
Cote d'Ivoire	CIV	Cluster 1	70 (58.8, 79.8)	60.3 (46.1, 72.3)	78.6 (69, 86)	55.5 (36.1, 72.2)
Croatia	HRV	Cluster 4	87 (84.4, 89.3)	84.1 (81.1, 86.8)	89 (86.6, 91.1)	87 (84.4, 89.3)
Cuba	CUB	Cluster 3	89.4 (86, 92.6)	86.4 (82.3, 90.4)	91.3 (88.3, 93.9)	84.2 (79, 89.9)
Cyprus	CYP	Cluster 4	92.4 (90.9, 93.6)	90.5 (88.8, 92)	93.3 (91.7, 94.5)	92.4 (90.9, 93.6)
Czechia	CZE	Cluster 4	86.8 (84.2, 88.9)	83.7 (80.7, 86.3)	89.2 (87, 91)	86.8 (84.2, 88.9)
Denmark	DNK	Cluster 4	87.9 (85.6, 89.9)	85.2 (82.5, 87.6)	89.7 (87.8, 91.4)	87.9 (85.6, 89.9)

Djibouti	DJI	Cluster 2	70.3 (56.7, 80.6)	62.9 (47.4, 75.5)	79.9 (72, 87)	56.2 (35, 72)
Dominican Republic	DOM	Cluster 3	88 (83.6, 91.7)	84.7 (78.9, 89.4)	90.7 (87.2, 93.6)	82.1 (75, 88.6)
Ecuador	ECU	Cluster 3	89.6 (85.2, 92.7)	86.7 (81.5, 90.6)	91.7 (89, 94.3)	84.5 (78.4, 89.7)
Egypt, Arab Rep.	EGY	Cluster 2	86.3 (81.5, 90.6)	82.2 (76.2, 87.7)	89.2 (85.3, 92.6)	79.9 (72.5, 87)
El Salvador	SLV	Cluster 3	90.1 (86.3, 93.1)	87.8 (83.3, 91.5)	92.1 (89, 94.5)	85.2 (79.6, 90.5)
Equatorial Guinea	GNQ	Cluster 1	81.6 (72.5, 88)	76.9 (65.7, 84.6)	87.1 (79.9, 91.7)	72.6 (58.9, 83.2)
Eritrea	ERI	Cluster 1	62.6 (43.7, 75.6)	54.1 (33.7, 69.3)	73.7 (61.7, 82.5)	44.9 (14.5, 66.1)
Estonia	EST	Cluster 4	84.7 (81.3, 87.2)	81.9 (78, 84.8)	89.3 (87, 91)	84.7 (81.3, 87.2)
Eswatini	SWZ	Cluster 2	57.3 (17.4, 74.1)	52.8 (12.4, 70.9)	79.5 (69.7, 86.4)	37.1 (-28, 64.3)
Ethiopia	ETH	Cluster 1	58.3 (38, 72.8)	46.3 (24, 64.5)	68.3 (50.7, 79.9)	38.3 (7.9, 61.2)
Fiji	FJI	Cluster 2	88 (83.5, 91.8)	83.6 (77.5, 88.6)	91.1 (87.3, 94.1)	82.2 (75.4, 88.8)
Finland	FIN	Cluster 4	92.1 (90.7, 93.3)	89.5 (87.8, 91.1)	93.5 (92.4, 94.6)	92.1 (90.7, 93.3)
France	FRA	Cluster 4	90.1 (87.9, 91.8)	87.8 (85.2, 89.8)	91.8 (89.9, 93.3)	90.1 (87.9, 91.8)
Gabon	GAB	Cluster 2	83.9 (76.7, 89.5)	79.7 (71.3, 86.6)	88.6 (83.4, 92.3)	76.2 (64.1, 85.2)
Gambia, The	GMB	Cluster 1	65.9 (52.6, 76.1)	55.1 (38.8, 68.4)	74.2 (61.9, 82.7)	49.5 (28.6, 68)
Georgia	GEO	Cluster 4	62.5 (47.3, 70.9)	58.1 (42.8, 66.8)	81.4 (77.5, 84.4)	62.5 (47.3, 70.9)
Germany	DEU	Cluster 4	91.1 (89.6, 92.4)	88.2 (86.2, 90)	93 (91.8, 94.1)	91.1 (89.6, 92.4)
Ghana	GHA	Cluster 1	64.8 (51, 76.1)	50.6 (33.8, 66.2)	74.7 (62.3, 82.9)	47.7 (25.8, 67)
Greece	GRC	Cluster 4	91.4 (89.6, 92.8)	88.9 (86.7, 90.6)	92.7 (91, 94)	91.4 (89.6, 92.8)
Grenada	GRD	Cluster 3	88.3 (84.3, 91.8)	85.2 (80.5, 89.6)	90.9 (87.7, 93.7)	82.6 (76.3, 88.8)
Guatemala	GTM	Cluster 2	85.7 (80.4, 90.2)	80.5 (73.7, 86.5)	88.8 (84.5, 92.2)	78.9 (70.4, 86.3)
Guinea	GIN	Cluster 1	62.1 (46.5, 73.8)	49.5 (30.9, 64.8)	72.1 (58, 81.7)	43.6 (19.4, 64.9)
Guinea-Bissau	GNB	Cluster 1	70.3 (57.5, 80.1)	64 (50.2, 75.4)	75.9 (64.8, 84.2)	55.9 (35.8, 72.9)
Guyana	GUY	Cluster 3	89.8 (86.1, 92.8)	85.4 (80.5, 89.7)	91.9 (88.8, 94.3)	84.8 (79.2, 90.3)
Haiti	HTI	Cluster 2	89.6 (86, 92.8)	85.3 (80.2, 89.9)	92.8 (90.3, 95)	84.7 (78.8, 90.3)
Honduras	HND	Cluster 2	88.5 (84.1, 92.2)	86.4 (81.5, 90.8)	90.8 (87.1, 93.8)	82.8 (76.2, 89.4)
Hungary	HUN	Cluster 4	87.4 (84.9, 89.4)	84.8 (82.1, 87.1)	89.6 (87.4, 91.3)	87.4 (84.9, 89.4)
Iceland	ISL	Cluster 4	91.1 (89.2, 92.6)	89 (86.8, 90.8)	92.3 (90.5, 93.7)	91.1 (89.2, 92.6)
India	IND	Cluster 2	52.2 (31.7, 66.9)	23.2 (-6.4, 46.1)	72.2 (60.8, 80.3)	28.8 (-1.3, 54.6)
Indonesia	IDN	Cluster 2	84.2 (78.6, 89.1)	74.4 (65.7, 82.5)	89.7 (85.6, 93.1)	76.6 (67.7, 85)
Iran, Islamic Rep.	IRN	Cluster 3	88.5 (83.2, 92.1)	85.4 (79.5, 89.9)	89.9 (85, 93.1)	82.8 (75.5, 89.2)
Iraq	IRQ	Cluster 2	87.5 (83.1, 91.6)	83.5 (77.8, 88.6)	90.4 (86.6, 93.5)	81.5 (74.2, 88.3)
Ireland	IRL	Cluster 4	91.7 (90, 93.2)	89.7 (87.6, 91.4)	92.6 (90.9, 94)	91.7 (90, 93.2)
Israel	ISR	Cluster 3	95.1 (93.5, 96.6)	93.6 (91.4, 95.5)	96 (94.5, 97.1)	92.7 (90.2, 95.3)
Italy	ITA	Cluster 4	93.7 (92.5, 94.6)	91.8 (90.2, 93)	95.1 (94.1, 95.8)	93.7 (92.5, 94.6)
Jamaica	JAM	Cluster 3	89.7 (86.3, 93)	87 (82.7, 91.1)	91.8 (88.9, 94.5)	84.9 (79.4, 90.5)
Japan	JPN	Cluster 4	91.9 (90.2, 93.3)	89.7 (87.6, 91.5)	93.9 (92.7, 94.9)	91.9 (90.2, 93.3)
Jordan	JOR	Cluster 3	90.9 (87.5, 93.7)	87.3 (82.6, 91.1)	92.6 (89.6, 94.8)	86.6 (81.7, 91.3)
Kazakhstan	KAZ	Cluster 2	78.2 (67.3, 85.6)	75.4 (64, 83.5)	89.7 (86, 92.9)	67.9 (50.1, 80.3)
Kenya	KEN	Cluster 1	69 (57.4, 78.6)	57.1 (41.8, 70.7)	76.6 (67.3, 84.2)	53.7 (36.3, 71.1)
Kiribati	KIR	Cluster 2	86.1 (80.5, 90.7)	80.7 (73.7, 87.1)	90.6 (86.2, 93.8)	79.6 (70.9, 86.9)
Korea, Dem. People's Rep.	PRK	Cluster 2	76.9 (61.5, 85.4)	74 (58.1, 83.3)	89.3 (85.1, 92.6)	65.6 (41.6, 80.3)
Korea, Rep.	KOR	Cluster 4	94.2 (92.6, 95.3)	92.6 (90.8, 93.9)	95.4 (94.3, 96.2)	94.2 (92.6, 95.3)
Kuwait	KWT	Cluster 3	90.7 (87.1, 93.5)	87.9 (83.6, 91.4)	91.8 (88.4, 94.3)	86.1 (80.5, 91.2)
Kyrgyz Republic	KGZ	Cluster 2	62.5 (35.3, 76.7)	58.9 (31.1, 74.1)	86.2 (81.5, 90.2)	44.5 (3.9, 67.5)
Lao PDR	LAO	Cluster 2	82.7 (76.1, 88.1)	71.6 (61, 80.2)	89 (84.6, 92.5)	74.4 (65.3, 83.7)
Latvia	LVA	Cluster 4	84.2 (80.7, 86.8)	81.1 (77.3, 84.1)	88.7 (86.5, 90.6)	84.2 (80.7, 86.8)
Lebanon	LBN	Cluster 3	89 (84.4, 92.5)	85.4 (80, 89.9)	90.9 (87, 94)	83.6 (76.4, 89.6)
Lesotho	LSO	Cluster 2	65.3 (44.4, 77.9)	60.5 (39, 74.2)	80 (72.3, 86.9)	49.1 (15, 68.8)

Liberia	LBR	Cluster 1	65.7 (51.1, 76.5)	57.1 (40.6, 70)	72.3 (59.3, 81.7)	48.7 (26.1, 68.3)
Libya	LBY	Cluster 3	89.7 (85.9, 92.8)	86.4 (81.5, 90.5)	91.7 (88.5, 94.3)	84.8 (78.7, 90.3)
Lithuania	LTU	Cluster 4	79.3 (72.9, 83.7)	76.1 (69.6, 80.9)	88.2 (85.8, 90)	79.3 (72.9, 83.7)
Luxembourg	LUX	Cluster 4	92.5 (91.1, 93.7)	90.3 (88.3, 91.8)	94.1 (92.9, 95)	92.5 (91.1, 93.7)
Madagascar	MDG	Cluster 1	61.7 (46.5, 74.6)	52.5 (35.4, 67.7)	70.2 (57.6, 80.9)	43.8 (19.3, 63.8)
Malawi	MWI	Cluster 1	73.5 (62, 82.2)	68.2 (55.7, 78.2)	79.3 (69, 86.2)	60.8 (42.8, 75)
Malaysia	MYS	Cluster 2	84.4 (78.8, 89.4)	76.4 (68.2, 83.9)	88.9 (84.6, 92.5)	76.8 (68, 85.2)
Maldives	MDV	Cluster 2	87.5 (83.2, 91.3)	80.6 (73.5, 86.5)	90.8 (87.3, 93.7)	81.6 (74.4, 88.5)
Mali	MLI	Cluster 1	52.2 (34.2, 66.9)	37.6 (14.5, 56.5)	62.5 (46.3, 74.9)	28.6 (-1.4, 54.2)
Malta	MLT	Cluster 4	91.7 (90.1, 93.1)	89.4 (87.4, 91.2)	93.8 (92.3, 94.9)	91.7 (90.1, 93.1)
Mauritania	MRT	Cluster 1	53.6 (33.7, 68)	41.5 (17.9, 59.3)	61.1 (42, 74)	31 (-0.7, 57.9)
Mauritius	MUS	Cluster 3	89.6 (86, 92.6)	85.6 (81, 89.8)	91.6 (88.6, 94.1)	84.5 (78.6, 89.9)
Mexico	MEX	Cluster 3	91.1 (88.3, 93.8)	87.9 (84.1, 91.5)	92.6 (90, 94.8)	87 (82.4, 91.6)
Micronesia, Fed. Sts.	FSM	Cluster 2	89.3 (85, 92.6)	84.2 (78.3, 89.1)	92.6 (89.2, 95)	84.2 (77.8, 89.9)
Moldova	MDA	Cluster 4	59.8 (40, 71.7)	56.7 (36.2, 68.6)	87.9 (85.4, 90)	59.8 (40, 71.7)
Mongolia	MNG	Cluster 2	77.2 (62.3, 85.3)	74 (58.7, 82.9)	88.5 (84.5, 92.1)	65.8 (42.7, 79.9)
Montenegro	MNE	Cluster 4	88.6 (86, 90.5)	86.3 (83.5, 88.5)	90.6 (88.3, 92.2)	88.6 (86, 90.5)
Morocco	MAR	Cluster 3	90.1 (87.4, 93)	86.9 (83.7, 90.7)	92.7 (90.7, 94.9)	85.4 (79.5, 90.7)
Mozambique	MOZ	Cluster 1	64.8 (48.5, 77)	54 (35, 69.2)	79.6 (71.1, 86.2)	47.6 (22.9, 67.5)
Myanmar	MMR	Cluster 2	73.1 (61.5, 81.8)	59.7 (44.4, 72.7)	85.9 (80.9, 90.2)	60.4 (41.4, 75.3)
Namibia	NAM	Cluster 2	70.1 (54.9, 80.4)	66.3 (50.5, 77.4)	82 (74.1, 87.5)	55.5 (32.3, 72.4)
Nepal	NPL	Cluster 2	72.3 (62, 80.8)	50.2 (32, 65.7)	85.1 (79.6, 90)	58.8 (42.7, 73.8)
Netherlands	NLD	Cluster 4	89.9 (87.7, 91.7)	87.2 (84.6, 89.4)	91.9 (90.1, 93.4)	89.9 (87.7, 91.7)
New Zealand	NZL	Cluster 4	93 (91.8, 94)	91 (89.4, 92.2)	94 (92.9, 94.8)	93 (91.8, 94)
Nicaragua	NIC	Cluster 3	89.9 (86.4, 93)	87.6 (83.3, 91.3)	92.2 (89.4, 94.6)	85.1 (79.5, 90.4)
Niger	NER	Cluster 1	52.8 (31.7, 68.1)	39 (13.8, 58.8)	62.9 (42.2, 75.2)	29.9 (-0.8, 54.6)
Nigeria	NGA	Cluster 1	57.6 (40.1, 72.3)	45.6 (24.2, 64.2)	68.6 (52.7, 80.5)	37.2 (8.4, 61.1)
North Macedonia	MKD	Cluster 4	88.1 (85.6, 90.2)	86 (83.2, 88.5)	90 (87.8, 91.9)	88.1 (85.6, 90.2)
Norway	NOR	Cluster 4	90.2 (88.4, 91.7)	87.6 (85.3, 89.5)	91.9 (90.3, 93.1)	90.2 (88.4, 91.7)
Oman	OMN	Cluster 3	90.6 (87.2, 93.7)	87.7 (83.5, 91.7)	91.7 (88.6, 94.5)	86 (80.6, 91)
Pakistan	PAK	Cluster 2	66.6 (54.4, 77.4)	48.4 (30.6, 65.1)	79.1 (70.9, 85.8)	51.1 (30, 68.9)
Panama	PAN	Cluster 3	88.3 (84.2, 91.9)	86.1 (81.4, 90.3)	90.4 (86.8, 93.3)	82.7 (75.8, 88.9)
Papua New Guinea	PNG	Cluster 2	74.9 (65.2, 83.1)	58.2 (41, 71.1)	84.6 (78.1, 89.8)	63 (48.2, 76.4)
Paraguay	PRY	Cluster 3	91.7 (89.1, 94.4)	89.3 (86, 92.7)	93 (90.4, 95.2)	87.7 (83.3, 92.3)
Peru	PER	Cluster 2	86.6 (81.6, 90.8)	83.5 (77.6, 88.6)	90.9 (87.7, 93.7)	80.3 (71.9, 87.4)
Philippines	PHL	Cluster 2	82.7 (75.5, 88.1)	74.3 (65.1, 81.8)	90.9 (87.6, 93.7)	74.4 (62.7, 84.3)
Poland	POL	Cluster 4	88.2 (85.7, 90.1)	85.9 (83.1, 88)	90.3 (88, 92)	88.2 (85.7, 90.1)
Portugal	PRT	Cluster 4	91 (89.2, 92.5)	88.3 (85.9, 90.2)	93.3 (92, 94.4)	91 (89.2, 92.5)
Puerto Rico	PRI	Cluster 3	88.3 (84.6, 91.8)	84.9 (80.2, 89.4)	90.5 (87.4, 93.5)	82.7 (77, 88.8)
Qatar	QAT	Cluster 3	91.3 (87.9, 94.2)	89 (85.1, 92.4)	92.2 (89, 94.7)	87.1 (81.7, 91.9)
Romania	ROU	Cluster 4	84.6 (81, 87.4)	81.7 (77.6, 84.8)	89 (86.5, 90.9)	84.6 (81, 87.4)
Russian Federation	RUS	Cluster 4	70 (55.7, 78.3)	66.9 (52.4, 75.6)	88.9 (86.5, 90.6)	70 (55.7, 78.3)
Rwanda	RWA	Cluster 1	74.6 (64.2, 83.1)	66.8 (54.9, 77.6)	81.4 (73.2, 88)	62.4 (46, 75.6)
Samoa	WSM	Cluster 2	88.2 (82.3, 92.3)	84.1 (77.1, 89.4)	90.8 (85.5, 94.3)	82.3 (74.7, 89.1)
Sao Tome and Principe	STP	Cluster 2	77.5 (67.8, 84.5)	68.8 (57, 78)	84.1 (75.7, 89.4)	66.4 (51.9, 79.1)
Saudi Arabia	SAU	Cluster 3	88.4 (83.9, 92.1)	85.4 (80.1, 90)	90.1 (86.1, 93.3)	82.6 (75.2, 89)
Senegal	SEN	Cluster 1	55.2 (37, 69.2)	45.7 (25.5, 61.9)	62.1 (44, 74.3)	33.3 (5.8, 58)
Serbia	SRB	Cluster 4	87.8 (85.1, 89.9)	85.5 (82.3, 87.9)	90.1 (87.6, 91.8)	87.8 (85.1, 89.9)
Seychelles	SYC	Cluster 2	86.1 (81.7, 90.4)	77.4 (69.9, 84.5)	90.9 (87.7, 93.7)	79.4 (72.7, 86.9)

Sierra Leone	SLE	Cluster 1	55.5 (39.4, 69.4)	42.2 (22.9, 60)	67.5 (54.3, 77.6)	34.5 (8.3, 57.9)
Singapore	SGP	Cluster 4	94 (92.6, 95)	92.3 (90.5, 93.6)	95.6 (94.5, 96.3)	94 (92.6, 95)
Slovak Republic	SVK	Cluster 4	87.1 (84.3, 89.3)	84.4 (81.1, 87)	89.2 (86.8, 91.2)	87.1 (84.3, 89.3)
Slovenia	SVN	Cluster 4	88.3 (86.1, 90.2)	85.4 (82.7, 87.8)	90.4 (88.6, 92.1)	88.3 (86.1, 90.2)
Solomon Islands	SLB	Cluster 2	87.4 (82.8, 91.3)	81.1 (74.1, 86.7)	91.6 (88, 94.4)	81.4 (73.8, 88)
Somalia	SOM	Cluster 1	64.2 (38.5, 77)	55.2 (28.8, 70.8)	79.3 (70.9, 86)	46.4 (8.1, 68.6)
South Africa	ZAF	Cluster 2	75.8 (65.7, 83.9)	72.3 (61.4, 81.4)	83.2 (77, 88.4)	64.1 (48.2, 77.6)
South Sudan	SSD	Cluster 1	55 (35.4, 70.4)	44.7 (23.6, 62.9)	67.5 (53.4, 78.1)	33.2 (1.9, 59.2)
Spain	ESP	Cluster 4	91.3 (89.6, 92.7)	88.7 (86.5, 90.5)	93.2 (91.9, 94.2)	91.3 (89.6, 92.7)
Sri Lanka	LKA	Cluster 2	87 (82.8, 90.9)	79.3 (72.2, 85.7)	91 (87.9, 93.7)	80.6 (72.6, 87.8)
St. Lucia	LCA	Cluster 3	88.7 (85.3, 92.2)	85.8 (81.6, 90.1)	91.2 (88.5, 93.9)	83.3 (77.3, 89.4)
St. Vincent and the Grenadines	VCT	Cluster 3	89.4 (85.8, 92.5)	86.5 (82, 90.4)	92 (89.2, 94.4)	84.2 (79.1, 90)
Sudan	SDN	Cluster 1	81.5 (73.1, 87.7)	75.5 (65.5, 83.7)	85.1 (77.2, 90.3)	72.3 (59.4, 82.5)
Suriname	SUR	Cluster 3	89.1 (85.5, 92.5)	86.1 (81.6, 90.4)	91.5 (88.4, 94.2)	83.8 (77.6, 89.6)
Sweden	SWE	Cluster 4	88.2 (85.7, 90.1)	85.8 (82.9, 88)	89.8 (87.7, 91.5)	88.2 (85.7, 90.1)
Switzerland	CHE	Cluster 4	90.6 (89.4, 91.5)	88.4 (87.2, 89.5)	92.1 (90.9, 92.9)	90.6 (89.4, 91.5)
Syrian Arab Republic	SYR	Cluster 2	83.3 (74.3, 90)	77.5 (65, 86.5)	88.4 (82.5, 92.7)	75.5 (60, 85.9)
Tajikistan	TJK	Cluster 2	66.3 (51.2, 77.3)	60.5 (43.5, 73.5)	80.1 (72.8, 86.6)	50.4 (25.2, 68.4)
Tanzania	TZA	Cluster 1	68.4 (55.8, 78.8)	57.6 (41.9, 70.6)	76.3 (66.1, 84.3)	53.2 (35.5, 71)
Thailand	THA	Cluster 2	87 (82.4, 91.1)	81.3 (75.1, 87.1)	91.4 (88.3, 94)	80.7 (72.8, 87.8)
Timor-Leste	TLS	Cluster 2	81 (73.6, 86.9)	67.8 (55.3, 77.7)	88.5 (83.5, 92.1)	71.8 (60.8, 82.3)
Togo	TGO	Cluster 1	66.7 (53.4, 77.3)	57.2 (41.7, 70.2)	73.9 (61.5, 82.5)	50.3 (27.7, 69.4)
Tonga	TON	Cluster 2	87.6 (82.5, 91.7)	83.1 (77.1, 88.6)	90.7 (86.1, 93.9)	81.6 (73.3, 88.9)
Trinidad and Tobago	TTO	Cluster 3	90.4 (87.3, 93.4)	88 (84.1, 91.6)	91.9 (89.2, 94.4)	85.9 (80.8, 90.9)
Tunisia	TUN	Cluster 3	89.4 (85.9, 92.6)	86.1 (81.5, 90.2)	91.2 (88.1, 93.8)	84.3 (78.6, 89.8)
Türkiye	TUR	Cluster 3	92.5 (89.9, 94.8)	90.2 (86.7, 93.1)	93.9 (91.8, 95.8)	88.9 (85, 92.8)
Turkmenistan	TKM	Cluster 2	77.3 (65.2, 85.3)	73.7 (61.1, 82.9)	87.2 (82.5, 91.3)	66.3 (47.2, 79.2)
Uganda	UGA	Cluster 1	78 (69.3, 85.3)	71.4 (60.9, 80.4)	84.5 (77.3, 89.5)	67.4 (51.6, 79.7)
Ukraine	UKR	Cluster 4	66.3 (48, 76.8)	63.2 (44.7, 73.7)	88.5 (85.9, 90.5)	66.3 (48, 76.8)
United Arab Emirates	ARE	Cluster 3	91.5 (88.4, 94.2)	89.2 (85.4, 92.5)	92.3 (89.1, 94.8)	87.5 (82.6, 92)
United Kingdom	GBR	Cluster 4	91.7 (90, 93.2)	89.4 (87.2, 91.3)	93.6 (92.1, 94.7)	91.7 (90, 93.2)
United States	USA	Cluster 4	94.3 (93.3, 95.3)	92.4 (91.1, 93.7)	94.9 (93.3, 95.9)	94.3 (93.3, 95.3)
Uruguay	URY	Cluster 3	94.1 (92.2, 95.9)	92 (89.4, 94.4)	95.3 (93.6, 96.7)	91.2 (88, 94.5)
Uzbekistan	UZB	Cluster 2	71.5 (55, 81.6)	67.5 (50.3, 78.6)	86.6 (81.7, 90.8)	57.8 (33.2, 74.1)
Vanuatu	VUT	Cluster 2	87 (81.7, 90.9)	81.2 (74.4, 86.6)	90.7 (86.2, 93.7)	80.6 (72.7, 87.7)
Venezuela, RB	VEN	Cluster 3	88.9 (84.7, 92.3)	86.6 (81.7, 90.7)	91 (87.4, 93.7)	83.4 (77.1, 89.4)
Viet Nam	VNM	Cluster 2	82.2 (75, 88.1)	74.1 (65, 82.5)	90.1 (86.4, 93.1)	73.7 (60.7, 83.6)
West Bank and Gaza	PSE	Cluster 3	91.5 (88.4, 94.2)	88.3 (84.5, 92.1)	92.7 (89.8, 95)	87.5 (82.2, 92.2)
Yemen, Rep.	YEM	Cluster 1	83.9 (77.4, 89.1)	78.7 (70.6, 85.7)	87.7 (82.8, 91.8)	76 (65.5, 84.7)
Zambia	ZMB	Cluster 1	70.9 (59.1, 80.6)	64.5 (51.4, 76)	77.6 (67.7, 85.5)	56.9 (36.5, 73.5)
Zimbabwe	ZWE	Cluster 1	79.8 (62.2, 87)	75.7 (57.5, 84.2)	88.8 (84.6, 92.5)	69.9 (43.3, 82.3)
Taiwan	TWN	Cluster 3	83.3 (77.7, 88.5)	79 (72.2, 85.5)	87.8 (83.6, 91.5)	75.5 (66.3, 84.5)

2.3.3 Actual vs. estimated optimal scenario comparison




Figure 28. Comparison of actual (IQVIA MIDAS) vs. median estimated optimal by analysis scenario (rows) and AWaRe category (columns) for CTAs in IQVIA MIDAS® with observed antibiotic use data available. Dashed line indicates where observed = expected. Scenario 1 = primary analysis, Scenario 2 = high watch scenario, Scenario 3 = unadjusted case counts & excl. TB, Scenario 4 = alternate benchmark CTA. Source: Actual DID based on IQVIA MIDAS® data for 2019, reflecting estimates of real-world activity. Copyright IQVIA. All Rights Reserved

Table 14. Estimated optimal total defined daily doses/1000 inhabitants/year (DID) and Access, Watch and Reserve DID for all four analysis scenarios compared to Actual DID in IQVIA MIDAS for 67 CTAs with available actual antibiotic use in IQVIA MIDAS. Scenario 1 = primary analysis, Scenario 2 = high watch scenario, Scenario 3 = unadjusted cases & excl. TB, Scenario 4 = alternate benchmark CTA

ISO3 Code	CTA Name	Cluster	AWaRe Category	Actual DID in IQVIA MIDAS*	Scenario 1	Scenario 2	Scenario 3	Scenario 4
DZA	Algeria	Cluster 3	Total DID	34.8 (33.7, 36.4)	14.4 (11, 20.5)	14.4 (11, 20.5)	14.4 (11, 20.6)	9.8 (7.3, 15)
DZA	Algeria	Cluster 3	Access DID	26.1 (25.6, 28.2)	12.9 (9.6, 19.2)	12.4 (9.1, 18.7)	13.2 (9.9, 19.5)	8.3 (5.9, 13.6)
DZA	Algeria	Cluster 3	Watch DID	5.6 (5.3, 5.7)	1.4 (1.2, 1.7)	1.9 (1.6, 2.2)	1.1 (0.9, 1.4)	1.4 (1.2, 1.7)
DZA	Algeria	Cluster 3	Reserve DID	0 (0, 0)	0.1 (0, 0.2)	0.1 (0, 0.2)	0 (0, 0.1)	0.1 (0, 0.2)
ARG	Argentina	Cluster 3	Total DID	14.5 (13.9, 16.1)	19.6 (15.3, 27.6)	19.6 (15.3, 27.6)	19.9 (15.5, 28)	13.2 (9.9, 20.1)
ARG	Argentina	Cluster 3	Access DID	9.4 (8.9, 10.7)	18.4 (14.1, 26.5)	18 (13.7, 26.1)	18.9 (14.5, 27.1)	12 (8.8, 18.9)
ARG	Argentina	Cluster 3	Watch DID	4.5 (4.2, 4.6)	1.1 (1, 1.2)	1.5 (1.4, 1.7)	0.8 (0.7, 0.9)	1.1 (1, 1.2)
ARG	Argentina	Cluster 3	Reserve DID	0 (0, 0)	0 (0, 0.1)	0 (0, 0.1)	0.1 (0.1, 0.3)	0 (0, 0.1)
AUS	Australia	Cluster 4	Total DID	22.8 (22.8, 22.8)	12.9 (11.2, 14.9)	12.9 (11.2, 14.9)	12.9 (11.2, 14.9)	12.9 (11.2, 14.9)
AUS	Australia	Cluster 4	Access DID	18.5 (18.5, 18.5)	12.1 (10.4, 14.1)	11.9 (10.2, 13.8)	12.3 (10.6, 14.2)	12.1 (10.4, 14.1)
AUS	Australia	Cluster 4	Watch DID	4.3 (4.3, 4.3)	0.8 (0.7, 0.8)	1 (0.9, 1.1)	0.6 (0.5, 0.7)	0.8 (0.7, 0.8)
AUS	Australia	Cluster 4	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0)	0.1 (0, 0.1)	0 (0, 0)
AUT	Austria	Cluster 4	Total DID	14.8 (14.8, 14.8)	10.8 (9.3, 12.4)	10.8 (9.3, 12.4)	10.8 (9.3, 12.5)	10.8 (9.3, 12.4)
AUT	Austria	Cluster 4	Access DID	8.8 (8.8, 8.8)	9.9 (8.5, 11.6)	9.7 (8.2, 11.3)	10.1 (8.6, 11.7)	9.9 (8.5, 11.6)
AUT	Austria	Cluster 4	Watch DID	5.7 (5.7, 5.7)	0.9 (0.8, 1)	1.1 (1, 1.3)	0.7 (0.6, 0.8)	0.9 (0.8, 1)
AUT	Austria	Cluster 4	Reserve DID	0.1 (0.1, 0.1)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
BGD	Bangladesh	Cluster 2	Total DID	18.8 (16.8, 19.9)	18.6 (14.4, 26.7)	18.6 (14.4, 26.7)	18.5 (14.2, 26.5)	12.6 (9.6, 19.4)
BGD	Bangladesh	Cluster 2	Access DID	6.3 (6.1, 6.7)	14.1 (9.9, 21.9)	10.9 (6.6, 18.9)	15.8 (11.6, 23.8)	8.1 (5.1, 15)
BGD	Bangladesh	Cluster 2	Watch DID	10.4 (8.7, 11.4)	4.1 (3.6, 4.8)	7.3 (6.4, 8.3)	2.5 (2.2, 3.1)	4.1 (3.6, 4.8)
BGD	Bangladesh	Cluster 2	Reserve DID	0.1 (0.1, 0.1)	0.4 (0.1, 1)	0.4 (0.1, 1)	0.1 (0, 0.4)	0.4 (0.1, 1)
BLR	Belarus	Cluster 4	Total DID	23.5 (23.5, 23.5)	10.5 (9, 12.1)	10.5 (9, 12.1)	10.5 (9, 12)	10.5 (9, 12.1)
BLR	Belarus	Cluster 4	Access DID	13 (13, 13)	8 (6.5, 9.8)	7.7 (6.2, 9.5)	9.3 (7.9, 10.9)	8 (6.5, 9.8)
BLR	Belarus	Cluster 4	Watch DID	8.5 (8.5, 8.5)	1.5 (1.4, 1.7)	1.8 (1.6, 2)	1.1 (1, 1.2)	1.5 (1.4, 1.7)
BLR	Belarus	Cluster 4	Reserve DID	0.1 (0.1, 0.1)	0.8 (0.5, 1.6)	0.8 (0.5, 1.6)	0 (0, 0.1)	0.8 (0.5, 1.6)
BEL	Belgium	Cluster 4	Total DID	25.6 (25.6, 25.6)	10.8 (9.4, 12.5)	10.8 (9.4, 12.5)	10.8 (9.4, 12.5)	10.8 (9.4, 12.5)
BEL	Belgium	Cluster 4	Access DID	15.8 (15.8, 15.8)	9.8 (8.4, 11.5)	9.5 (8.1, 11.2)	10 (8.6, 11.7)	9.8 (8.4, 11.5)
BEL	Belgium	Cluster 4	Watch DID	9.8 (9.8, 9.8)	1 (0.9, 1.2)	1.3 (1.2, 1.5)	0.8 (0.7, 0.9)	1 (0.9, 1.2)
BEL	Belgium	Cluster 4	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0.1)	0 (0, 0)
BIH	Bosnia and Herzegovina	Cluster 4	Total DID	23.8 (22.1, 26.2)	8 (7, 9.2)	8 (7, 9.2)	8 (6.9, 9.1)	8 (7, 9.2)
BIH	Bosnia and Herzegovina	Cluster 4	Access DID	15.3 (14.1, 17.6)	7.1 (6, 8.2)	6.9 (5.8, 8)	7.2 (6.1, 8.4)	7.1 (6, 8.2)
BIH	Bosnia and Herzegovina	Cluster 4	Watch DID	7 (6.6, 7.8)	1 (0.8, 1.1)	1.1 (1, 1.3)	0.8 (0.7, 0.9)	1 (0.8, 1.1)
BIH	Bosnia and Herzegovina	Cluster 4	Reserve DID	0 (0, 0.1)	0 (0, 0)	0 (0, 0)	0 (0, 0.1)	0 (0, 0)

ISO3 Code	CTA Name	Cluster	AWaRe Category	Actual DID in IQVIA MIDAS*	Scenario 1	Scenario 2	Scenario 3	Scenario 4
BRA	Brazil	Cluster 3	Total DID	13.4 (11.8, 14.5)	21.7 (16.6, 30.7)	21.7 (16.6, 30.8)	21.9 (16.8, 31.1)	14.7 (11.2, 22.6)
BRA	Brazil	Cluster 3	Access DID	7.2 (7, 7.6)	19.6 (14.5, 28.6)	19 (13.8, 28.1)	20.1 (14.9, 29.1)	12.6 (9.1, 20.6)
BRA	Brazil	Cluster 3	Watch DID	5.6 (4.5, 7)	2 (1.8, 2.2)	2.6 (2.4, 2.8)	1.6 (1.4, 1.8)	2 (1.8, 2.2)
BRA	Brazil	Cluster 3	Reserve DID	0 (0, 0.1)	0.1 (0.1, 0.3)	0.1 (0.1, 0.3)	0.3 (0.1, 0.5)	0.1 (0.1, 0.3)
BGR	Bulgaria	Cluster 4	Total DID	22.3 (22.3, 22.3)	7.7 (6.7, 8.9)	7.8 (6.7, 8.9)	7.7 (6.6, 8.9)	7.7 (6.7, 8.9)
BGR	Bulgaria	Cluster 4	Access DID	10.3 (10.3, 10.3)	6.7 (5.6, 7.8)	6.5 (5.4, 7.6)	6.9 (5.8, 8)	6.7 (5.6, 7.8)
BGR	Bulgaria	Cluster 4	Watch DID	11.7 (11.7, 11.7)	1 (0.9, 1.2)	1.2 (1.1, 1.4)	0.8 (0.7, 0.9)	1 (0.9, 1.2)
BGR	Bulgaria	Cluster 4	Reserve DID	0 (0, 0)	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)
CAN	Canada	Cluster 4	Total DID	15.8 (15.8, 15.8)	16.9 (14.5, 19.4)	16.9 (14.5, 19.4)	16.8 (14.5, 19.4)	16.9 (14.5, 19.4)
CAN	Canada	Cluster 4	Access DID	10.7 (10.7, 10.7)	16.1 (13.7, 18.6)	15.8 (13.4, 18.3)	16.2 (13.8, 18.7)	16.1 (13.7, 18.6)
CAN	Canada	Cluster 4	Watch DID	5.1 (5.1, 5.1)	0.8 (0.7, 0.9)	1.1 (1, 1.2)	0.6 (0.5, 0.6)	0.8 (0.7, 0.9)
CAN	Canada	Cluster 4	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0)	0.1 (0, 0.2)	0 (0, 0)
CHL	Chile	Cluster 3	Total DID	13 (11.8, 14.5)	18.5 (14.3, 26.1)	18.5 (14.3, 26.1)	18.7 (14.5, 26.4)	12.4 (9.3, 19.4)
CHL	Chile	Cluster 3	Access DID	7 (6.6, 7.9)	17.6 (13.5, 25.1)	17.2 (13.2, 24.8)	17.9 (13.7, 25.6)	11.5 (8.4, 18.5)
CHL	Chile	Cluster 3	Watch DID	5.2 (4.7, 6.8)	0.8 (0.8, 0.9)	1.2 (1.1, 1.3)	0.6 (0.6, 0.7)	0.8 (0.8, 0.9)
CHL	Chile	Cluster 3	Reserve DID	0 (0, 0)	0 (0, 0.1)	0 (0, 0.1)	0.1 (0.1, 0.3)	0 (0, 0.1)
COL	Colombia	Cluster 3	Total DID	12.9 (11.4, 14.5)	19 (14.5, 27.3)	19 (14.5, 27.3)	19.2 (14.6, 27.6)	12.9 (10.4, 19.3)
COL	Colombia	Cluster 3	Access DID	7.7 (7.3, 9.1)	17.5 (13.1, 25.8)	17.2 (12.7, 25.4)	18 (13.5, 26.4)	11.5 (8.9, 17.9)
COL	Colombia	Cluster 3	Watch DID	4.8 (3.7, 5.9)	1.4 (1.2, 1.6)	1.7 (1.5, 2)	1.1 (1, 1.4)	1.4 (1.2, 1.6)
COL	Colombia	Cluster 3	Reserve DID	0 (0, 0)	0.1 (0, 0.2)	0.1 (0, 0.2)	0.1 (0, 0.2)	0.1 (0, 0.2)
HRV	Croatia	Cluster 4	Total DID	21.2 (21.2, 21.2)	8.2 (7.1, 9.6)	8.2 (7.1, 9.6)	8.2 (7.1, 9.6)	8.2 (7.1, 9.6)
HRV	Croatia	Cluster 4	Access DID	13.4 (13.4, 13.4)	7.2 (6.1, 8.5)	6.9 (5.8, 8.3)	7.3 (6.2, 8.7)	7.2 (6.1, 8.5)
HRV	Croatia	Cluster 4	Watch DID	7.8 (7.8, 7.8)	1.1 (0.9, 1.2)	1.3 (1.2, 1.5)	0.9 (0.7, 1)	1.1 (0.9, 1.2)
HRV	Croatia	Cluster 4	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0.1)	0 (0, 0)
CZE	Czechia	Cluster 4	Total DID	17.6 (17.6, 17.6)	7.9 (6.9, 9.1)	7.9 (6.9, 9.1)	7.9 (6.8, 9.1)	7.9 (6.9, 9.1)
CZE	Czechia	Cluster 4	Access DID	9.9 (9.9, 9.9)	6.9 (5.8, 8)	6.6 (5.6, 7.8)	7.1 (6, 8.2)	6.9 (5.8, 8)
CZE	Czechia	Cluster 4	Watch DID	6.6 (6.6, 6.6)	1 (0.9, 1.2)	1.3 (1.1, 1.4)	0.8 (0.7, 0.9)	1 (0.9, 1.2)
CZE	Czechia	Cluster 4	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0.1)	0 (0, 0)
DOM	Dominican Republic	Cluster 3	Total DID	12.3 (10.3, 14.7)	15.5 (11.9, 21.5)	15.5 (11.9, 21.5)	15.5 (11.9, 21.6)	10.5 (7.8, 16.3)
DOM	Dominican Republic	Cluster 3	Access DID	7.4 (5.4, 9.7)	13.6 (10, 19.8)	13.1 (9.5, 19.4)	14.1 (10.5, 20.3)	8.6 (5.9, 14.5)
DOM	Dominican Republic	Cluster 3	Watch DID	3.9 (3.6, 4.4)	1.8 (1.5, 2.1)	2.3 (2, 2.7)	1.3 (1.2, 1.6)	1.8 (1.5, 2.1)
DOM	Dominican Republic	Cluster 3	Reserve DID	0 (0, 0)	0 (0, 0.1)	0 (0, 0.1)	0.1 (0, 0.3)	0 (0, 0.1)
ECU	Ecuador	Cluster 3	Total DID	45.2 (43.4, 45.9)	18 (14.1, 25.7)	18 (14.1, 25.7)	18.2 (14.2, 26)	12.2 (9.2, 18.4)

ISO3 Code	CTA Name	Cluster	AWaRe Category	Actual DID in IQVIA MIDAS*	Scenario 1	Scenario 2	Scenario 3	Scenario 4
ECU	Ecuador	Cluster 3	Access DID	10 (9.9, 10.1)	16.1 (12, 23.8)	15.6 (11.4, 23.3)	16.7 (12.6, 24.4)	10.3 (7.2, 16.5)
ECU	Ecuador	Cluster 3	Watch DID	33.6 (31.6, 34.1)	1.7 (1.5, 1.9)	2.3 (2, 2.5)	1.4 (1.2, 1.6)	1.7 (1.5, 1.9)
ECU	Ecuador	Cluster 3	Reserve DID	0.1 (0.1, 0.1)	0.1 (0.1, 0.5)	0.1 (0.1, 0.5)	0.1 (0, 0.2)	0.1 (0.1, 0.5)
EGY	Egypt, Arab Rep.	Cluster 2	Total DID	33.9 (33.9, 33.9)	13.4 (10.3, 18.9)	13.4 (10.3, 18.9)	13.3 (10.2, 18.8)	9 (6.8, 14.1)
EGY	Egypt, Arab Rep.	Cluster 2	Access DID	17.9 (17.9, 17.9)	11.5 (8.4, 17.2)	11 (7.8, 16.6)	11.9 (8.7, 17.5)	7.2 (5, 12.2)
EGY	Egypt, Arab Rep.	Cluster 2	Watch DID	9.6 (9.6, 9.6)	1.8 (1.6, 2)	2.3 (2.1, 2.6)	1.4 (1.2, 1.5)	1.8 (1.6, 2)
EGY	Egypt, Arab Rep.	Cluster 2	Reserve DID	0.3 (0.3, 0.3)	0.1 (0, 0.1)	0.1 (0, 0.1)	0.1 (0, 0.2)	0.1 (0, 0.1)
EST	Estonia	Cluster 4	Total DID	13.5 (12.1, 14.9)	10.1 (8.7, 11.8)	10.1 (8.8, 11.8)	10.1 (8.7, 11.8)	10.1 (8.7, 11.8)
EST	Estonia	Cluster 4	Access DID	7.5 (6.9, 8.6)	8.6 (7.2, 10.3)	8.3 (6.9, 10)	9 (7.6, 10.7)	8.6 (7.2, 10.3)
EST	Estonia	Cluster 4	Watch DID	5.9 (4.8, 6.5)	1.3 (1.2, 1.5)	1.6 (1.5, 1.8)	1.1 (1, 1.2)	1.3 (1.2, 1.5)
EST	Estonia	Cluster 4	Reserve DID	0.1 (0, 0.1)	0.2 (0.1, 0.4)	0.2 (0.1, 0.4)	0 (0, 0)	0.2 (0.1, 0.4)
FIN	Finland	Cluster 4	Total DID	13.7 (13.7, 13.7)	10.6 (9.3, 12.3)	10.6 (9.3, 12.2)	10.6 (9.3, 12.3)	10.6 (9.3, 12.3)
FIN	Finland	Cluster 4	Access DID	10.3 (10.3, 10.3)	9.7 (8.4, 11.5)	9.5 (8.2, 11.2)	9.9 (8.6, 11.6)	9.7 (8.4, 11.5)
FIN	Finland	Cluster 4	Watch DID	3.1 (3.1, 3.1)	0.8 (0.8, 0.9)	1.1 (1, 1.2)	0.7 (0.6, 0.7)	0.8 (0.8, 0.9)
FIN	Finland	Cluster 4	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
FRA	France	Cluster 4	Total DID	25.1 (25.1, 25.1)	10.7 (9.3, 12.4)	10.7 (9.3, 12.4)	10.7 (9.3, 12.3)	10.7 (9.3, 12.4)
FRA	France	Cluster 4	Access DID	17.5 (17.5, 17.5)	9.7 (8.2, 11.3)	9.4 (8, 11.1)	9.8 (8.4, 11.5)	9.7 (8.2, 11.3)
FRA	France	Cluster 4	Watch DID	6.5 (6.5, 6.5)	1 (0.9, 1.2)	1.3 (1.2, 1.5)	0.9 (0.8, 1)	1 (0.9, 1.2)
FRA	France	Cluster 4	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
DEU	Germany	Cluster 4	Total DID	14 (14, 14)	10.9 (9.5, 12.6)	10.9 (9.5, 12.6)	10.9 (9.5, 12.6)	10.9 (9.5, 12.6)
DEU	Germany	Cluster 4	Access DID	8 (8, 8)	9.9 (8.5, 11.6)	9.6 (8.2, 11.3)	10.1 (8.7, 11.8)	9.9 (8.5, 11.6)
DEU	Germany	Cluster 4	Watch DID	5.8 (5.8, 5.8)	0.9 (0.9, 1)	1.3 (1.1, 1.4)	0.7 (0.7, 0.8)	0.9 (0.9, 1)
DEU	Germany	Cluster 4	Reserve DID	0.1 (0.1, 0.1)	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)
GRC	Greece	Cluster 4	Total DID	37.5 (36.7, 38.8)	10 (8.7, 11.7)	10 (8.7, 11.7)	10 (8.7, 11.7)	10 (8.7, 11.7)
GRC	Greece	Cluster 4	Access DID	16.2 (16.1, 16.7)	9.2 (7.9, 10.9)	8.9 (7.6, 10.7)	9.3 (8, 11)	9.2 (7.9, 10.9)
GRC	Greece	Cluster 4	Watch DID	20.6 (20.1, 21.8)	0.8 (0.8, 0.9)	1.1 (1, 1.2)	0.6 (0.6, 0.7)	0.8 (0.8, 0.9)
GRC	Greece	Cluster 4	Reserve DID	0.1 (0.1, 0.1)	0 (0, 0.1)	0 (0, 0.1)	0.1 (0, 0.2)	0 (0, 0.1)
HUN	Hungary	Cluster 4	Total DID	15.2 (15.2, 15.2)	7.8 (6.8, 9)	7.8 (6.8, 9)	7.7 (6.7, 9)	7.8 (6.8, 9)
HUN	Hungary	Cluster 4	Access DID	7.6 (7.6, 7.6)	6.8 (5.8, 8)	6.6 (5.6, 7.8)	6.9 (6, 8.1)	6.8 (5.8, 8)
HUN	Hungary	Cluster 4	Watch DID	7.5 (7.5, 7.5)	1 (0.8, 1.1)	1.2 (1, 1.3)	0.8 (0.7, 0.9)	1 (0.8, 1.1)
HUN	Hungary	Cluster 4	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0.1)	0 (0, 0)
IND	India	Cluster 2	Total DID	18.3 (16, 21)	14.7 (11.4, 20.7)	14.7 (11.4, 20.8)	14.5 (11.2, 20.5)	9.9 (7.5, 15.5)
IND	India	Cluster 2	Access DID	4.5 (4, 7.8)	7.6 (3.8, 13.7)	3.4 (-0.8, 9.5)	10.5 (7, 16.3)	2.8 (-0.1, 8.2)
IND	India	Cluster 2	Watch DID	9.3 (7.8, 10.5)	6 (5.3, 7)	10.3 (8.9, 11.7)	3.9 (3.3, 4.9)	6 (5.3, 7)

ISO3 Code	CTA Name	Cluster	AWaRe Category	Actual DID in IQVIA MIDAS*	Scenario 1	Scenario 2	Scenario 3	Scenario 4
IND	India	Cluster 2	Reserve DID	0.2 (0.2, 0.2)	1 (0.4, 2.8)	1 (0.4, 2.8)	0.2 (0.1, 0.4)	1 (0.4, 2.8)
IRL	Ireland	Cluster 4	Total DID	25.3 (25.3, 25.3)	11.3 (9.9, 13.1)	11.3 (9.9, 13.1)	11.3 (9.8, 13.1)	11.3 (9.9, 13.1)
IRL	Ireland	Cluster 4	Access DID	16.7 (16.7, 16.7)	10.4 (8.9, 12.2)	10.1 (8.7, 12)	10.4 (9, 12.3)	10.4 (8.9, 12.2)
IRL	Ireland	Cluster 4	Watch DID	8.5 (8.5, 8.5)	0.9 (0.8, 1)	1.1 (1, 1.3)	0.8 (0.7, 0.9)	0.9 (0.8, 1)
IRL	Ireland	Cluster 4	Reserve DID	0.1 (0.1, 0.1)	0 (0, 0)	0 (0, 0)	0.1 (0, 0.1)	0 (0, 0)
ITA	Italy	Cluster 4	Total DID	24.7 (24.7, 24.7)	10.7 (9.3, 12.3)	10.7 (9.3, 12.3)	10.7 (9.3, 12.3)	10.7 (9.3, 12.3)
ITA	Italy	Cluster 4	Access DID	11.5 (11.5, 11.5)	10.1 (8.7, 11.6)	9.9 (8.4, 11.4)	10.2 (8.8, 11.8)	10.1 (8.7, 11.6)
ITA	Italy	Cluster 4	Watch DID	13.1 (13.1, 13.1)	0.6 (0.6, 0.7)	0.9 (0.8, 0.9)	0.5 (0.4, 0.5)	0.6 (0.6, 0.7)
ITA	Italy	Cluster 4	Reserve DID	0.1 (0.1, 0.1)	0 (0, 0.1)	0 (0, 0.1)	0.1 (0, 0.1)	0 (0, 0.1)
JPN	Japan	Cluster 4	Total DID	12.8 (12.8, 12.8)	12.8 (11.2, 14.8)	12.8 (11.2, 14.9)	12.8 (11.1, 14.8)	12.8 (11.2, 14.8)
JPN	Japan	Cluster 4	Access DID	2.3 (2.3, 2.3)	11.8 (10.1, 13.8)	11.5 (9.8, 13.6)	12 (10.3, 14.1)	11.8 (10.1, 13.8)
JPN	Japan	Cluster 4	Watch DID	10.4 (10.4, 10.4)	1 (0.9, 1.2)	1.3 (1.2, 1.5)	0.8 (0.7, 0.9)	1 (0.9, 1.2)
JPN	Japan	Cluster 4	Reserve DID	0.1 (0.1, 0.1)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
JOR	Jordan	Cluster 3	Total DID	11.9 (10.6, 13.7)	12.5 (9.5, 18.1)	12.5 (9.5, 18.1)	12.7 (9.6, 18.3)	8.5 (6.3, 13.1)
JOR	Jordan	Cluster 3	Access DID	6.3 (5.8, 8)	11.4 (8.4, 16.9)	10.9 (8, 16.4)	11.7 (8.7, 17.3)	7.4 (5.1, 11.9)
JOR	Jordan	Cluster 3	Watch DID	4.5 (4.1, 5.6)	1.1 (1, 1.3)	1.6 (1.4, 1.8)	0.9 (0.8, 1.1)	1.1 (1, 1.3)
JOR	Jordan	Cluster 3	Reserve DID	0 (0, 0)	0 (0, 0.1)	0 (0, 0.1)	0.1 (0, 0.1)	0 (0, 0.1)
KAZ	Kazakhstan	Cluster 2	Total DID	18.2 (18.2, 18.2)	12.3 (9.4, 17.3)	12.3 (9.4, 17.3)	12.4 (9.5, 17.6)	8.3 (6.2, 12.7)
KAZ	Kazakhstan	Cluster 2	Access DID	8.9 (8.9, 8.9)	9.6 (6.7, 14.7)	9.3 (6.3, 14.3)	11.1 (8.2, 16.3)	5.6 (3.2, 10.2)
KAZ	Kazakhstan	Cluster 2	Watch DID	8.8 (8.8, 8.8)	1.7 (1.5, 1.9)	2 (1.8, 2.3)	1.2 (1.1, 1.5)	1.7 (1.5, 1.9)
KAZ	Kazakhstan	Cluster 2	Reserve DID	0 (0, 0)	1 (0.5, 1.9)	1 (0.5, 1.9)	0 (0, 0.1)	1 (0.5, 1.9)
KOR	Korea, Rep.	Cluster 4	Total DID	25.2 (25.2, 25.2)	12.1 (10.4, 14.3)	12.1 (10.4, 14.3)	12.1 (10.4, 14.3)	12.1 (10.4, 14.3)
KOR	Korea, Rep.	Cluster 4	Access DID	11.4 (11.4, 11.4)	11.4 (9.7, 13.5)	11.2 (9.6, 13.4)	11.5 (9.9, 13.7)	11.4 (9.7, 13.5)
KOR	Korea, Rep.	Cluster 4	Watch DID	13.3 (13.3, 13.3)	0.6 (0.6, 0.7)	0.8 (0.7, 0.9)	0.5 (0.4, 0.5)	0.6 (0.6, 0.7)
KOR	Korea, Rep.	Cluster 4	Reserve DID	0 (0, 0)	0.1 (0, 0.2)	0.1 (0, 0.2)	0.1 (0, 0.2)	0.1 (0, 0.2)
KWT	Kuwait	Cluster 3	Total DID	11.2 (10.1, 12.3)	13.4 (10.2, 19.1)	13.4 (10.1, 19.1)	13.5 (10.3, 19.3)	9 (6.8, 14.1)
KWT	Kuwait	Cluster 3	Access DID	4.3 (4, 4.7)	12.1 (8.9, 17.8)	11.8 (8.5, 17.4)	12.4 (9.1, 18.2)	7.7 (5.4, 12.8)
KWT	Kuwait	Cluster 3	Watch DID	6.2 (5.4, 7.3)	1.2 (1.1, 1.5)	1.6 (1.4, 1.8)	1.1 (0.9, 1.3)	1.2 (1.1, 1.5)
KWT	Kuwait	Cluster 3	Reserve DID	0 (0, 0)	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0)	0 (0, 0.1)
LVA	Latvia	Cluster 4	Total DID	12.7 (12.7, 12.7)	10.2 (8.9, 11.7)	10.2 (8.9, 11.7)	10.2 (8.9, 11.7)	10.2 (8.9, 11.7)
LVA	Latvia	Cluster 4	Access DID	9 (9, 9)	8.6 (7.3, 10.2)	8.3 (7, 9.9)	9 (7.7, 10.6)	8.6 (7.3, 10.2)
LVA	Latvia	Cluster 4	Watch DID	3.7 (3.7, 3.7)	1.4 (1.3, 1.6)	1.7 (1.6, 1.9)	1.1 (1, 1.2)	1.4 (1.3, 1.6)
LVA	Latvia	Cluster 4	Reserve DID	0 (0, 0)	0.2 (0.1, 0.4)	0.2 (0.1, 0.4)	0.1 (0, 0.1)	0.2 (0.1, 0.4)
LBN	Lebanon	Cluster 3	Total DID	28.6 (27.3, 30.4)	13.2 (9.9, 18.5)	13.2 (9.9, 18.5)	13.3 (10, 18.7)	8.9 (6.6, 13.7)

ISO3 Code	CTA Name	Cluster	AWaRe Category	Actual DID in IQVIA MIDAS*	Scenario 1	Scenario 2	Scenario 3	Scenario 4
LBN	Lebanon	Cluster 3	Access DID	16.3 (15.8, 17.7)	11.7 (8.5, 17.1)	11.2 (8, 16.7)	12.1 (8.8, 17.6)	7.4 (5.1, 12.3)
LBN	Lebanon	Cluster 3	Watch DID	10.3 (10, 12.1)	1.4 (1.2, 1.7)	1.9 (1.6, 2.2)	1.1 (0.9, 1.5)	1.4 (1.2, 1.7)
LBN	Lebanon	Cluster 3	Reserve DID	0 (0, 0)	0 (0, 0.1)	0 (0, 0.1)	0.1 (0, 0.2)	0 (0, 0.1)
LTU	Lithuania	Cluster 4	Total DID	16.7 (16.7, 16.7)	10.3 (8.9, 11.7)	10.3 (8.9, 11.7)	10.2 (8.9, 11.7)	10.3 (8.9, 11.7)
LTU	Lithuania	Cluster 4	Access DID	11.7 (11.7, 11.7)	8.1 (6.7, 9.7)	7.8 (6.4, 9.4)	9 (7.6, 10.6)	8.1 (6.7, 9.7)
LTU	Lithuania	Cluster 4	Watch DID	4.8 (4.8, 4.8)	1.5 (1.4, 1.7)	1.9 (1.7, 2)	1.1 (1, 1.3)	1.5 (1.4, 1.7)
LTU	Lithuania	Cluster 4	Reserve DID	0 (0, 0)	0.6 (0.3, 1.1)	0.6 (0.3, 1.1)	0.1 (0, 0.1)	0.6 (0.3, 1.1)
LUX	Luxembourg	Cluster 4	Total DID	25.2 (23.8, 26.9)	10.9 (9.4, 12.7)	10.9 (9.4, 12.7)	10.9 (9.3, 12.7)	10.9 (9.4, 12.7)
LUX	Luxembourg	Cluster 4	Access DID	14.5 (13.3, 15.1)	10.1 (8.5, 11.9)	9.9 (8.3, 11.6)	10.3 (8.7, 12)	10.1 (8.5, 11.9)
LUX	Luxembourg	Cluster 4	Watch DID	10.7 (9.6, 11.4)	0.8 (0.7, 0.9)	1.1 (0.9, 1.2)	0.6 (0.6, 0.7)	0.8 (0.7, 0.9)
LUX	Luxembourg	Cluster 4	Reserve DID	0.1 (0, 0.1)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
MEX	Mexico	Cluster 3	Total DID	9.2 (7.9, 10.5)	17.9 (13.7, 25.5)	17.9 (13.7, 25.5)	18.1 (13.9, 25.8)	12 (9.1, 18.7)
MEX	Mexico	Cluster 3	Access DID	3.9 (3.6, 4.4)	16.3 (12.2, 24)	15.7 (11.6, 23.4)	16.7 (12.5, 24.6)	10.4 (7.5, 17.1)
MEX	Mexico	Cluster 3	Watch DID	4.1 (3.3, 5.6)	1.5 (1.4, 1.7)	2.1 (1.9, 2.3)	1.2 (1.1, 1.4)	1.5 (1.4, 1.7)
MEX	Mexico	Cluster 3	Reserve DID	0 (0, 0)	0.1 (0, 0.1)	0.1 (0, 0.1)	0.1 (0, 0.2)	0.1 (0, 0.1)
MAR	Morocco	Cluster 3	Total DID	16.6 (15.2, 18.4)	16.6 (14, 22.9)	16.6 (14, 22.9)	16.6 (14, 22.9)	11.4 (8.5, 17.3)
MAR	Morocco	Cluster 3	Access DID	11.8 (10.5, 13.2)	14.9 (12.4, 21.2)	14.4 (11.8, 20.7)	15.3 (12.8, 21.7)	9.7 (6.8, 15.7)
MAR	Morocco	Cluster 3	Watch DID	3.5 (3.2, 4)	1.5 (1.4, 1.8)	2.1 (1.9, 2.3)	1.2 (1, 1.4)	1.5 (1.4, 1.8)
MAR	Morocco	Cluster 3	Reserve DID	0 (0, 0)	0.1 (0, 0.3)	0.1 (0, 0.3)	0 (0, 0.1)	0.1 (0, 0.3)
NLD	Netherlands	Cluster 4	Total DID	9.7 (9.7, 9.7)	10.7 (9.2, 12.4)	10.7 (9.2, 12.4)	10.6 (9.2, 12.4)	10.7 (9.2, 12.4)
NLD	Netherlands	Cluster 4	Access DID	6.9 (6.9, 6.9)	9.6 (8.1, 11.3)	9.3 (7.8, 11.1)	9.8 (8.3, 11.5)	9.6 (8.1, 11.3)
NLD	Netherlands	Cluster 4	Watch DID	2.8 (2.8, 2.8)	1.1 (0.9, 1.2)	1.4 (1.2, 1.5)	0.8 (0.8, 1)	1.1 (0.9, 1.2)
NLD	Netherlands	Cluster 4	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
NZL	New Zealand	Cluster 4	Total DID	24.1 (24.1, 24.1)	14.3 (12.5, 16.4)	14.3 (12.5, 16.4)	14.3 (12.5, 16.4)	14.3 (12.5, 16.4)
NZL	New Zealand	Cluster 4	Access DID	19.1 (19.1, 19.1)	13.3 (11.5, 15.4)	13 (11.2, 15.1)	13.4 (11.6, 15.5)	13.3 (11.5, 15.4)
NZL	New Zealand	Cluster 4	Watch DID	4.9 (4.9, 4.9)	1 (0.9, 1.1)	1.3 (1.2, 1.4)	0.8 (0.8, 0.9)	1 (0.9, 1.1)
NZL	New Zealand	Cluster 4	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0.1)	0 (0, 0)
NOR	Norway	Cluster 4	Total DID	13.5 (13.5, 13.5)	11.7 (10.2, 13.5)	11.7 (10.2, 13.5)	11.7 (10.2, 13.5)	11.7 (10.2, 13.5)
NOR	Norway	Cluster 4	Access DID	10.9 (10.9, 10.9)	10.6 (9, 12.4)	10.3 (8.7, 12.1)	10.8 (9.2, 12.6)	10.6 (9, 12.4)
NOR	Norway	Cluster 4	Watch DID	2.6 (2.6, 2.6)	1.1 (1, 1.2)	1.4 (1.3, 1.6)	0.9 (0.8, 1)	1.1 (1, 1.2)
NOR	Norway	Cluster 4	Reserve DID	0 (0, 0)	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)
PAK	Pakistan	Cluster 2	Total DID	24.6 (22, 27.4)	19.9 (15.2, 28)	19.9 (15.2, 28)	19.8 (15.1, 28)	13.5 (10.1, 20.6)
PAK	Pakistan	Cluster 2	Access DID	10.9 (10.4, 14.3)	13.2 (8.5, 21.6)	9.6 (4.7, 18)	15.6 (10.9, 24)	6.8 (3.2, 14.4)
PAK	Pakistan	Cluster 2	Watch DID	10.8 (10.1, 12.6)	5.9 (5.2, 7)	9.5 (8.4, 11.1)	4 (3.4, 5)	5.9 (5.2, 7)

ISO3 Code	CTA Name	Cluster	AWaRe Category	Actual DID in IQVIA MIDAS*	Scenario 1	Scenario 2	Scenario 3	Scenario 4
PAK	Pakistan	Cluster 2	Reserve DID	0.1 (0.1, 0.2)	0.6 (0.3, 1.7)	0.6 (0.3, 1.7)	0.1 (0, 0.3)	0.6 (0.3, 1.7)
PER	Peru	Cluster 2	Total DID	14.5 (13.2, 16)	20.5 (16, 28.7)	20.5 (16, 28.7)	20.6 (16.1, 28.9)	13.9 (10.3, 21.7)
PER	Peru	Cluster 2	Access DID	6.5 (6.1, 7.9)	17.7 (13.3, 25.9)	17 (12.5, 25.2)	18.7 (14.2, 27)	11.1 (7.5, 19)
PER	Peru	Cluster 2	Watch DID	5.2 (4.7, 6.8)	2.3 (2.1, 2.6)	2.9 (2.7, 3.3)	1.8 (1.6, 2)	2.3 (2.1, 2.6)
PER	Peru	Cluster 2	Reserve DID	0.1 (0, 0.1)	0.4 (0.2, 0.9)	0.4 (0.2, 0.9)	0.1 (0, 0.3)	0.4 (0.2, 0.9)
POL	Poland	Cluster 4	Total DID	22.8 (22.8, 22.8)	8.4 (7.3, 9.7)	8.4 (7.3, 9.7)	8.4 (7.3, 9.7)	8.4 (7.3, 9.7)
POL	Poland	Cluster 4	Access DID	12.5 (12.5, 12.5)	7.4 (6.3, 8.7)	7.2 (6.1, 8.5)	7.6 (6.4, 8.8)	7.4 (6.3, 8.7)
POL	Poland	Cluster 4	Watch DID	8.9 (8.9, 8.9)	1 (0.9, 1.1)	1.2 (1, 1.3)	0.8 (0.7, 0.9)	1 (0.9, 1.1)
POL	Poland	Cluster 4	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0.1)	0 (0, 0)
PRT	Portugal	Cluster 4	Total DID	20.8 (20.8, 20.8)	10.6 (9.3, 12.4)	10.6 (9.3, 12.4)	10.6 (9.3, 12.3)	10.6 (9.3, 12.4)
PRT	Portugal	Cluster 4	Access DID	12.9 (12.9, 12.9)	9.7 (8.3, 11.4)	9.4 (8, 11.1)	9.9 (8.5, 11.6)	9.7 (8.3, 11.4)
PRT	Portugal	Cluster 4	Watch DID	7.7 (7.7, 7.7)	0.9 (0.8, 1)	1.2 (1.1, 1.4)	0.6 (0.6, 0.7)	0.9 (0.8, 1)
PRT	Portugal	Cluster 4	Reserve DID	0 (0, 0)	0 (0, 0.1)	0 (0, 0.1)	0.1 (0, 0.1)	0 (0, 0.1)
PRI	Puerto Rico	Cluster 3	Total DID	19.1 (19.1, 19.1)	15.6 (12.3, 22)	15.6 (12.4, 22)	15.7 (12.4, 22.1)	10.6 (8.1, 16.3)
PRI	Puerto Rico	Cluster 3	Access DID	9.6 (9.6, 9.6)	13.8 (10.5, 20.2)	13.3 (9.9, 19.7)	14.2 (10.9, 20.6)	8.8 (6.3, 14.5)
PRI	Puerto Rico	Cluster 3	Watch DID	9.4 (9.4, 9.4)	1.8 (1.6, 2)	2.3 (2.1, 2.6)	1.4 (1.2, 1.6)	1.8 (1.6, 2)
PRI	Puerto Rico	Cluster 3	Reserve DID	0.1 (0.1, 0.1)	0 (0, 0.1)	0 (0, 0.1)	0.1 (0, 0.2)	0 (0, 0.1)
ROU	Romania	Cluster 4	Total DID	27.3 (27.3, 27.3)	7.8 (6.8, 9.1)	7.8 (6.8, 9.1)	7.8 (6.8, 9)	7.8 (6.8, 9.1)
ROU	Romania	Cluster 4	Access DID	14.2 (14.2, 14.2)	6.7 (5.6, 7.8)	6.4 (5.3, 7.6)	7 (5.9, 8.1)	6.7 (5.6, 7.8)
ROU	Romania	Cluster 4	Watch DID	12.6 (12.6, 12.6)	1.1 (0.9, 1.2)	1.3 (1.2, 1.4)	0.8 (0.7, 0.9)	1.1 (0.9, 1.2)
ROU	Romania	Cluster 4	Reserve DID	0 (0, 0)	0.1 (0.1, 0.3)	0.1 (0.1, 0.3)	0.1 (0, 0.2)	0.1 (0.1, 0.3)
RUS	Russian Federation	Cluster 4	Total DID	17.1 (17.1, 17.1)	11.2 (9.7, 13)	11.2 (9.7, 13)	11.2 (9.7, 13)	11.2 (9.7, 13)
RUS	Russian Federation	Cluster 4	Access DID	8 (8, 8)	7.8 (5.8, 9.8)	7.5 (5.4, 9.4)	9.9 (8.5, 11.7)	7.8 (5.8, 9.8)
RUS	Russian Federation	Cluster 4	Watch DID	7.6 (7.6, 7.6)	1.8 (1.6, 2)	2.2 (2, 2.4)	1.2 (1.1, 1.4)	1.8 (1.6, 2)
RUS	Russian Federation	Cluster 4	Reserve DID	0 (0, 0)	1.5 (0.7, 2.9)	1.5 (0.7, 2.9)	0 (0, 0.1)	1.5 (0.7, 2.9)
SAU	Saudi Arabia	Cluster 3	Total DID	20.8 (20.8, 20.8)	14.1 (10.6, 19.8)	14.1 (10.6, 19.8)	14.2 (10.7, 20)	9.5 (7.2, 14.7)
SAU	Saudi Arabia	Cluster 3	Access DID	10.7 (10.7, 10.7)	12.4 (8.9, 18)	12 (8.5, 17.6)	12.8 (9.2, 18.5)	7.9 (5.5, 13.1)
SAU	Saudi Arabia	Cluster 3	Watch DID	10.1 (10.1, 10.1)	1.5 (1.3, 1.9)	2 (1.7, 2.3)	1.3 (1.1, 1.7)	1.5 (1.3, 1.9)
SAU	Saudi Arabia	Cluster 3	Reserve DID	0 (0, 0)	0.1 (0, 0.3)	0.1 (0, 0.3)	0.1 (0, 0.1)	0.1 (0, 0.3)
SRB	Serbia	Cluster 4	Total DID	29.3 (28.9, 30)	10.2 (8.8, 11.8)	10.2 (8.8, 11.8)	10.2 (8.8, 11.8)	10.2 (8.8, 11.8)
SRB	Serbia	Cluster 4	Access DID	16.2 (16, 16.7)	9 (7.6, 10.6)	8.7 (7.3, 10.3)	9.1 (7.8, 10.8)	9 (7.6, 10.6)
SRB	Serbia	Cluster 4	Watch DID	12.2 (12.1, 12.7)	1.2 (1.1, 1.4)	1.5 (1.3, 1.7)	1 (0.8, 1.2)	1.2 (1.1, 1.4)
SRB	Serbia	Cluster 4	Reserve DID	0 (0, 0)	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)

ISO3 Code	CTA Name	Cluster	AWaRe Category	Actual DID in IQVIA MIDAS*	Scenario 1	Scenario 2	Scenario 3	Scenario 4
SGP	Singapore	Cluster 4	Total DID	11 (11, 11)	12.6 (10.8, 14.6)	12.6 (10.8, 14.6)	12.6 (10.8, 14.6)	12.6 (10.8, 14.6)
SGP	Singapore	Cluster 4	Access DID	6.7 (6.7, 6.7)	11.8 (10, 13.9)	11.6 (9.8, 13.7)	12 (10.2, 14.1)	11.8 (10, 13.9)
SGP	Singapore	Cluster 4	Watch DID	4.2 (4.2, 4.2)	0.7 (0.6, 0.8)	0.9 (0.8, 1.1)	0.5 (0.5, 0.6)	0.7 (0.6, 0.8)
SGP	Singapore	Cluster 4	Reserve DID	0 (0, 0)	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)
SVK	Slovak Republic	Cluster 4	Total DID	23 (23, 23)	8 (6.9, 9.3)	8 (6.9, 9.3)	7.9 (6.8, 9.2)	8 (6.9, 9.3)
SVK	Slovak Republic	Cluster 4	Access DID	8.2 (8.2, 8.2)	6.9 (5.8, 8.2)	6.7 (5.6, 8)	7.1 (5.9, 8.3)	6.9 (5.8, 8.2)
SVK	Slovak Republic	Cluster 4	Watch DID	12.2 (12.2, 12.2)	1 (0.9, 1.2)	1.2 (1.1, 1.4)	0.8 (0.7, 0.9)	1 (0.9, 1.2)
SVK	Slovak Republic	Cluster 4	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0.1)	0 (0, 0)
SVN	Slovenia	Cluster 4	Total DID	15.7 (15.2, 16.3)	7.7 (6.7, 8.9)	7.7 (6.7, 8.9)	7.7 (6.7, 8.8)	7.7 (6.7, 8.9)
SVN	Slovenia	Cluster 4	Access DID	11.2 (10.9, 11.4)	6.8 (5.8, 7.9)	6.6 (5.6, 7.7)	6.9 (5.9, 8.1)	6.8 (5.8, 7.9)
SVN	Slovenia	Cluster 4	Watch DID	4.5 (4.2, 4.9)	0.9 (0.8, 1)	1.1 (1, 1.2)	0.7 (0.6, 0.8)	0.9 (0.8, 1)
SVN	Slovenia	Cluster 4	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
ZAF	South Africa	Cluster 2	Total DID	15.6 (15.6, 15.6)	23.3 (18.1, 32.9)	23.4 (18.1, 32.9)	23.3 (18.1, 32.9)	15.8 (12, 24.2)
ZAF	South Africa	Cluster 2	Access DID	11.8 (11.8, 11.8)	17.6 (12.2, 27.5)	16.8 (11.4, 26.7)	19.4 (14.1, 28.9)	10.1 (5.9, 18.7)
ZAF	South Africa	Cluster 2	Watch DID	3.6 (3.6, 3.6)	4.8 (4.1, 5.8)	5.6 (4.9, 6.6)	3.8 (3.2, 4.9)	4.8 (4.1, 5.8)
ZAF	South Africa	Cluster 2	Reserve DID	0 (0, 0)	0.8 (0.3, 2.2)	0.8 (0.3, 2.2)	0.1 (0, 0.2)	0.8 (0.3, 2.2)
ESP	Spain	Cluster 4	Total DID	26.9 (26.9, 26.9)	10.5 (8.9, 12)	10.5 (8.9, 12)	10.4 (8.9, 12)	10.5 (8.9, 12)
ESP	Spain	Cluster 4	Access DID	16.9 (16.9, 16.9)	9.5 (8, 11.1)	9.3 (7.7, 10.8)	9.7 (8.2, 11.3)	9.5 (8, 11.1)
ESP	Spain	Cluster 4	Watch DID	9.6 (9.6, 9.6)	0.9 (0.8, 1)	1.2 (1.1, 1.3)	0.7 (0.6, 0.7)	0.9 (0.8, 1)
ESP	Spain	Cluster 4	Reserve DID	0.1 (0.1, 0.1)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
LKA	Sri Lanka	Cluster 2	Total DID	11.2 (10.1, 12.1)	15.9 (12.2, 22.7)	15.9 (12.2, 22.7)	16 (12.2, 22.8)	10.8 (8, 16.6)
LKA	Sri Lanka	Cluster 2	Access DID	5.1 (4.9, 5.6)	13.8 (10.2, 20.6)	12.6 (8.9, 19.5)	14.5 (10.8, 21.3)	8.7 (5.9, 14.6)
LKA	Sri Lanka	Cluster 2	Watch DID	5.9 (4.8, 6.7)	2.1 (1.8, 2.4)	3.3 (2.9, 3.8)	1.4 (1.2, 1.7)	2.1 (1.8, 2.4)
LKA	Sri Lanka	Cluster 2	Reserve DID	0.1 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)
SWE	Sweden	Cluster 4	Total DID	13.6 (13.1, 14.5)	11.7 (10.1, 13.5)	11.7 (10.1, 13.5)	11.7 (10.1, 13.5)	11.7 (10.1, 13.5)
SWE	Sweden	Cluster 4	Access DID	9.6 (9.3, 9.8)	10.3 (8.8, 12.1)	10 (8.5, 11.8)	10.5 (8.9, 12.3)	10.3 (8.8, 12.1)
SWE	Sweden	Cluster 4	Watch DID	3.9 (3.6, 4.5)	1.4 (1.2, 1.5)	1.6 (1.5, 1.8)	1.2 (1, 1.3)	1.4 (1.2, 1.5)
SWE	Sweden	Cluster 4	Reserve DID	0 (0, 0.1)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
CHE	Switzerland	Cluster 4	Total DID	11 (11, 11)	11 (11, 11)	11 (11, 11)	11 (11, 11)	11 (11, 11)
CHE	Switzerland	Cluster 4	Access DID	6.7 (6.7, 6.7)	10 (9.8, 10.1)	9.7 (9.6, 9.9)	10.1 (10, 10.2)	10 (9.8, 10.1)
CHE	Switzerland	Cluster 4	Watch DID	4.2 (4.2, 4.2)	1 (0.9, 1.1)	1.3 (1.1, 1.4)	0.9 (0.8, 1)	1 (0.9, 1.1)
CHE	Switzerland	Cluster 4	Reserve DID	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
TWN	Taiwan	Cluster 3	Total DID	15.7 (15.7, 15.7)	11.1 (8.6, 15.7)	11.1 (8.6, 15.7)	11 (8.5, 15.6)	7.4 (5.7, 11.4)
TWN	Taiwan	Cluster 3	Access DID	10.6 (10.6, 10.6)	9.2 (6.7, 13.9)	8.7 (6.2, 13.4)	9.6 (7.1, 14.2)	5.6 (3.8, 9.6)

ISO3 Code	CTA Name	Cluster	AWaRe Category	Actual DID in IQVIA MIDAS*	Scenario 1	Scenario 2	Scenario 3	Scenario 4
TWN	Taiwan	Cluster 3	Watch DID	4.8 (4.8, 4.8)	1.8 (1.6, 2)	2.2 (2, 2.5)	1.3 (1.1, 1.5)	1.8 (1.6, 2)
TWN	Taiwan	Cluster 3	Reserve DID	0.1 (0.1, 0.1)	0.1 (0, 0.3)	0.1 (0, 0.3)	0.1 (0, 0.1)	0.1 (0, 0.3)
THA	Thailand	Cluster 2	Total DID	23.6 (23.6, 23.6)	20.1 (15.6, 28.2)	20.1 (15.6, 28.2)	20.1 (15.6, 28.3)	13.6 (10.2, 20.6)
THA	Thailand	Cluster 2	Access DID	17 (17, 17)	17.5 (12.9, 25.5)	16.3 (11.7, 24.5)	18.5 (13.8, 26.6)	11 (7.6, 18)
THA	Thailand	Cluster 2	Watch DID	6.5 (6.5, 6.5)	2.3 (2.1, 2.6)	3.5 (3.1, 3.8)	1.6 (1.4, 1.8)	2.3 (2.1, 2.6)
THA	Thailand	Cluster 2	Reserve DID	0 (0, 0)	0.2 (0.1, 0.7)	0.2 (0.1, 0.7)	0.1 (0, 0.4)	0.2 (0.1, 0.7)
TUN	Tunisia	Cluster 3	Total DID	33.8 (33.8, 33.8)	13.4 (10.3, 18.9)	13.4 (10.3, 18.9)	13.5 (10.3, 19)	9 (6.8, 13.9)
TUN	Tunisia	Cluster 3	Access DID	23.4 (23.4, 23.4)	12 (8.9, 17.5)	11.6 (8.4, 17)	12.3 (9.1, 17.8)	7.5 (5.4, 12.4)
TUN	Tunisia	Cluster 3	Watch DID	8.3 (8.3, 8.3)	1.4 (1.2, 1.6)	1.8 (1.6, 2.1)	1.2 (1, 1.4)	1.4 (1.2, 1.6)
TUN	Tunisia	Cluster 3	Reserve DID	0 (0, 0)	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)
TUR	Turkiye	Cluster 3	Total DID	34.2 (34.2, 34.2)	18.4 (13.9, 25.8)	18.4 (13.9, 25.8)	18.6 (14, 26.2)	12.4 (9.4, 19.2)
TUR	Turkiye	Cluster 3	Access DID	17.9 (17.9, 17.9)	17 (12.5, 24.4)	16.6 (12, 24)	17.4 (12.8, 25)	11 (8, 17.8)
TUR	Turkiye	Cluster 3	Watch DID	15.4 (15.4, 15.4)	1.3 (1.2, 1.5)	1.8 (1.6, 2)	1.1 (1, 1.3)	1.3 (1.2, 1.5)
TUR	Turkiye	Cluster 3	Reserve DID	0.1 (0.1, 0.1)	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)
ARE	United Arab Emirates	Cluster 3	Total DID	27.7 (26.7, 28.6)	13.5 (10.2, 19.1)	13.5 (10.2, 19.1)	13.7 (10.3, 19.4)	9.2 (6.8, 14.6)
ARE	United Arab Emirates	Cluster 3	Access DID	12.1 (11.8, 12.7)	12.4 (9.1, 18)	12 (8.8, 17.7)	12.6 (9.3, 18.4)	8 (5.6, 13.4)
ARE	United Arab Emirates	Cluster 3	Watch DID	15.2 (14.2, 15.9)	1.1 (1, 1.4)	1.4 (1.3, 1.7)	1 (0.8, 1.2)	1.1 (1, 1.4)
ARE	United Arab Emirates	Cluster 3	Reserve DID	0 (0, 0)	0 (0, 0.1)	0 (0, 0.1)	0.1 (0, 0.2)	0 (0, 0.1)
GBR	United Kingdom	Cluster 4	Total DID	19.7 (19.7, 19.7)	11.6 (10.1, 13.4)	11.6 (10.1, 13.4)	11.5 (10.1, 13.4)	11.6 (10.1, 13.4)
GBR	United Kingdom	Cluster 4	Access DID	13.2 (13.2, 13.2)	10.6 (9.1, 12.5)	10.3 (8.9, 12.2)	10.8 (9.3, 12.6)	10.6 (9.1, 12.5)
GBR	United Kingdom	Cluster 4	Watch DID	6.5 (6.5, 6.5)	0.9 (0.8, 1.1)	1.2 (1.1, 1.4)	0.7 (0.6, 0.7)	0.9 (0.8, 1.1)
GBR	United Kingdom	Cluster 4	Reserve DID	0.1 (0.1, 0.1)	0 (0, 0)	0 (0, 0)	0.1 (0, 0.2)	0 (0, 0)
USA	United States	Cluster 4	Total DID	23.7 (23.7, 23.7)	16.2 (14.1, 18.7)	16.2 (14.1, 18.7)	16.2 (14.1, 18.7)	16.2 (14.1, 18.7)
USA	United States	Cluster 4	Access DID	16.7 (16.7, 16.7)	15.2 (13.2, 17.8)	14.9 (12.9, 17.5)	15.3 (13.2, 17.9)	15.2 (13.2, 17.8)
USA	United States	Cluster 4	Watch DID	6.9 (6.9, 6.9)	0.9 (0.8, 0.9)	1.2 (1.1, 1.3)	0.6 (0.6, 0.7)	0.9 (0.8, 0.9)
USA	United States	Cluster 4	Reserve DID	0.1 (0.1, 0.1)	0 (0, 0.1)	0 (0, 0.1)	0.2 (0.1, 0.4)	0 (0, 0.1)
URY	Uruguay	Cluster 3	Total DID	16.1 (15.7, 16.7)	18.7 (14.4, 26.6)	18.7 (14.4, 26.6)	18.9 (14.6, 26.9)	12.6 (9.5, 19.5)
URY	Uruguay	Cluster 3	Access DID	9.5 (9.3, 9.9)	17.6 (13.3, 25.5)	17.2 (13, 25.1)	18 (13.7, 26)	11.5 (8.3, 18.4)
URY	Uruguay	Cluster 3	Watch DID	6.2 (5.9, 6.3)	1.1 (1, 1.2)	1.5 (1.3, 1.6)	0.7 (0.7, 0.8)	1.1 (1, 1.2)
URY	Uruguay	Cluster 3	Reserve DID	0 (0, 0.1)	0 (0, 0.1)	0 (0, 0.1)	0.1 (0.1, 0.3)	0 (0, 0.1)
VNM	Viet Nam	Cluster 2	Total DID	26.4 (26.4, 26.4)	14.2 (10.8, 19.9)	14.2 (10.8, 19.9)	14.2 (10.7, 19.9)	9.6 (7.3, 14.7)
VNM	Viet Nam	Cluster 2	Access DID	13.5 (13.5, 13.5)	11.7 (8.3, 17.5)	10.5 (7.1, 16.4)	12.8 (9.4, 18.6)	7 (4.6, 12.2)
VNM	Viet Nam	Cluster 2	Watch DID	12.3 (12.3, 12.3)	2.1 (1.8, 2.4)	3.2 (2.8, 3.7)	1.4 (1.2, 1.7)	2.1 (1.8, 2.4)

ISO3 Code	CTA Name	Cluster	AWaRe Category	Actual DID in IQVIA MIDAS*	Scenario 1	Scenario 2	Scenario 3	Scenario 4
VNM	Viet Nam	Cluster 2	Reserve DID	0 (0, 0)	0.4 (0.2, 1.2)	0.4 (0.2, 1.2)	0 (0, 0.1)	0.4 (0.2, 1.2)

* Source: Actual DID based on IQVIA MIDAS® data for 2019, reflecting estimates of real-world activity. Copyright IQVIA. All Rights Reserved

REFERENCES

1. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index: Norwegian Institute of Public Health; [Available from: https://atcddd.fhi.no/atc_ddd_index/].
2. World Health Organization. AWaRe classification of antibiotics for evaluation and monitoring of use. In: Control and Response Strategies (CSR) EME, Health Product Policy and Standards (HPS), Medicines Selection, IP and Affordability (MIA), WHO Headquarters (HQ), editor. Geneva: WHO; 2023.
3. Global Burden of Disease Results Tool 2021 [Internet]. 2024. Available from: <https://gbd2021.healthdata.org/gbd-results/>.
4. GBD 2021 Demographics Collaborators. Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950-2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021. *Lancet*. 2024;403(10440):1989-2056.
5. GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. *Lancet*. 2024;403(10440):2133-61.
6. Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. *The Lancet*. 2020;395(10219):200-11.
7. World Health Organization. The WHO AWaRe (Access, Watch, Reserve) antibiotic book. Geneva: World Health Organization; 2022.
8. GBD Diarrhoeal Diseases Collaborators. Global, regional, and national age-sex-specific burden of diarrhoeal diseases, their risk factors, and aetiologies, 1990-2021, for 204 countries and territories: a systematic analysis for the Global Burden of Disease Study 2021. *Lancet Infect Dis*. 2025;25(5):519-36.
9. Bender RG, Sirota SB, Swetschinski LR, Dominguez R-MV, Novotney A, Wool EE, et al. Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990–2021: a systematic analysis from the Global Burden of Disease Study 2021. *The Lancet Infectious Diseases*. 2024;24(9):974-1002.
10. European Centre for Disease Prevention and Control. Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals. Stockholm; 2024.
11. Versporten A, Zarb P, Caniaux I, Gros M-F, Drapier N, Miller M, et al. Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: results of an internet-based global point prevalence survey. *The Lancet Global Health*. 2018;6(6):e619-e29.
12. Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *The Lancet*. 2022;399(10325):629-55.
13. Naghavi M, Vollset SE, Ikuta KS, Swetschinski LR, Gray AP, Wool EE, et al. Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050. *The Lancet*. 2024;404(10459):1199-226.
14. World Development Indicators: Population estimates and projections [Internet]. World Bank. [cited 08/07/2024].
15. Department of Household Registration. End of Year - Statistics: Department of Household Registration, Ministry of the Interior, Republic of China (Taiwan); 2023 [Available from: Department of Household Registration, Ministry of the Interior, Republic of China (Taiwan)].
16. World Development Indicators: Rural population (% of total population) [Internet]. World Bank. [cited 08/07/2024].
17. United Nations Department of Economic and Social Affairs Population Division. World Urbanization Prospects: the 2018 Revision. New York: United Nations; 2019.
18. Clark A, Jit M, Warren-Gash C, Guthrie B, Wang HHX, Mercer SW, et al. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. *The Lancet Global Health*. 2020;8(8):e1003-e17.
19. World Development Indicators: UHC Service Coverage Index [Internet]. [cited 08/07/2024].
20. GBD 2017 SDG Collaborators, Lozano R, Fullman N, Abate D, Abay SM, Abbafati C, et al. Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related

Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. *The Lancet*. 2018;392(10159):2091-138.

21. International Vaccine Access Center (IVAC). Pneumococcal Conjugate Vaccine (PCV) Introduction & Use: Johns Hopkins Bloomberg School of Public Health; 2024 [Available from: view-hub.org/vaccine/pcv].
22. GBD 2020 Release 1 Vaccine Coverage Collaborators, Galles NC, Liu PY, Updike RL, Fullman N, Nguyen J, et al. Measuring routine childhood vaccination coverage in 204 countries and territories, 1980–2019: a systematic analysis for the Global Burden of Disease Study 2020, Release 1. *The Lancet*. 2021;398(10299):503-21.
23. World Health Organization U. Pneumococcal vaccination coverage [Available from: <https://immunizationdata.who.int/global/wiise-detail-page/pneumococcal-vaccination-coverage>].
24. International Vaccine Access Center (IVAC). Rotavirus Vaccine (Rota) Introduction & Use: Johns Hopkins Bloomberg School of Public Health; 2024 [Available from: <https://view-hub.org/vaccine/rota>].
25. World Health Organization U. Rotavirus vaccination coverage [Available from: <https://immunizationdata.who.int/global/wiise-detail-page/rotavirus-vaccination-coverage>].
26. Weiss DJ, Nelson A, Vargas-Ruiz CA, Gligorić K, Bavadekar S, Gabrilovich E, et al. Global maps of travel time to healthcare facilities. *Nature Medicine*. 2020;26(12):1835-8.
27. National health Workforce Accounts database [Internet]. World Health Organization. [cited 05/07/2024]. Available from: <https://apps.who.int/nhwportal>; <https://www.who.int/activities/improving-health-workforce-data-and-evidence>.
28. Haakenstad A, Irvine CMS, Knight M, Bintz C, Aravkin AY, Zheng P, et al. Measuring the availability of human resources for health and its relationship to universal health coverage for 204 countries and territories from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. *The Lancet*. 2022;399(10341):2129-54.
29. World Development Indicators: Physicians (per 1000 people) [Internet]. World Bank. [cited 08/07/2024].
30. World Development Indicators: Nurses and midwives (per 1000 people) [Internet]. World Bank. [cited 08/07/2024].
31. World Development Indicators: GNI per capita, Atlas method (current US\$) [Internet]. World Bank. [cited 08/07/2024].
32. National Statistics Republic of China (Taiwan). 09. National Economics and Business Activities: Per capita income and consumption [Available from: https://eng.stat.gov.tw/News_Content.aspx?n=4302&s=232171].
33. Maldonado L, Olivo V. Is Venezuela Still an Upper-Middle-Income Country? Estimating the GNI per Capita for 2015–2021. 2022.
34. United Nations. Per capita GNI at current prices - US dollars. In: Division UNS, editor. *UN Data2024*.
35. American Samoa Government. American Samoa Statistical Yearbook 2022. In: Division DoCSaA, editor. 2022.
36. Government of Guam. Guam Statistical Yearbook. In: Bureau of Statistics and Plans OotG, editor. 2023.
37. Republic of Korea. North Korea Statistics: Gross National Income. In: Cooperation Ool, editor. 2024.
38. World Development Indicators: Poverty headcount ratio at \$2.15 a day (2017 PPP) [Internet]. [cited 05/07/2024].
39. World Development Indicators: People using safely managed sanitation services (% of population) [Internet]. [cited 08/07/2024].
40. Siribhadra A, Ngamprasertchai T, Rattanaumpawan P, Lawpoolsri S, Luvira V, Pitisuttithum P. Antimicrobial Stewardship in Tropical Infectious Diseases: Focusing on Dengue and Malaria. *Trop Med Infect Dis*. 2022;7(8).
41. Weiss DJ, Nelson A, Vargas-Ruiz CA, Gligorić K, Bavadekar S, Gabrilovich E, et al. Motorized friction surface. 2020.
42. Open Spatial Demographic Data and Research [Internet]. [cited 05/07/2024]. Available from: <https://hub.worldpop.org/>.
43. World Development Indicators: People using at least basic sanitation services (% of population) [Internet]. [cited 08/07/2024].
44. Boogaart KGvd. Using the R package "compositions". 2005.

45. Aitchison J, Barcel'o-Vidal C, Egozcue JJ, Pawlowsky-Ghahn V. A consise guide to the algebraic geometric structure of the simplex, the sample space for compositional data analysis. *Terra Nostra*. 2002;03.
46. Egozcue JJ, Pawlowsky-Ghahn V, Mateu-Figueras G, Barcel'o-Vidal C. Isometric logratio transformations for compositional data analysis. *Mathematical Geology*. 2003;35(3):279-300.
47. Meacock TZMSR. Use of compositional covariates in linear regression: problems and solutions. Health Econometrics and Data Group Working Paper. 2023.
48. Browne AJ, Chipeta MG, Haines-Woodhouse G, Kumaran EPA, Hamadani BHK, Zaraa S, et al. Global antibiotic consumption and usage in humans, 2000-18: a spatial modelling study. *Lancet Planet Health*. 2021;5(12):e893-e904.
49. Klein EY, Impalli I, Poleon S, Denoel P, Cipriano M, Van Boeckel TP, et al. Global trends in antibiotic consumption during 2016–2023 and future projections through 2030. *Proceedings of the National Academy of Sciences*. 2024;121(49).
50. Klein EY, Van Boeckel TP, Martinez EM, Pant S, Gandra S, Levin SA, et al. Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. *Proceedings of the National Academy of Sciences*. 2018;115(15):E3463-E70.
51. World Health Organization. Global Antimicrobial Resistance and Use Surveillance System (GLASS) report. Antibiotic use data for 2022. 2025.
52. Marbac M, Sedki M. Variable selection for model-based clustering using the integrated complete-data likelihood. *Statistics and Computing*. 2017;27(4):1049-63.
53. Marbac M, Sedki M, Patin T. Variable Selection for Mixed Data Clustering: Application in Human Population Genomics. *Journal of Classification*. 2020;37(1):124-42.
54. World Health Organization. Global Action Plan on Antimicrobial Resistance. Geneva: World Health Organization; 2015.
55. GBD 2019 Healthcare Access and Quality Collaborators. Assessing performance of the Healthcare Access and Quality Index, overall and by select age groups, for 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019. *Lancet Glob Health*. 2022;10(12):e1715-e43.
56. Andrej-Nikolai Spiess, Mullen KM. Standard 'nls' framework that uses 'nls.lm' for fitting.
57. Moré JJ, editor *The Levenberg-Marquardt algorithm: Implementation and theory*. Numerical Analysis; 1978 1978//; Berlin, Heidelberg: Springer Berlin Heidelberg.
58. World Health Organization. Key updates to the treatment of drug-resistant tuberculosis: rapid communication. Geneva: World Health Organization; 2024.
59. World Health Organization. WHO operational handbook on tuberculosis. Module 4: treatment and care. Geneva: World Health Organization; 2025.
60. Antillon M, Saad NJ, Baker S, Pollard AJ, Pitzer VE. The Relationship Between Blood Sample Volume and Diagnostic Sensitivity of Blood Culture for Typhoid and Paratyphoid Fever: A Systematic Review and Meta-Analysis. *The Journal of Infectious Diseases*. 2018;218(suppl_4):S255-S67.
61. Baker S, Blohmke CJ, Maes M, Johnston PI, Darton TC. The Current Status of Enteric Fever Diagnostics and Implications for Disease Control. *Clinical Infectious Diseases*. 2020;71(Supplement_2):S64-S70.
62. World Health Organization. Typhoid 2023 [Available from: [who.int/news-room/fact-sheets/detail/typhoid](https://www.who.int/news-room/fact-sheets/detail/typhoid)].
63. Andrews JR, Baker S, Marks F, Alsan M, Garrett D, Gellin BG, et al. Typhoid conjugate vaccines: a new tool in the fight against antimicrobial resistance. *The Lancet Infectious Diseases*. 2019;19(1):e26-e30.
64. Mogasale V, Ramani E, Mogasale VV, Park J. What proportion of Salmonella Typhi cases are detected by blood culture? A systematic literature review. *Annals of Clinical Microbiology and Antimicrobials*. 2016;15(1).
65. Wolf A, Dedman D, Campbell J, Booth H, Lunn D, Chapman J, et al. Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum. *International Journal of Epidemiology*. 2019;48(6):1740-g.
66. National Institute for Health and Care Excellence (NICE). Pyelonephritis (acute): antimicrobial prescribing. 2024.
67. National Institute for Health and Care Excellence (NICE). UTI (lower): antimicrobial prescribing. 2025.

68. Thean LJ, Jenney A, Engelman D, Romani L, Wand H, Mudaliar J, et al. Hospital admissions for skin and soft tissue infections in a population with endemic scabies: A prospective study in Fiji, 2018–2019. *PLOS Neglected Tropical Diseases*. 2020;14(12):e0008887.
69. Gomes Siqueira GL, Alves De Olinda R, Barbosa De Siqueira CM, Barros De Vasconcelos Sá Torres A, De Carvalho Viana Corrêa L, De Assis Silva Lacerda F, et al. Non-necrotizing and necrotizing soft tissue infections in South America: A retrospective cohort study. *Annals of Medicine and Surgery*. 2020;59:24-30.
70. Choe H-S, Lee S-J, Cho Y-H, Çek M, Tandoğdu Z, Wagenlehner F, et al. Aspects of urinary tract infections and antimicrobial resistance in hospitalized urology patients in Asia: 10-Year results of the Global Prevalence Study of Infections in Urology (GPIU). *Journal of Infection and Chemotherapy*. 2018;24(4):278-83.
71. Song JH, Oh WS, Kang CI, Chung DR, Peck KR, Ko KS, et al. Epidemiology and clinical outcomes of community-acquired pneumonia in adult patients in Asian countries: a prospective study by the Asian network for surveillance of resistant pathogens. *Int J Antimicrob Agents*. 2008;31(2):107-14.
72. Lopardo GD, Fridman D, Raimondo E, Albornoz H, Lopardo A, Bagnulo H, et al. Incidence rate of community-acquired pneumonia in adults: a population-based prospective active surveillance study in three cities in South America. *BMJ Open*. 2018;8(4):e019439.
73. Ferrer M, Traverso C, Cilloniz C, Gabarrus A, Ranzani OT, Polverino E, et al. Severe community-acquired pneumonia: Characteristics and prognostic factors in ventilated and non-ventilated patients. *PLOS ONE*. 2018;13(1):e0191721.
74. Ellis Simonsen SM, Van Orman ER, Hatch BE, Jones SS, Gren LH, Hegmann KT, et al. Cellulitis incidence in a defined population. *Epidemiology and Infection*. 2006;134(2):293-9.
75. GLASS dashboard Global AMU data [Internet]. World Health Organization. 2025 [cited 02/10/2025]. Available from: https://worldhealthorg.shinyapps.io/glass-dashboard/_w_2adc71e405d247f891587628eb644974/_w_df46d3ae21ed4ce3b3e2d29f610917b8/#!/amu.